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1  Introduction 
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1 Introduction 
1.1 Pharmacotherapy in elderly 
Evidence of efficacy and safety of new drug products is based primarily on results of one 
or more randomized, placebo-controlled clinical trials, which generally derive “one-size-
fits all” dosing regimens for new drug products [1]. However, patients respond differently 
to medications due to many reasons, which can either be intrinsic (e.g., age, weight, 
metabolic capacity, genetic constitution etc.) or extrinsic (e.g., comedication, comorbidity, 
etc.). Consequently, flat dosing regimens can have serious impact on efficacy and safety of 
the individual patient. In contrast, the purpose of “personalizing” drug therapy is to 
optimize the benefit and minimize the harm of medication interventions on a patient-by-
patient basis [1]. Although personalized treatment regimens should be the first choice, 
initial drug labels often lack useful and explicit label information even for larger patient 
groups with special needs, e.g. for special population groups [2]. Individualization is then 
left to the physician, using the “art of medicine” based on experience, clinical judgment, 
and unique and frequently intangible factors related to a patient. The situation becomes 
even more complex in the case of elderly patients due to the lack of actual data from 
dedicated clinical trials in this heterogeneous population. In addition, optimal 
pharmacotherapy in elderly is hampered by highly variable organ functions, comorbidity, 
high drug-drug interaction potential, and lack of adherence to medication. 
Provided that the Western society is growing increasingly older, there is a need for well 
controlled treatment strategies to improve the efficancy and safety of drug therapies in 
older adults. In particular, the impact of changes in body functions in elderly patients 
compared to healthy subjects needs to be better understood in order to provide optimal 
pharmacotherapy in this special patient population. For example, ageing is associated with 
changes in cellular, tissue, and organ function as well as an increased probability of 
suffering from multiple illnesses. Given this framework and the knowledge on age-related 
physiological and functional changes, it is important to tailor pharmacotherapy in the 
elderly to the age subgroups [3].  
Introduction 2 
_________________________________________________________________________ 
The International Conference on Harmonization (ICH) Efficacy Guideline E7 defines the 
elderly patient as a person of the standard retirement age 65 years or older [4]. In order to 
account for inter-individual variability in this large age group, the ICH purposes a further 
split of the elderly population into ‘young old’ (65 to 74 years), the ‘old’ (75 to 84 years), 
and the ‘oldest old’ (≥ 85 years). Within this framework, the classification of geriatric 
patients by age groups becomes important to account for differences related to 
physiological and functional changes observed in these patients with age [5]. 
However, a chronological age (years since birth) classification is often not ideally suited 
for designing pharmacotherapy for the elderly patient because it may or may not 
appropriately reflect the patient’s actual “biological age”. Age-related changes are highly 
heterogeneous due to the dynamic interplay between multiple, complex and poorly 
understood genetic, environmental, and disease-related risk factors. As a consequence, flat 
dosing regimens that fail to take the biological age into account are unlikely to 
appropriately meet the medication needs of the individual elderly patient [6]. 
1.2 Current status and need for clinical studies in elderly 
To account for the increasing number of older adults and their special pharmacotherapeutic 
needs, the ICH E7 guideline recommends the inclusion of a meaningful number of geriatric 
patients (age 65 years of age and older) in phase III or phase II/III of clinical drug 
development. Even more ideal are exclusively dedicated geriatric trials in order to 
appropriately account for comorbidity and investigate the influence of polymedication in 
the elderly patient. In particular, the guideline arbitrarily recommends the inclusion of at 
least 100 geriatric patients to identify clinically relevant differences [4]. This allows for an 
assessment of deviating dose response and varying degrees of efficacy with increasing age. 
Based on this framework, the United States Food and Drug Administration (FDA) 
proposes to include data for elderly patients of all subgroups mentioned in ICH E7 for the 
marketing application of new drugs [7]. These subgroups should be considerable in size 
and comparable to respective patient numbers for the respective disease [8]. 
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However, even if the intent behind present regulations is the inclusion of different groups 
of elderly patients in clinical trials, these recommendations are frequently not fully 
implemented. For example, in the phase II and III Type II Diabetes Mellitus (T2DM) trials, 
only one percent of the study population is older than 75 years of age [9]. In addition, the 
outcome of a typical trial may not accurately reflect clinical reality because elderly 
subjects included in clinical trials are mostly the ‘young old’, healthy older adults who 
have fewer and less severe comorbidity [10]. An exemplary case is shown in Figure 1-1 for 
simvastatin, where the clinical trial population [11] was compared to the actual target 
patient population for lipid-lowering medication among publicly insured patients in 
Germany [12]. Age distributions of these two populations clearly differ. 
Older adults that are generally underrepresented in clinical trial settings include patients 
with dementia, non-native speakers, functionally dependent (nursing home or homebound) 
and those who are unable to consent to participate in a research study [13]. These patients 
live often geographically isolated from studies conducted at large medical centers. 
Similarly, patients with advanced comorbidity are also often excluded. It is not surprising 
that 61 % of new cancers are diagnosed in the elderly, whereas only 25 % of oncology trial 
participants can be assigned to this age group [14]. As a consequence, insufficient data is 
often available from geriatric clinical trials intended to develop geriatric-specific dosing 
information [15]. Therefore, ‘start low, go slow’ recommendations for pharmacotherapy 
are common. These empirical dosing approaches may lead to an increase in mortality as 
evident from over-treating hypertension and diabetes mellitus in older adults [16].  
1.3 Precision medicine approaches in the elderly 
This need for more precise dosing recommendations for older adults has been addressed at 
various levels of complexity ranging from expert consensus-based to physiologically based 
personalized medicine approaches. 
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Figure 1-1  Simvastatin clinical trials population compared to the prescription pattern 
for lipid-lowering medication for publicly insured patients in Germany 
stratified by age. Trial population is shown in dark grey bars and was 
adopted from Martin et al. [11] whereas the German patient population is 
visualized in light grey bars [12]. 
1.3.1 Expert consensus-based personalized medicine approaches 
Expert consensus-based personalized medicine approaches are intended to optimize 
medication use by guiding the avoidance of medications that place older adults at an 
increased risk of adverse events and for which safer alternatives exist.  
Beers criteria 
The Beers Criteria for inappropriate medications were developed by expert consensus in 
1991 and have been updated in 1997, 2003, 2012, and 2015 [17-21]. These criteria identify 
medications with risks that may be greater than their benefits for people 65 years or older, 
and were developed to “guide” health care professionals prescribing for older adult 
patients. Although they have been used as a quality of care measure by many health care 
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systems, these criteria were not intended to imply that these medications are absolutely 
“contraindicated”. In addition, many newer medications are not included in the criteria and 
issues of inappropriate drug interactions or drug class duplications are not captured [22]. 
Studies to date have struggled to demonstrate a clear correlation between adherence to 
Beers Criteria recommendations and improved clinical outcomes. 
STOPP/START criteria 
The Screening Tool of Older People’s Prescriptions (STOPP) and the Screening Tool to 
Alert to Right Treatment (START) were first published in 2008 [23] and were updated in 
2015 [24]. Like the Beers Criteria, STOPP Criteria were developed through expert review 
using the Delphi consensus methodology and are intended to identify medications to be 
avoided in older adults. The START Criteria were developed through a similar 
methodology to identify medication prescribing omissions. A comparison between the 
STOPP and the 2003 Beers Criteria found that patients taking a medication from the 
STOPP list were 85 % more likely to have an adverse drug event than those without a 
STOPP list drug. No association was found with the 2003 Beers criteria [25]. 
Priscus list 
In order to facilitate a safe pharmacotherapy for older adults in Germany, an initiative of 
German physicians and scientists summarized potentially inappropriate medications for the 
German drug market and released it under the name Priscus list in 2010 [26]. As a starting 
point, the Beers criteria as well as similar lists from Canada [27] and France [28] were 
screened to identify overlaps with the German drug market, since specific prescription 
guidelines or habits as well as drug authorization may differ between countries. This list 
was extended by potentially harmful drugs for older adults available on the German 
market. Finally, this list was reviewed by experts using the Delphi consensus methodology.  
FORTA list 
The “Fit for the Aged” (FORTA) list is a clinical tool developed by the University of 
Heidelberg [29]. Similarly to the Priscus list, the FORTA list is tailored for German 
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geriatricians, but is the first classification system in which both negative and positive 
recommendations are combined. The list should aid geriatricians towards a safe 
prescription for individual indications instead of an assessment guided by a negative list. 
Similar to other lists, a two-round Delphi procedure was conducted for the FORTA list. A 
subsequent validation trial run suggests that the application of the FORTA list leads to an 
improvement of medication quality and a reduction of adverse drug reactions (ADRs).[30]. 
One of the major concerns about using a “hit list” approach includes lack of allowance for 
exceptions (e.g., palliative care). On the other hand, drugs that are considered beneficial 
may still present a high risk for adverse drug events in medically complex older adults. 
Budnitz et al. investigated hospital admissions due to ADEs and pointed out that only a 
few drugs cause the majority of hospitalizations [31]. Warfarin and insulins are the primary 
suspects for ADEs. However, the retrospective review of emergency room and hospital 
claims data may underestimate the true medication-related risks in older adults as many 
adverse-effects (i.e. dry mouth, incontinence, anorexia, confusion) are not captured in 
electronic health records [32]. 
1.3.2 Genome-based personalization approaches for the elderly 
During the past two decades, the quest for identifying the genetic basis for ageing has 
sparked an entire field of research that focuses on cellular ageing processes. The study of 
nutrient signaling pathways, reactive oxygen species (i.e. “free radicals”), telomere length, 
DNA repair mechanisms, and mitochondrial dysfunction have been of particular interest 
because they represent cellular mechanisms for senescence and apoptosis [33]. Studies in 
centenarians (age ≥ 100 years) have gained prominence in evaluating the genetic basis for 
extreme longevity and the delay of frailty [34]. Several genes, such as APOE and 
FOXO3A, have been associated with ageing [35] in Genome Wide Association Studies 
(GWAS). GWAS determine statistical correlations between the genomic variability among 
individuals and the phenotypic variability among the same individuals [36]. The impact of 
the genomic variability of these “ageing genes” on the pharmacokinetics (PK) and 
pharmacodynamics (PD) of drugs in older adults remains unknown.  
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Genotype-guided dosing in the elderly  
Genotype-guided dosing regimens are available for many drugs [37-39]. They are intended 
to enable safer and more effective drug treatment by identifying genetic sources of inter-
individual variability needed to optimize dosing strategies by reducing toxicity and 
increasing efficacy of a given drug treatment. Regardless of the genotype, elderly patients 
may present higher drug levels than younger patients when the same dose is administered 
to both patient populations due to age-related reduction of intrinsic clearance capacity. In 
addition, the variance in Cytochrome P-450 (CYP) functionality with age may result in a 
multiplicative effect on metabolism [40]. As an example, venlafaxine plasma 
concentrations are 18-fold higher in elderly CYP2D6 poor metabolizers than in non-elderly 
poor metabolizers [40, 41]. In spite of the limited number of elderly poor metabolizers 
included in this study, an important observation was that all of them had serum venlafaxine 
and O-desmethylvenlafaxine (pharmacologically active compound) levels were above the 
upper recommended therapeutic limit [41].  
Warfarin is another prominent example for genotype-guided (CYP2C9 and VKORC1) 
dosing regimens. Although age was not identified as the most significant covariate, a 
reduction of dose requirement of 0.2 mg per day per decade, independent of genotype and 
weight, was observed [42]. Because the impact of the CYP variation on the PK may be 
more pronounced and clinically meaningful in older adults, all possible covariates 
including age and genotype should be considered to develop a comprehensive dosing 
strategy regardless of its time-consuming and costly nature [43, 44].  
The genome-based disease risk assessment 
Certain diseases are associated with age or have an increased prevalence in the elderly. 
Based on genomic testing, estimates can conceptually be made for the incidence and/or 
prognosis of these diseases. However, the genetic basis for most diseases remains poorly 
understood. For example, the efforts invested to develop clinically useful genomic tests 
that can predict a higher risk for Alzheimer’s disease in individual patients have not yet 
been fruitful and currently available results still remain elusive.  
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Whereas pharmacogenomic considerations for drug usage might not vary with increasing 
age, the benefit for a timely diagnosis will become more important for the elderly 
population. Similarly, understanding a patient’s genetic variation is needed in order to 
optimize dosing strategies to reduce toxicity and increase efficacy of a particular drug 
treatment. 
1.4 Biomarkers 
The development of drug treatments in the elderly is limited by the lack of reliable 
biomarkers in this special patient population. For example, current efforts for developing 
effective medications for the prevention and treatment of Alzheimer’s disease are 
hampered by the lack of established biomarkers, both for preclinical detection and for 
monitoring clinical treatment response [45]. 
Given that many body functions either change or lose physiologic capacity as subjects 
become older, it is still unclear which of the identified biomarkers in healthy adults are 
equally applicable to the elderly patient. In addition, elderly patients may have different 
disease progression, lifestyle, comorbidity and poly-medication which may require the 
combination of different biomarkers or scores to obtain more specific measures of the drug 
response in this population. Ideally, the dynamic interplay between all above factors should 
be quantified to establish appropriate dosing regimens and support precision medicine 
approaches in the elderly.  
Type II Diabetes Mellitus is a good example for the complexity of factors involved in the 
identification of appropriate biomarkers in the older adults. The general guidelines for 
controlling T2DM in elderly patients recommend higher target levels of glycosylated 
hemoglobin (HbA1C) than in younger adults [46]. This recommendation is in part the result 
of the ACCORD trial, where even though a premature termination was required after a 
median duration of 3.5 years because of higher mortality in the group targeting lower 
HbA1C levels, it provided the first evidence that hypoglycemia and other adverse effects 
are more frequent in older patients [46, 47]. Hypoglycemia is related with serious morbid 
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outcomes in the elderly population, such as falls, cognitive decline, autonomic dysfunction, 
depression, recurrent hypoglycemia, poor adherence, and possible cardiac ischemia or 
arrhythmia, which may contribute to poor function and poor prognosis [46, 48]. In 
addition, the regulatory feedback mechanisms involved in the maintenance of glucose 
homeostasis are defective in older people, which lead to an increased risk of 
hypoglycemia. Antidiabetic drugs with lower glycemic variability should, therefore, be 
part of the first-line treatments of T2DM in older adults. In addition, ageing is related with 
a progressive impairment in carbohydrate tolerance (possibly due to disorderly insulin 
release), reduced insulin production and reduced glucagon-like peptide 1 (GLP-1) 
secretion, increased adiposity, sarcopenia, and physical inactivity [46, 47, 49, 50]. In 
elderly patients, the relative contribution of postprandial glucose to blood glucose levels is 
higher than that of fasting glucose. Therefore, selecting antidiabetic therapies that are more 
efficacious in postprandial glucose control for older adults may also be considered for 
these patients [46]. 
1.5 Quantitative personalized medicine approaches 
Mathematical and statistical approaches that integrate information on the drugs’ PK and 
PD as well as the disease at the population and the individual patient level have been 
increasingly used in drug development and regulatory decision making since the 1990s. 
Compared to the expert consensus-based approaches introduced earlier, quantitative 
approaches typically use information on the dynamic interplay between drug(s), 
pharmacology, disease pathogenesis, and intrinsic as well as extrinsic patient factors to 
characterize and predict age-dependent changes in elderly patients and to personalize drug 
treatments in this population. The highly variable organ function(s) in the elderly 
population and the resulting variability in absorption, distribution, metabolism and 
elimination (ADME) as well as in the PD processes need to be considered to develop 
appropriate dose-exposure-response relationships. The establishment of these relationships 
is typically more problematic in elderly patients, but is important for optimal dose selection 
for this population [51]. This challenge may be met by the combined use of quantitative 
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approaches (e.g., population pharmacokinetics (PopPK) or physiologically based PK 
(PBPK) models) and prospective clinical trials. This combined approach will allow to 
identify a trial design and treatment regimen with the highest probability of maximizing 
desired effects while minimizing undesired side effects and may thus help to reduce cost 
and burden to the elderly patient. 
Figure 1-2 shows an example of how a combination of quantitative clinical pharmacology 
approaches (PopPK and PBPK models) and clinical trials can serve as a tool for 
establishing safe and effective dosing regimens for older adults. Both modeling methods 
complement each other and are adapted gradually. In a first stage, the preclinical 
information is used to facilitate the mechanistic understanding of the drug´s PK/PD 
behavior and to develop a preliminary PBPK/PD model including the physiological 
pathways identified to play a major role. Model predictions can then be used to guide the 
design of the clinical studies in an iterative manner (learning and confirming cycles that are 
used to inform both modeling approaches) and used to assist dosing decision making. Once 
the PK/PD data from the clinical trials is available, PopPK/PD analysis can then be used to 
validate the predictions and to further confirm the PBPK/PD model assumptions. This step 
will allow a better understanding of the drug’s behavior in humans together with its 
associated inter-individual variability, and can also be used as supportive evidence for drug 
labelling. The updated PBPK/PD model can then be used to bridge the PK/PD to the 
elderly population (geriatric PK/PD model) by informing the model on age-related 
physiological changes, alterations in the pathophysiology and to extrapolate the clinical 
response to streamline the design of a confirmatory trial in the population of older adults. 
Again at this stage, the PK or PK/PD data arising from a confirmatory trial can be used to 
evaluate the effects of age on the geriatric PK/PD parameters when data from different age 
populations are available, also confirming the PBPK/PD modelling outcomes, and 
allowing the selection of the most appropriate dosing regimens in different categories of 
older adults.  
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Figure 1-2  Interplay of qualitative pharmacokinetic approaches to inform and confirm 
geriatric dosing strategies during drug development.  PBPK (lower stream) 
and PopPK (upper stream) model development run in parallel during early 
clinical development, the interplay can gain importance after certain 
decision points (main development stream) in order to inform and 
streamline subsequent trials (dashed box) or clinical decisions for older 
adults. 
This approach has been extensively used in clinical drug development for children [52] and 
could also be used for extrapolation of adult dosing regimens to older adults. 
It should be noted, however, that in isolation, information on PK is of limited clinical 
utility and needs to be linked to the corresponding PD response. Whereas the impact of age 
on a drug’s PK is typically easier to assess, respective changes in PD remain understudied. 
Therefore, a robust understanding about the mode of action coupled with reliable 
appropriate measures is essential for the age-related PD assessment. Drugeffects are most 
often based on a complex molecular cascade [53]. For example, the density of receptors 
can be reduced with increasing age as shown for α-adrenergic [54] or µ-receptors [55]. It 
also seems that there is increased sensitivity to various central nervous system drugs, 
including benzodiazepines, halothane, metoclopramide, and narcotic analgesics, as patients 
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become older [56]. Whereas some of these effects can be studied directly in elderly 
patients, our understanding of many PD effects relies on extrapolated animal data [57]. 
1.5.1 Population pharmacokinetic/pharmacodynamic approaches 
The majority of the currently employed population approaches are descriptive (non-
mechanistic or empirical) in nature and use statistically robust criteria to characterize the 
data. These methods, however, can be optimized by the inclusion of physiology-related 
processes to improve their predictive performance and further increase their applicability 
[58, 59]. As an example, PK scaling approaches are intended to extrapolate the dose-
exposure relationship from a well characterized population to the special population of 
interest by defining specific physiological processes in the model. Whereas exposure 
matching using allometric scaling is most commonly employed in pediatrics [60], age- or 
organ function-based (e.g. creatinine clearance) scaling approaches are frequently 
employed in geriatrics [61]. For example, the FDA label for the anticoagulant apixaban 
[62] recommends age-, weight-, and serum creatinine-based dosing. The normal dose is 5 
mg twice daily except for patients with two of the three factors: age ≥ 80 years, body 
weight ≤ 60 kg and serum creatinine ≥ 1.5 mg/dL. Under these circumstances, the dose is 
reduced to half of the normal dose. “Scaling by size only” (i.e. allometric scaling) 
approaches typically face limitations in the presence of non-linearity. For pediatrics, non-
linearity is typically the result of enzyme ontogeny, whereas other factors, such as changes 
in body composition, play a bigger role among older adults. Ideal body weights based on 
age do not exist for geriatric patients and hypervolemic states from congestive heart 
failure, cirrhosis, and nephrotic syndrome are common. Even accurate height and weight 
measures may be unattainable in patients who are bedridden or have amputations, 
contractures or kyphosis. Therefore, a frail, medically complex 79 year-old would be more 
appropriate for the reduced dose of apixaban than a healthy 80 year old.  
Although population approaches are typically descriptive and drug-centric in nature, they 
are routinely employed for dose selection and clinical trial design. They further allow for 
evaluation of covariates, both genetic and non-genetic, in order to account for inter-
individual differences in patients’ dose-concentration-response relationships [63]. Once 
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established and qualified, population models can be used to address specific questions, 
either during drug development or in clinical practice [64]. During drug development, they 
can be applied to address specific questions on e.g. the dose-concentration-response 
(PK/PD) relationship of a drug or combination of drugs in a given patient population, 
which can then be prospectively qualified in a clinical trial setting. If linked to 
epidemiological, biological, clinical or real-world patient data, these methods can be used 
to simulate a virtual elderly patient population, which can be used to assess the benefit-risk 
relationship of a given treatment in a given patient population. One prominent example for 
the application of this innovative approach is the Alzheimer’s disease progression 
simulator. This simulator integrates patient-level data with information from the 
neuroimaging initiative database and pooled literature data in a drug-disease trial model 
[65]. This model then allows simultaneously evaluating multiple factors that contribute to 
the heterogeneity of the disease and its manifestation, which can then be used to project an 
individual patient’s disease progression. These approaches have gained popularity for 
characterizing the progression of highly heterogeneous diseases in the absence of distinct 
information on the onset and trajectory of an individual’s disease. As such, this simulator 
provides a powerful approach for enriching our knowledge on patient cohorts with small 
sample sizes, i.e., chronically understudied elderly patients. 
Given the practical limitations outlined earlier, this approach can be applied to optimize the 
clinical development of drugs in older adults, thus reducing the number of subjects to 
include in the study, as well as the number of samples per patient and the number of 
studies required to characterize drug PK/PD behavior. Combining these innovative 
simulation approaches with prospective clinical trials may therefore be helpful to establish 
respective geriatric dosing recommendations, whereas reducing cost and burden to the 
elderly patient. The use of sparse sampling designs may be a solution to improve the 
recruitment of the oldest study patients overcoming some of the barriers to participation (as 
time in the center by the accommodation of blood withdrawals in more flexible sampling 
windows, or the number of days required for participation). 
Once in the clinic, especially for those drugs with narrow therapeutic index and high 
variability (i.e. difficult to be managed in clinical settings), population models can be 
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applied in combination with posterior Bayesian estimations to integrate the underlying PK 
or PK/PD mechanism of a drug along with patient specific covariates (characteristics) to 
aid in the prediction of the right dose for each individual patient [66-73]. Ideally, these 
individualization methods for complicated drugs should be applied during drug 
development to find the right dose for the right patient prior to market entry. However, 
such pharmaco-statistical methods have found limited application at the bedside to date. 
This is primarily due to a lack of practitioner-friendly decision support tool interfaces, 
which are needed to facilitate the translation of biomarker data and other patient-specific 
information into actionable treatment recommendations, without burdening practitioners 
with the underlying technical details [74]. 
1.5.2 Physiologically based approaches 
PBPK models are set up to characterize and predict drug exposure at different target sites 
by dividing the biological system into a number of compartments, each representing a 
different organ or tissue. These organs or tissues are connected through arterial and venous 
blood flow. PBPK models consist of three distinct parts (Figure 1-3):  
1) A drug-specific component that characterizes the physicochemical properties of the drug 
(e.g., pKa, molecular weight, log P), which can be predicted on the basis of in vitro assays. 
2) A system-specific component that describes the functioning of the underlying 
physiological system, which can differ between and within species, e.g. between adult and 
elderly patients. 
3) A trial design component that characterizes the impact of intrinsic (e.g. disease state, 
genetic constitution) and extrinsic (e.g. diet, smoking, drug-drug interactions) factors on 
the drug’s PK as well as the trial design [60, 75].  
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Figure 1-3 Representation of the general building blocks which can be part of a PBPK 
model. Some components may be optional depending on the model 
considered [75]. logP: octanol/water partition-coefficient, logD: 
octanol/water distribution-coefficient, logMA: membrane/water partition-
coefficient, pKa: acid dissociation constant in log scale, pKb: basic 
dissociation constant in log scale, Km: Michaelis-Menten constant, Vmax: 
maximal rate of the reaction, Kd: dissociation constant, EHC: enterohepatic 
circulation. 
Although PBPK models have been especially used in regulatory applications to 
characterize and predict the impact of drug-drug interactions, they are becoming popular 
for testing and understanding the PK in specific populations, such as pediatrics, but also to 
perform in vitro – in vivo extrapolations, to translate the PK cross-species and within-
species as well as for pharmacogenomic purposes, evaluating the effect of organ 
impairment on drug elimination, investigations on drug absorption, and combinations 
thereof [76]. They may also serve as screening tools during early stages of drug 
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development to facilitate strategic decision-making to select those compounds with a more 
favorable PK and formulation properties [77]. 
Although PBPK approaches are uniquely positioned for evaluating the dose-exposure 
relationship in clinically understudied populations, such as pediatric patients, this approach 
has found little application for elderly patients thus far. There are some ongoing initiatives 
that attempt to expand PBPK modeling and simulation platforms to geriatrics by 
accounting for changes in the underlying physiology and for the age-related decline in the 
organ function, as well as for the influence of pathophysiological conditions [78, 79]. Once 
established and qualified, these expanded PBPK models may also serve as a platform to 
evaluate the impact of other clinically relevant factors, such as drug-drug interactions in 
elderly patients in the absence of actual clinical trial data, ideally as a basis for future 
confirmatory prospective studies. 
The subsequent next step is the use of PBPK/PD models for integrating relevant 
information on PK (e.g., changes in metabolic capacity, or transporter expression) and PD 
(e.g., changes in receptor expression and activity) in order to select an optimal treatment 
and dosing regimen [80, 81]. Thus, these PBPK/PD models can be used for the 
individualization of drug and dosing regimens in the elderly by accounting for differences 
in e.g. organ function, genetic make-up, or general physiology [82]. However, it should be 
noted that both, implementation and predictive performance of these approaches, will rely 
on the use of clinically relevant biomarkers for the elderly patient as well as on the 
suitability of the physiological database used for model development. 
1.6 Development and qualification of an elderly PBPK database 
An elderly PBPK platform combined with age-related information on pathway or target 
abundance changes can be applied to develop novel treatment strategies. However, a 
comprehensive qualification upfront is essential in order to build confidence towards any 
PBPK application. Similar to pediatrics or the adult age range, a verified and/or qualified 
elderly PBPK database can be considered as the foundation for further consideration of 
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specific diseases in the elderly PBPK approach. Such a database allows a diversification of 
age- and/or disease-related physiological alterations. Although multimorbidity hampers a 
clear disease-related pathophysiological distinction, changes due to healthy ageing can 
clearly be separated with an elderly patient PBPK approach. Once the PK alterations with 
increasing age are physiologically informed, shifts in PD patterns can be explained by the 
plain exposure-response relationship.  
1.6.1 Database development 
The integrated use of PBPK/PD and their predictive performance relies on the concerted 
use of physiological, demographic, and genetic information. These PBPK/PD models 
consequently require the use of highly curated databases, which summarize our knowledge 
on human anatomy and (patho-) physiology as well as changes thereof with age. Jadhav et 
al. outlined the steps necessary to develop and qualify a model that appropriately 
characterizes the fate of a given drug in a particular patient population [2]. In addition to 
the fate of the drug, changes in the biological systems with age need to be considered in 
order to appropriately characterize and predict the dynamic changes in the interplay 
between drug, patient and potentially disease.  
The establishment of databases for older adults is hampered by the fact that changes in the 
underlying physiology may or may not correlate well with chronological age and heavily 
depend on extrinsic and intrinsic factors. These factors are typically not normally 
distributed and can be significantly affected by comorbidity and comedication. For 
example, acute medical illness and hospitalization can profoundly affect biological ageing, 
whereas therapeutic or lifestyle interventions may lead to partial regeneration [83]. The 
rates at which anatomical, physical and cognitive impairment progresses with age differ in 
pace, which results in pharmacological heterogeneity in elderly patients. Finally, there are 
gender-specific differences in ageing that need to be considered. Whereas menopause 
represents a distinct event in women’s lives, which is associated with distinct biological 
changes in the female body, ageing is a much more heterogeneous process in men [79, 84]. 
The World Health Organization (WHO) consequently recommends ten-year age bins for 
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ageing studies to capture the various degrees of physiological and biological changes in 
this patient group [6]. 
Whereas functional, physical or cognitive age-related changes are frequently monitored in 
sizeable study cohorts, anatomical and (patho-)physiological changes are primarily 
investigated in cross-sectional studies [85]. The general lack of longitudinal data also poses 
a challenge for our ability to compare results from different studies. This becomes 
particularly apparent when today’s humans are compared to their age-matched counterparts 
from previous decades, who tended to be smaller and less obese than today’s average adult 
[86]. The comorbidity and medication profiles are also different. This phenomenon is also 
referred to as ‘secular trend’ and needs to be considered when developing a database that 
includes data from previous decades. 
1.6.2 Database qualification steps 
Once a physiological database that accounts for age-related changes in physiology has 
been established, a rigorous qualification process is needed to ensure its broader validity 
and applicability. There has been a lot of controversy in the recent years on what is the best 
approach for qualifying PBPK platforms and models, highlighting the need for well-
defined model development and qualification criteria [87]. However, this is not a new 
challenge and solutions are offered in the US Environmental Protection Agency (EPA) 
guideline [88], the European Medicines Agency (EMA) guideline [89], and the FDA 
guidance [90]. 
External model qualification is an overarching theme in all of the current best practices for 
PBPK model development and qualification. It refers to the use of one or more data sets 
that have not been used for model development to test the model’s descriptive and 
predictive performance and, thus, the assumptions made during model development. The 
same concept also applies for associated model parameters [75]. A major advantage of 
PBPK models and associated databases is that this verification step does not have to be 
performed on a one off basis, i.e. for each drug, because the underlying anatomy and 
physiology of the biological system does not change with each drug. As a consequence, a 
distinction between biological system-specific and drug-specific model components can be 
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made. Whereas biological system specific model components characterize the functioning 
of the underlying biological system, drug-specific model components characterize the 
physicochemical properties of the drug. 
Both model components can be qualified independently from one another. In other words, 
once a biological system has been characterized by biological system-specific model 
components, the PBPK model’s setup is completed through the integration of system-
independent, drug-specific parameters [91]. Of course, this concept also applies the other 
way around, e.g. by acknowledging changes in the biological system with age via the use 
of time-varying functions, while keeping the drug-specific model components constant. 
These time-dependent changes in the biological system are typically “mapped out” through 
the use of probe compounds. Changes in the probe compounds’ distribution and 
elimination patterns serve as indirect measures of changes in e.g. metabolic capacity, 
perfusion or tissue composition. 
Hence, PBPK models for selected probe drugs should be built for healthy young adults 
first and subsequently be scaled to the age-range of interest (see Figure 1-4). An 
appropriate step-by-step ADME process-driven qualification should consider the following 
elements and exclude subsequent characteristics when selecting the paradigm compounds: 
1) The first test compounds should be characteristic for the extracellular space 
(e.g. aminoglycosides, ibuprofen). This property allows for a description 
and concomitant qualification of changes in blood volume and interstitial 
space with age. Preferably, the test compounds for this step should freely 
distribute in the absence of tissue binding.  
2) Once this first task has been accomplished, the impact of plasma protein 
binding and changes therein with age can be verified in a second step 
through the use of probe compounds that show extensive plasma protein 
binding in the absence of tissue distribution. The latter will also provide an 
estimate of age-related changes in extracellular body water. 
3) As tissue concentrations and biopsy studies in elderly are rarely performed, 
changes in drug tissue distribution need to be qualified by informing the 
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age-related changes of the accountable process. Here, the changes of the 
volume of distribution can be evaluated as a measure for altered tissue 
distribution. Turnheim et al. gathered literature information on the volume 
of distribution shifts between adults and elderly which can be used as a test 
set for these steps [84]. When the reported elderly to young ratio of volume 
of distribution was related to the compound’s octanol/water partition-
coefficient (Log P value), a tendency to a gradual increase of volume of 
distribution in elderly was observed for compounds with a Log P >2 [92]. 
The reversed tendency was inferred for more hydrophilic compounds. 
Volume of distribution qualification steps as parametrized for young adults 
will be governed by the age-related changes in organ size and blood flow. 
4) Thereafter, the impact of age on elimination pathways can be qualified 
within an elderly PBPK approach. Firstly, characteristic single elimination 
pathway compounds should be selected for qualification to assess in a later 
stage the shifting extraction ratios of drugs with multiple elimination 
pathways.  
 Renal clearance mediated by a descending glomerular filtration rate (GFR) 
needs to be qualified by testing hydrophilic drugs solely eliminated by 
filtration without subsequent reabsorption or secretion processes.  
 Hepatic elimination can be governed by the hepatic perfusion in case of high 
extraction drugs (e.g. propranolol, metoprolol, morphine) or by the intrinsic 
clearance mediated by a certain enzymatic process besides shifts in the 
unbound fraction for low extraction drugs (CYP-paradigm substrates). 
Qualification should proceed via single-elimination pathway compounds. 
Multiple pathway elimination compounds can serve for additional 
assessments.  
5) Once the major systemic processes driving distribution, metabolism and 
excretion have been qualified, the following step is to assess factors 
influencing the oral absorption. Gastric emptying and transit time or passive 
absorption due to alterations of the surface area may be qualified using 
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relatively small, Biopharmaceutics Drug Disposition Classification System 
(BDDCS) class I molecules such as paracetamol or caffeine [93]. In addition 
first pass effects, especially intestinal metabolism can be characterized.  
 
Figure 1-4  Database qualification and verification steps. Bars represent the body 
composition of a 30 year old individual, a septuagenarian, and a 
nonagenarian male with their relative organ volumes as part of the total 
body weight. 
Once established and qualified, a major advantage of PBPK models is their ability to 
characterize and predict the dynamic interplay between multiple biological processes, such 
as the interplay between multiple metabolic enzymes. This ability can also be used to 
evaluate the impact of ageing on a drug’s hepatic clearance. Clearance of drugs which are 
excreted to more than 70 % from blood or plasma upon passage through the liver (i.e., high 
extraction drugs) is mainly restricted by the liver blood flow, whereas clearance of low 
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extraction drugs (excreted to less than 30 %) is dependent on the metabolic capacity of the 
eliminating organ, in this case, the liver. Whereas the majority of studies does not report a 
significant impact of age on enzyme-mediated processes, the situation is heterogeneous for 
elimination via phase 1 and 2 metabolism [94]. One of the major CYP enzyme complexes, 
the 2C subfamily, is involved in the metabolism of frequently used drugs in elderly 
patients, such as anticonvulsants and non-steroidal anti-inflammatory drugs [95]. 
CYP2C19 is also needed for the enzymatic bioactivation of clopidogrel, a widely used 
anticoagulant, into its pharmacologically active metabolite [96]. Whereas the expression of 
CYP2C9 and CYP2C19 appears to be unaffected by age, the respective clearance values of 
drugs eliminated via these pathways seem to be decreasing. The CYP2D subfamily, on the 
other hand, seems to maintain its metabolic activity with increasing age [95, 97, 98]. The 
situation seems less clear-cut for the CYP3A4 subfamily since contradictory reports exist 
in the literature [95]. In addition, conjugation, acetylation, glucuronidation and sulfation 
are generally not influenced by age [99]. Whereas different metabolites can be formed in 
children compared to adults, this does not seem to be the case in the elderly [95]. 
The selection of probe compounds and the sequence described above is certainly idealistic. 
It is consequently possible that not all steps are applicable to all/other specific populations, 
e.g., due to the lack of appropriate data. However, it should be aimed for both, a general 
physiology verification and specific ADME process-driven qualification procedure once a 
new specific population PBPK database is established and prior to its use for modeling 
purposes. Qualification for intended use is especially important, when considering high 
impact applications [89]. Figure 1-4 depicts the database, as the backbone of a platform, 
qualification and verification steps. The described procedure defines criteria towards a fit-
for-purpose characterization of a PBPK specific population database requiring a reliable 
standard PBPK framework. However, the qualification of the specific model for each 
compound should be predefined and considered with strong criteria mainly for drugs with 
narrow therapeutic index. For such purpose, the best practice of model assessment 
proposed by the WHO [100] is frequently applied. A recent investigation revealed a lack of 
consensus in the model qualification and verification practices for the majority of peer-
reviewed PBPK models published between 2008 and 2015, where 56 % of the articles did 
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not pre-define the criteria to evaluate the successful performance of the model for it 
specific purpose [101]. Importantly, for narrow therapeutic index drugs, a 30 % or 2-fold 
deviation in the prediction of plasma concentrations or PK parameters were applied as 
qualification criteria but only in less than half of the studies whereas the other half had no 
criteria. These results highlight the need for consensus to decide on best practices to 
qualify PBPK models. In addition, the criteria actually used for model evaluation might be 
too soft for narrow therapeutic index drugs for which failures in the selection of the 
optimal dose can have fatal consequences. It is important to remark that the level of 
qualification determines the confidence into the extrapolative power, especially, when the 
prediction requires increased prior system knowledge. Moreover, when the model is going 
to be used to impact drug labelling, as for example to decide the dose recommendation for 
older adults, it is very important to ensure its adequate performance for this purpose, as the 
model-based decision taken will affect clinical practice and will have direct consequences 
for the patient.  
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2 Scope and objectives of this work 
The goal of this study is the development, qualification and application of a PBPK 
population model for elderly individuals that considers typical (patho-) physiological 
conditions associated with ageing. This study was conducted in three projects.  
In the first project, the literature was reviewed with a focus on age-related (patho-) 
physiological changes in European elderly subjects. The goal of this part was to extend an 
existing PBPK database for European adults based on the International Commission on 
Radiological Protection (ICRP) report [102] to encompass the full course of healthy 
ageing, through to the age of 100 years. 
In the second project, paradigm compounds were identified to qualify the capability of the 
PBPK population model and to predict distribution and elimination of these compounds. 
The developed elderly PBPK database was used to predict plasma drug concentration over 
time profiles for the single elimination pathway drugs morphine and furosemide. 
Calculated PK parameters were compared to literature findings to statistically evaluate the 
predictive performance of the PBPK population model. 
In the final project, reliability of predictions outside the simulated adult age range towards 
the extremes of ages for the multi-elimination pathway compound ciprofloxacin was 
assessed. Mean data of published clinical trials were identified and used for the 
ciprofloxacin PBPK model building, simulation and verification process. Whereas model 
simulations were conducted within the model building scenario, predictive performance on 
both ends of the age scale was assessed using data on individual patients from multiple 
trials. 
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3 Methods 
3.1 Software programs 
The PBPK modeling software Open Systems Pharmacology suite (OSP Suite, www.open-
systems-pharmacology.org) was used for all whole-body PBPK models [75]. It comprises 
the PBPK software tool PK-Sim® version 7.2.0 and the systems biology platform MoBi®, 
which allows in-depth mechanistic modeling. Parameter optimization was conducted with 
the MoBi® Toolbox for MATLAB® version 7.2.0, release 2013b (The MathWorks, Inc., 
Natick, MA, USA; www.mathworks.com/products/matlab.html) using the Monte Carlo 
algorithm of the statistical toolbox. MATLAB® was also used for data processing, 
statistical analysis, PK parameter calculation and the creation of graphics. Scan Data, an 
in-house developed software tool of Bayer Technology Services, was used to extract data 
from published figures. 
3.1.1 Open Systems Pharmacology suite 
The Open Systems Pharmacology suite is an open source PBPK software tool for which 
the source code is publicly available. This specialized software platform provides a generic 
PBPK model framework for the physiology of predefined species and populations. It 
includes physiological databases that are combined with compound- specific information 
as well as biometric data, and are used to parametrize a PBPK model on a whole-body 
level. 
Anatomy and physiology 
The generic PBPK software tool represents 18 organs and tissues and provides a large 
dataset for age-dependent anatomical and physiological parameters over the entire human 
life span [75]. The tissues and organs are characterized by its anatomical and physiological 
properties. Therefore, tissue size and composition, as well as perfusion rates are available 
within the software database. Within the PBPK framework, an organ is structurally 
represented in sub-compartments, namely the intracellular, interstitial and vascular space. 
The organs are connected by three blood pools. The arterial and venous blood pool 
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summarize the in- and outflux of each organ, whereas the portal vein adds up all blood 
flows emanating from the gastro-intestinal (GI) tract organs.  
Drug properties 
Drug-specific properties are mainly characterized by physicochemical parameters which 
can usually be obtained by in vitro measurements. Key parameters such as lipophilicity or 
molecular weight are used to estimate membrane permeability or distribution behavior. 
Drug solubility determines the availability for absorption of a compound in the GI tract, 
whereas pKa values are used to calculate pH-dependent solubility changes. 
Formulation 
In vitro dissolution profiles in biorelevant media, such as the Fasted State Simulated 
Intestinal Fluid (FaSSIF) and the Fed State Simulated Intestinal Fluid (FeSSIF), have been 
established. When used in standardized in vitro dissolution test methods, such media allow 
simulating the in vivo disintegration and dissolution behavior of orally administered dosage 
forms [103]. This dissolution profiles together with drug PK profiles can be used to 
establish an in vitro–in vivo correlation (IVIVC). The dissolution profiles can be 
represented by different kinetic functions, for which the Weibull function is the most 
common. This function is characterized by a shape parameter b corresponding to the 
dissolution shape and indicating the course of the dissolution being either exponential 
(b = 1), sigmoid (b > 1), or parabolic (b < 1). The dissolution time (50 % dissolved) defines 
the time after the start of dissolution, when 50 % of the administered dose is dissolved and, 
thus, corresponding to the scale parameter of the Weibull function. 
Distribution models 
Small molecules can generally distribute in all kinds of tissues in the body. 
Experimentally, the quantification of this compound-specific distribution is very labor-
intensive. A major advance in PBPK modeling came with the use of calculation methods 
for organ/plasma partition coefficients describing the concentration ratios at steady-state 
between tissue and plasma. Various concepts for mechanistic correlations have been 
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developed for the in silico estimation of organ/plasma partition coefficients. Based on 
tissue composition, these coefficients can account for the distribution between drug-
binding tissue constituents, such as proteins or lipids, on the one hand, and water on the 
other. Although the principles are very similar in all cases, the calculation methods deviate 
with respect to the kind of parameters used and resulting in different values of tissue 
concentration. All known partition coefficient models assume that tissue is composed of a 
limited number of components, and they all include partition coefficients for water/protein 
and lipid/water. These two partition coefficients are usually calculated from so-called 
surrogate in vitro measurements. The total organ/plasma partition coefficient is then 
calculated as a weighted sum of the partition coefficients for all of the components; the 
weights are the volume fractions of each component. Importantly, the distribution of a drug 
within aqueous and organic tissue components is always assumed to be homogenous and 
passive. The most widely used concepts for calculating organ/plasma partition are briefly 
introduced below: 
 Poulin et al. calculate the lipo-hydrophilicity of tissue as a mixture of neutral lipids, 
phospholipids, and water [104, 105]. In addition to the volumetric tissue 
composition, fraction unbound (fu), lipophilicity (log P and log D), and pKa are 
used as compound-specific input parameters. Here as well as in all the following 
concepts for the calculation of organ/plasma partition coefficients, fu quantifies 
specific reversible binding to proteins in plasma and tissue, whereas lipophilicity 
accounts for nonspecific binding to lipids.  
 Rodgers et al. extended the concepts of Poulin et al. to electrostatic interactions at 
physiological pH [106, 107]. These include binding of ionized and unionized drugs 
to acidic phospholipids and neutral lipids, respectively. Also electrostatic drug 
interactions with extracellular proteins are taken into account. Consequently, the 
partition coefficients are calculated taking into account the lipophilicity and pKa 
value of the drug and the pH values of the tissues. 
 Willmann et al. extended the concept of Poulin et al. by additionally considering 
proteins as a tissue component [108, 109]. Moreover, Willmann et al. use 
membrane affinity (log MA) to quantify partitioning between water and an artificial 
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cellular membrane as a measure for lipophilicity by using an empirical equation 
[110]. This model is implemented in the PK-Sim software as the PK-Sim standard 
distribution model. 
Parameter identification 
In case experimental data are given, the reverse question for the true input parameters 
needed to achieve a simulation with output curves corresponding to the given experimental 
data might occur. This reverse problem is called parameter identification. Since the 
parameter identification run deals with an optimization problem, the residuals between 
observed data and corresponding simulation output should be minimized by varying the 
selected input parameters in a given range. A variety of algorithms exists to solve 
optimization problems, however, only the Monte Carlo algorithm was applied for the 
modelling tasks in this thesis. The required effort and the quality of the solution depend on 
several factors, e.g. number and bounds of the input parameters of interest, complexity of 
the model or the quality of start values for the input parameters. 
3.2 Development of an elderly PBPK population model 
3.2.1 Collection of data on anthropometric, anatomical and (patho-) physiological 
changes with age 
The previously established database of Thompson et al. [85] provided a sound basis for 
establishing a PBPK model for the elderly age range, but needed extension. Exact data on 
sex, race and disease diversification, as well as details regarding covariates, are pivotal for 
establishing predictive PBPK models. Body weight and height or body mass index 
(anthropometric measures) as well as anatomical and (patho-) physiological parameters 
were searched for in PUBMED using the filters ‘Species-Human’ and ‘Ages-Aged: 65 + 
years’. Additional terms such as ‘age’, ‘ag(e)ing’, ‘elderly’ and ‘old’ were added for 
refinement where needed. For parameters that yielded only sparse literature in this initial 
search, an additional screen was performed in Google Scholar and MEDPILOT. Inclusion 
criteria were (a) clear assignment of sex, (b) clear assignment of race, (c) a comprehensible 
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statement regarding the method of analysis, and (d) ruling out of effects of medication or 
disease on subjects’ physiology. Studies that included longitudinal surveillance were 
preferred. Since in vivo measurements of organ size are not directly comparable to 
measurements obtained from autopsy reports, the former were taken into consideration 
only for the evaluation of muscle, fat, and blood flow [111]. Furthermore, for each study 
cohort the available details about body composition, for example fat mass, fat-free mass 
and lean-body mass, as well as total body water were extracted and used as covariates. A 
second literature screen was performed for the ageing that occurs between 30 and 65 years 
of age (younger adults), in order to refine the existing physiological information and, thus, 
ensure that the data on ageing were continuous for the purpose of modeling. 
In total, 19 studies from the database of Thompson et al. were used. After the second 
literature search data from 97 additional studies was added to build the ageing PBPK 
model. 
3.2.2 Data processing 
Since biological and chronological ageing differ, the data was analyzed in 10-year age 
bins, as recommended by the WHO [6]. The gathered literature was analyzed such that a 
polygonal function could be established, by defining ten-year standards for organ and 
blood-flow rates. In most cases values were reported as a geometric mean (?̅?𝑖), with the 
corresponding standard deviation (𝑆𝐷). Extracted organ weights were processed to an 
overall mean (?̅?) by applying the following equation: 
?̅? =
∑ 𝑛𝑖?̅?𝑖
𝑖
𝑖=1
∑ 𝑛𝑖
𝑖
𝑖=1
 
(Eq. 1) 
 
Here, ?̅?𝑖 is the mean of the i
th study and 𝑛𝑖 represents the number of test persons in that 
study. In order to compute the overall standard deviation (𝑆𝐷) for a certain age bin, the 
following equation was used considering the standard deviations from each study (𝑆𝐷𝑖): 
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𝑆𝐷 = √
1
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) 
(Eq. 2) 
 
In cases where the reported study mean and standard deviation define a lognormal 
distribution, the associated geometric mean value ?̅?𝑖 and standard deviation 𝑆𝐷𝑖 of the 
lognormal distribution were calculated to obtain comparable parameters, as follows: 
?̅?𝑖 = 𝑒
?̅?𝑖+
𝑆𝐷𝑖
2
2  (Eq. 3) 
 
𝑆𝐷𝑖 = √(𝑒𝑆𝐷𝑖
2
− 1) ∙ 𝑒2?̅?𝑖+𝑆𝐷𝑖
2
 
(Eq. 4) 
3.2.3 Workflow for elderly PBPK model development 
The workflow for this study is described in Figure 3-1. Since biological and chronological 
ageing differ, the data was analyzed in 10-year age bins, as recommended by the WHO [6] 
and interpolated linearly. Thus, the data was pooled into 7 age bins covering the age range 
of 30 to 100 years, in order to derive the distinctive age-related body composition along the 
lifespan throughout the European dataset. In cases where the pooling did not lead to an 
acceptable description of the organ ageing process because of insufficient data, additional 
data from North American and Australian subjects were included. 
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Figure 3-1  Workflow for the knowledge-driven physiologically based pharmacokinetic 
(PBPK) ageing approach.  The solid line represents the work of the current 
study; the broken line depicts the potential usage of an ageing PBPK model. 
ADME: the absorption, distribution, metabolism and excretion processes; 
PK: pharmacokinetics. 
Body composition for the same age might also vary between different historic time periods 
due to variations in anthropometric measures or potential impact of national nutrition [86]. 
In order to cope with these secular trends of study data published over the course of several 
decades, a reference anthropometric measure was generated for the age range of the ageing 
model considered for each 10-year time period over the past 60 years. It was applied 
whenever study data were stated without the corresponding subjects’ anthropometric 
measures, to normalize organ weights for the scaling approach based on Willmann et al. 
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[112]. The underlying assumption of this approach is the correlation between organ sizes 
and their perfusion rates with body height, weight or mass index for a given age, gender 
and race. Starting from a mean individual, the anatomy and physiology of a target 
individual is scaled based on its anthropometric deviation from the mean individual.  
The reported organ volumes originated mostly from autopsy studies, and thus represent 
cellular mass. They were used mainly in determining respective organ volumes, specific 
vascular fractions, the interstitial fractions, and the cytosolic proteins [113]. 
For each age bin the processed organ masses were summed up and found to reach 91-95 % 
of the body weight; the gap accounts for smaller organs not captured in this model, for 
example the adrenal glands, thyroid, tongue and prostate. In order to reach the final body 
weights, muscle and fat mass was increased in proportion to this gap. 
Age-related changes in organ blood flow rates were accounted for as changes in cardiac 
output. Blood flow rates and cardiac output values were taken from the literature. The sum 
of all organ blood flows should be equal to the cardiac output. Thus, the unknown age-
dependent organ blood flows were scaled with regard to their relative cardiac output 
contributions in adults as postulated by the ICRP report [102] to match the age-related 
changes in cardiac output. In these cases, the ratio between organ blood flow rate and 
cardiac output remained the same over the age span. 
A virtual 30 year old individual was created using PK-Sim® [112]. Based on this 
individual, a virtual population [n=5000] for each sex was generated by only predefining 
the desired age range from 30 to 100 years. This population was used for checks of 
physiological consistency. Body water distribution and single, simulated sizes for each 
organ by the newly age-informed virtual population were compared to unused datasets or 
nomograms.  
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3.2.4 Database qualification 
In order to assess the predictive ability of the knowledge-driven PBPK ageing approach, 
two compounds with different major elimination pathways were selected: the high-
extraction drug morphine, which is eliminated up to 90 % by hepatic metabolism, and 
furosemide, which is eliminated mainly by the kidney. Model building parameters are 
listed in Table 3-1. The literature was screened for observed plasma concentration-time 
profiles and the corresponding PK parameters in healthy European volunteers ranging from 
young adults to the extremely elderly. Group data were preferred, but whenever individual 
data with a description of the subject’s anthropometric measures was provided, 
corresponding virtual individuals were created. In case of missing anthropometric 
information, age-respective mean values were used. The reported intrinsic clearance values 
were used for the young adult simulation. Predictability of age-related impact on PK was 
then assessed in three steps. First, simulated plasma concentration-time profiles in the 
elderly were compared to observed profiles. In the second step, age-related changes in 
elimination were evaluated from shifts in elimination half-life (t1/2). Finally, altered body 
composition and changes in the relationship between total body water and fat mass were 
assessed by calculating volume of distribution at steady state (Vss) performing a non-
compartmental analysis. Two-sided 1.25-fold and 2-fold levels of prediction accuracy for 
the ratio of predicted to observed values for plasma concentrations, t1/2 and Vss were 
applied for each compound.  
Morphine 
Morphine is a strong opioid analgesic indicated for cancer pain. Because of its basic 
alkaloid structure, morphine has a low lipid solubility. It is metabolized by several 
pathways leading to dihydromorphinone and normorphine. The plasma protein binding to 
albumin, globulin and glycoproteins of morphine is independent of its exposure. The drug 
has a high hepatic extraction ratio that is not affected by dose [114]. In the PBPK model, 
the metabolism of morphine was implemented as an intrinsic hepatic elimination process 
and thus affected only by age-dependent changes of hepatic blood flow and tissue size. 
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Furosemide 
The loop diuretic agent furosemide induces the production of urine from water and sodium. 
It is moderately lipophilic and undergoes only minor metabolism in the liver, which is 
incorporated into the PBPK model as a non-specific intrinsic process. As furosemide is 
highly bound to albumin, renal elimination is driven mainly by tubular secretion, which 
delivers the compound to its site of action. Although clearance is transporter driven, the 
magnitude is accepted to be dose-linear for the therapeutic range [115]. Thus, tubular 
secretion was implemented as an intrinsic process in addition to passive glomerular 
filtration. Changes in kidney tissue and the vasculature are known to alter renal elimination 
of furosemide, and thus delivery to the target located at the luminal side of the sodium-
potassium-chloride cotransporter in the loop of Henle [116]. 
Table 3-1  Overview of input parameters for the PBPK models of furosemide and 
morphine 
Parameter Furosemide Morphine 
Physicochemical   
Molecular weight (g/mol) 330.74 285.30 
Log P 1.75a 0.89 [117] 
pKa  4.25 (acidic)a 7.90 (basic)a 
Fraction unbound 0.03 [118] 0.80 [119] 
   
Distribution   
Partition coefficient model Willmann et al. b [108, 109] Willmann et al. b [108, 109] 
Cellular permeability model Willmann et al. b [108, 109] Willmann et al. b [108, 109] 
   
Elimination   
GFR fraction 1 1 
Renal clearance 
(mL/min/kg) 
1.61 [120] - 
Hepatic clearance 
(mL/min/kg) 
0.77 [120] 19.10 [119] 
Log P: octanol-water partition coefficient, pKa: acid dissociation constant in log scale, GFR fraction: defines, if drug is 
only filtrated (1), reabsorbed (<1) or additionally secreted (>1) 
a Information obtained from Drugbank (http://www.drugbank.ca) 
b Willmann et al. is defined as the PK-Sim® standard 
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Statistical analysis 
After the PBPK model was built using observed adult data, studies in the elderly were 
simulated by creating virtual individuals matching anthropometric measures of the clinical 
study populations or individuals. Virtual individuals were generated by two means: using 
either the physiology of a young adult as an uninformed simulation; or using the 
physiological information for the elderly gathered within this study as an age-informed 
simulation. The precision of simulated PK parameters was evaluated with the root mean 
squared prediction error (RMSE) and the bias based on the mean prediction error (ME) by 
weighing the residuals by the reciprocal concentration. In order to estimate the 
improvement when applying the age-informed physiology for the predictions of the elderly 
data set, a relative bias was calculated by subtracting the informed from the uninformed 
predictions (ΔME). The same procedure was used to calculate the precision difference 
(ΔRMSE). The change was also set into relation to the uninformed predictions and 
expressed in percent. 
3.3 Application of a lifespan PBPK population model for 
ciprofloxacin 
3.3.1 Available data 
At first, a comprehensive review of the published literature was performed focusing on 
pharmacokinetic information on ciprofloxacin following intravenous and oral 
administration in mainly healthy adults. Studies containing measured plasma 
concentration-time profiles, urinary excretion or the fractions for different elimination 
pathway contributions were gathered and extracted, respectively. In a second search step, 
pharmacokinetic studies in pediatrics and geriatrics were screened and analyzed. In case 
studies were conducted in patients, the impact of respective diseases or health condition on 
the pharmacokinetics in adults was reevaluated and excluded if confirmed. Since cystic 
fibrosis (CF) was identified as a covariate in a population pharmacokinetics analysis [121], 
studies including CF patients were excluded as well as studies in patients suffering from 
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sepsis [122, 123], organ impairment [124, 125], ectomy or observed during any other 
surgical procedures [126, 127]. Cancer patients were not considered due to contradicting 
observations derived from small study groups in this highly heterogeneous patient group 
[128, 129]. Furthermore, the study population should clearly represent a well-defined age 
group to allow an age-related PK assessment.  
In total, 122 clinical studies reporting ciprofloxacin adult PK data published between 1983 
and 2017 were screened, out of which 69 were considered in this study. The identified 
studies are listed in the Appendix (Table A-1 and Table A-2). For the pediatric age range, 4 
studies were identified, whereas 14 studies were gathered for the geriatric age group. These 
studies are summarized in Table 3-2. 
In addition to mean study data, individual plasma concentration-time profiles were 
gathered for pediatric and geriatric patients. Adult and geriatric individual plasma 
concentration-time profiles were obtained from three trials [130-132]. The 22 older adults 
were aged between 60 and 74 years of age and received 400 mg ciprofloxacin TID 
intravenously and a single 250 mg dose orally.  
 
Table 3-2  Summary of clinical studies of ciprofloxacin sorted by dose in pediatrics 
and older adults used to define the prediction scenarios in this study and to 
assess the predictive performance of the ciprofloxacin PBPK model 
Population Dosage 
Reference 
Age 
[Years] 
Females 
[%] 
Weight 
[kg] 
Height 
[cm] 
n Route Formulation 
Dose 
[mg] 
Regimea 
Pediatrics 
2-15 35   60 iv suspension 10+ BID [133] 
0.7-7.1 54 14.3 
(6.4-23.8) 
90.5 
(65-126) 
16 iv suspension 10+ TID [134] 
2-15 35 72.1 
(66.8–78.8) 
 60 po suspension 10+ BID [135] 
5-14* 43 5.5 
(4.1-7.1) 
 7 po unknown 15+  [136] 
1-5 43 11.8 
(8.3-17.3) 
 7 po unknown 15+  [136] 
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Population Dosage 
Reference 
Age 
[Years] 
Females 
[%] 
Weight 
[kg] 
Height 
[cm] 
n Route Formulation 
Dose 
[mg] 
Regimea 
Elderly 
66-90 78 66 
(49.1-102.7) 
168 
(149-182) 
9 iv unknown 200  [137] 
57-84 0 69 
(52-80) 
168 
(155-175) 
14 iv unknown 200  [138] 
67-83 0 72 
(50-80) 
 14 iv solution 200  [139] 
65-87 35 65.6 
(42-101) 
 17 iv solution 200 BID [140] 
44-96 95.5 67.09 
(40-111) 
160 
(150-178) 
44 iv solution 200 BID [141] 
63-76 0 76.9  8 iv solution 250  [142] 
67-83 0   6 iv solution 400 TID [130] 
67-83 100   6 iv solution 400 TID [130] 
60-73 40 65 
(57-74) 
 10 po tablet 250  [131] 
71-86 0 65.1 
(51-79) 
161 
(154-170) 
12 po tablet 500  [143] 
63-76 0 76.9  8 po tablet 500  [142] 
65-87 35 65.6 
(42-101) 
 17 po tablet 500 BID [140] 
63-76 0 76.9  8 po tablet 500 BID [142] 
68-76 0 62.1 
(47.7-69.5) 
 6 po tablet 750 BID [144] 
61-82 0 70 
(58-80) 
 15 po tablet 750  [145] 
64-92 40 56.5 
(43.6-95.7) 
 20 po tablet 750 BID [146] 
58-77 10 64.3 
(50-93) 
 10 po unknown 750  [147] 
66-90 78 63.4 
(49.1-66.6) 
168 
(149-182) 
6 po unknown 750  [137] 
Values are expressed with ranges (in parentheses) 
a Frequency of dose administration. BID twice a day; TID three times a day 
* Age expressed in weeks 
+ Dose in mg/kg bodyweight 
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For the children, a previously published data-driven population modelling dataset was used 
[121]. CF patients were discarded from the dataset resulting in 236 (143 male and 93 
female) children included for this study. The individuals were treated for various infections 
and received 10 mg/kg twice a day (BID) orally or three times a day (TID) intravenously. 
In total, 763 plasma concentration-time data points sampled in non-CF children were 
available for this study.  
3.3.2 PBPK model development of ciprofloxacin 
Intravenous administration 
The ciprofloxacin PBPK model building process was performed stepwise as depicted in the 
workflow scheme shown in Figure 3-2. First, physico-chemical data available in the 
literature were incorporated into an initial adult PBPK model. Reported mass balance data 
suggest 65.3% urinary and 11.4 % fecal excretion of unchanged ciprofloxacin after seven 
days following intravenous administration, whereas 19.6 % of the dose accounted for 
metabolites and 3.8 % were unaccounted [148]. Considering the reported mass-balance 
information, two first-order hepatic and two renal clearance processes were implemented 
in the model. Renal clearance processes include a passive GFR and an unspecific first-
order tubular secretion to account for the renal clearance exceeding GFR. The active 
process was left unspecific although contribution of several transporters such as the ATP-
binding cassette (ABC) drug efflux transporters [149] or organic anion transporters (OAT) 
[150] are discussed but not finally elucidated. Besides a first-order hepatic metabolism 
mediated by CYP1A2 [151], an additional active, unspecific GI-tract secretion was 
included. This process encounters the rapid GI transcellular and biliary secretion of 
ciprofloxacin [148, 152, 153]. The resulting luminal concentrations were consolidated by a 
continuous fraction of bile released into the gut. Less than 3 % of the mass balance 
information was not accounted for and proportionally distributed across all elimination 
processes. 
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Figure 3-2 Schematic workflow of the ciprofloxacin PBPK model building and 
including estimated parameters, incorporated data and model verification. 
iv: intravenous, po: per os. 
Oral administration and formulation 
The mechanistic absorption model in PK-Sim® allows the identification of different factors 
contributing to the rate-limiting processes affecting the oral absorption of ciprofloxacin. 
Therefore, active uptake and dissolution profiles were estimated based on concentration-
time profiles after oral administration of the solution, suspensions and immediate release 
formulations containing 100 to 750 mg active ingredient. Since the intestinal permeability 
(Pint) is a global parameter of the GI tract in PK-Sim
®, the effective surface area 
enhancement factor (AeffFactor), a multiplier of Pint in each intestinal segment of the GI 
tract [154], was estimated for each segment. By this, segmental net absorption impacted by 
active influx or efflux and deviating from the estimated passive absorption can be 
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accounted for by a respective increase or decrease of each AeffFactor. Finally, in vivo 
dissolution was informed for each dosage form and dose level. The formulation and 
subsequent granulate disintegration and dissolution for each dosage form was estimated 
and assumed to follow a Weibull function. Similarly to parenteral administration, observed 
plasma concentration-time profiles following single and multiple administrations of oral 
doses were pooled for parameter identification. This allowed a separation of formulation- 
or GI tract-dependent influences.  
3.3.3 PBPK model verification 
In order to verify the adult intravenous and oral administration model of ciprofloxacin, 
population simulations in adult reference populations were compared to independent 
datasets (Table A-1 and Table A-2). Population simulations for each study and dosing 
scenario contained 1000 individuals matching the respective study characteristics. The 
performance of the adult ciprofloxacin PBPK model was assessed visually by goodness-of-
fit plots of mean plasma concentration-time study data. Furthermore, the infinite and 
timely limited area under the plasma drug concentration-time curve (AUCinf and AUC0-tau) 
and, additionally for oral administration, the maximum plasma concentration (Cmax) were 
determined using the non-compartmental approach of PK-Sim®. Mean model simulations 
were compared to mean literature observations. For the PK parameters ratio tests, model 
performance was evaluated by applying the bioequivalence criteria of 1.25-fold and the 
common 2-fold criteria [100] for simulation scenarios inside and predictions outside the 
model-building age range.  
3.3.4 Scaling of the adult model for predictions in pediatric and geriatric patients 
Once the final adult ciprofloxacin PBPK model was verified, exposure resulting from 
different dosing scenarios for both ends of the age scale outside of the previously simulated 
range were predicted by applying the underlying anatomical and physiological age-
dependencies, as well as age-related clearance and protein binding information [79, 113, 
155]. The predictions were carried out without any adjustment of substance-specific 
parameters defined for the adult reference ciprofloxacin model. 
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Scaling of the implemented clearance processes to the pediatric population age range was 
based on a previously published analysis [155]. For the scaling to the older adults, the 
active tubular secretion process was assumed to decrease proportionally to the GFR with 
increasing age. Therefore, the ageing function of the implemented unspecific tubular 
secretion was linked to the ageing GFR [79]. The hepatic elimination processes mediated 
by CYP1A2 and the unspecific biliary secretion were scaled in comparison with adult 
capability on a per-organ weight basis for the elderly population. This indirect scaling 
considered the age-dependent changes in liver size and perfusion, protein binding and 
hematocrit [79]. 
Formulation information derived during the model building process for adults were carried 
forward for the predictions in pediatrics and older adults. Age-dependent information on 
gastric emptying time, the pH of the GI tract, small intestinal transit times and the 
intestinal surface area were applied as defined in the underlying Open Systems 
Pharmacology database and published previously [156]. Since the specific transporters 
contributing to absorption and elimination of ciprofloxacin have not been fully elucidated 
yet, the effect of the maturation and ageing processes on these pathways is unknown. The 
resulting uncertainty can be minimized based on respective GI tract measure changes over 
age since transport processes are normalized to the surface area [154].  
The scaled prediction scenarios were generated based on available literature data for 
clinical observations in children and older adults summarized in Table 3-2. Whenever the 
specific formulation administered was not stated in the respective study, the use of a single 
immediate-release tablet for the respective fixed dose and a solution for a body weight-
based dose was assumed for the prediction. 
The previously described model verification tests were also performed to allow a 
predictive performance analysis for scaling to the investigated age ranges. Additionally, 
AUC and Cmax predictions over the entire lifespan were compared to clinically observed 
data. 
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3.3.5 Sensitivity analysis 
The impact of certain parameter changes was estimated in a sensitivity analysis for 
simulated Cmax following oral administration and AUC for representative individuals 
characterizing different regions in parameters’ space. Investigating the influence of 
parameters on outputs provides valuable information on model performance, reliability, 
and significance of the results achieved.  
The sensitivity analysis covered the entire age range assessed in this simulation study and 
was calculated for all 136 non-derived model parameters. The remaining parameters in the 
PBPK model were derived from these and were therefore investigated implicitly. Age 
classes were defined following the FDA binning [52] for the pediatric age range and 
continued with ten-year age steps from 30 years to the oldest old with testing the mean 
individual of each age bin.  
The total sensitivity of the PBPK model is calculated by adding up each sensitivity of all 
parameters. In this analysis, parameters contributing to reach a cut-off defined by capturing 
90 % of the cumulated total sensitivity were discussed. Therefore, parameter sensitivities 
were added up in a descending order starting with the parameter with the highest 
sensitivity until 90 % of the cumulated total sensitivity was reached. The more parameters 
needed to achieve the cut-off criteria, the better the robustness of a PBPK model. In case 
only a few parameters are needed, these should be well informed in order to rely on 
subsequent predictions. 
Sensitivity analysis was performed numerically by varying each parameter separately with 
the factors 1/1.1, 1/1.05, 1.05, and 1.1. Individual sensitivity was then calculated as the 
slope of the linear regression line through the relative pharmacokinetic parameter changes 
in dependence of the different parameter variations. In other words, the sensitivity S was 
calculated for the representative virtual individuals detailed above as the average for the 4 
perturbations Δ of different magnitude according to 
𝑆𝑖,𝑗 =
∑
∆𝑘𝑃𝐾𝑗
∆𝑘𝑝𝑖
∙
𝑝𝑖
𝑃𝐾𝑗
𝑛
𝑘=1
𝑛
 
(Eq. 5) 
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with n = 4 and PK standing for the two (i.e. j=1,2) pharmacokinetic parameter outputs, p 
standing for the different parameters (i=1,2,…,136), and 𝑘 representing the number of 
tested individuals. The pi/PKj-factor serves as normalization to the nominal values, which 
is important when comparing the influence of different characteristics and parameter 
values. Thus, the sensitivity values are dimensionless quantities. By this, a sensitivity of -
1.0 implies that a 10% increase of the parameters, leads to a 10% decrease of the 
pharmacokinetic parameter value, and a sensitivity of +0.5 implies that a 10% increase of 
the parameters, leads to a 5% increase of the pharmacokinetic parameter value. 
For each pharmacokinetic parameter output (PKj) and parameter (pi), maximal sensitivity 
values were defined as the maximum of the absolute sensitivity value for the set of all 
individuals Ind: 
𝑆𝑀𝑎𝑥,𝑖,𝑗 = max
𝑘
{|𝑆𝑖,𝑗,𝑘|: 𝑘 ∈ 𝐼𝑛𝑑} (Eq. 6) 
The parameters were then sorted in descending order according to 𝑆𝑀𝑎𝑥,𝑖,𝑗. Mean 
parameter sensitivity values and their standard deviations were defined accordingly. 
For each individual k, the variances of the sensitivity values were cumulated in order of 
their sorting defined above, according to 
𝑆𝐶𝑢𝑚,𝑘,𝑙,𝑗 =  
∑ |𝑆𝑖,𝑗,𝑘|
𝑙
𝑖=1
∑ |𝑆𝑖,𝑗,𝑘|
136
𝑖=1
 (Eq. 7) 
with l=1,…,136. The cumulated sensitivity as defined above includes normalization to the 
absolute total sensitivity. Therefore, the normalized total sensitivity Stotal = SCum,k,136 j equals 
to 1. A cut-off is defined by capturing 90 % of the cumulated total sensitivity. Since the 
sum of parameters needed to reach the cut-off as well as the identified parameters within 
this range might differ between the analyzed age groups, common and deviating 
parameters within this range were discussed.  
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4 Results 
The overall body composition over the course of ageing as implemented in the PBPK 
population model for elderly is listed in Table 4-1, visualized in Figure 4-1 as progression 
of mean organ weights with ageing and in Figure 4-2 as distribution of mean organ weights 
over age as a fraction of body weight.  
 
Figure 4-1  Distributions of mean organ weight from newborns to individuals up to 
100 years of age. .Blood pools represent arterial and venous blood, as well 
as blood in the portal vein, GI-tract summarizes the stomach, small and 
large intestine. 
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Figure 4-2  Mean organ weights from early adulthood up to 100 years of age as 
percentage of body weight. .Blood pools represent arterial and venous 
blood, as well as blood in the portal vein, GI-tract summarizes the stomach, 
small and large intestine. 
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Table 4-1  Anthropometric measures, organ and tissue weights including blood as used 
in the elderly PBPK model 
Parameter 
Age [years] 
30 c 40 50 60 70 80 90 100 
Body 
weight (kg) 
f 60.0 63.3 65.2 65.5 62.2 56.1 53.7 45.2 
m 73.0 74.4 73.0 72.0 71.1 68.1 64.9 55.6 
          
Height 
(cm) 
f 163.0 160.9 160.0 158.3 155.4 151.7 150.0 147.9 
m 176.0 175.1 173.9 171.2 167.4 165.5 163.8 157.6 
Organ masses (g) a 
Blood 
Pools b 
f 1899.4 1921.1 1961.2 1946.9 1847.7 1692.6 1634.5 1357.0 
m 2264.6 2269.5 2234.9 2180.2 2111.3 2042.5 1976.5 1739.5 
          
Bone 
f 9121.5 8886.3 8676.1 8401.8 7811.6 6981.4 6619.0 6263.5 
m 11817.8 11848.0 11481.6 11091.6 10355.0 9637.1 8969.0 8300.9 
          
Brain 
f 1357.0 1352.3 1347.6 1315.1 1287.3 1241.4 1169.4 1097.4 
m 1508.8 1506.9 1502.9 1463.3 1434.3 1400.1 1372.1 1344.2 
          
Fat 
f 19348.0 20002.5 23815.4 26993.0 27884.7 25694.5 25020.6 20171.4 
m 14868.0 16309.7 16676.5 17920.7 19447.4 19947.7 20691.0 17082.3 
          
Gonads 
f 13.1 13.0 6.6 5.3 5.2 5.1 5.1 4.9 
m 40.3 40.8 35.0 33.5 31.9 30.6 30.3 29.5 
          
Heart 
f 328.4 340.0 355.6 377.1 399.1 413.5 431.2 412.9 
m 417.2 434.3 439.1 454.6 464.8 441.4 437.9 425.1 
          
Kidney 
f 403.4 401.7 400.5 383.4 364.2 325.2 308.8 295.8 
m 437.7 475.9 468.1 455.6 441.7 395.7 366.7 355.9 
          
Liver 
f 1905.5 1881.0 1867.7 1679.8 1504.9 1423.4 1329.5 1189.4 
m 2357.8 2324.5 2206.0 2041.3 1714.6 1417.3 1324.0 1202.0 
          
Lung 
f 1009.5 1021.4 1038.8 1023.8 1005.4 849.1 804.5 637.3 
m 1294.3 1334.7 1337.4 1349.0 1271.8 1138.0 1007.4 978.0 
          
Muscle 
f 20276.2 23058.3 21300.1 18971.2 15746.4 13367.8 12394.3 10060.6 
m 32338.6 32318.2 31180.6 29600.0 28562.1 26524.8 23657.0 19534.0 
          
Pancreas 
f 169.5 170.3 163.8 158.7 148.5 131.9 128.0 122.6 
m 190.3 190.8 183.6 178.2 165.4 149.9 143.7 139.5 
          
Skin 
f 2723.5 2773.2 2836.2 2829.5 2725.8 2559.1 2493.8 2223.5 
m 3760.9 3790.2 3745.1 3692.0 3635.2 3537.0 3439.7 3122.6 
          
Spleen 
f 219.2 197.7 190.7 182.4 164.5 149.7 99.4 78.7 
m 243.4 221.9 208.2 197.0 186.6 160.4 133.4 108.4 
f:female, m:male 
a Organ masses for GI organs were kept constant for females (1274.5 g) and males (1304.8 g) over the investigated age 
range 
b Blood pools represent arterial and venous blood as well as blood in the portal vein 
c Physiological and anatomical information of the 30 years old individual is derived from the ICRP reference man [102]  
47  Results 
_________________________________________________________________________ 
4.1 Physiological changes in the elderly 
4.1.1 Anthropometric measures 
Anthropometric measures were stated in almost every physiologic study. In addition, 
comprehensive European anthropometric studies were used, and coverage was dense for 
the age ranges of 30 to 100 years old [157-167]. 
In general, men tended to be taller and heavier than women at any age stage. Both sexes 
showed an increase in body mass to the age of 55 years, and then a progressive decrease. 
This decline starts at a 1.5 % decrease per decade and rises to nearly 10 % per decade 
between 90 and 100 years of age. Body height starts to decrease in early adulthood, after 
the age of 30 years, as visualized in Figure 4-3. As with body weight, the decrease sets on 
with a low rate of 1 % per decade and is comparable for men and women. In women this 
rate accelerates after menopause, culminating in a 4.2 % decrease of body height per 
decade in female nonagenarians. In males, height loss during the 10th decade averages only 
about 3.5 %. 
 
Figure 4-3  Age-dependent changes in body height, comparison between simulations 
and observations in females and males. Simulated individuals are 
represented in grey dots [n=5000] whereas observations of reference mean 
data are visualized in black circles. The reference data was gathered from 
anthropometric studies or studies where body height appeared as covariate. 
The sizes of the black circles indicate the relative numbers of subjects.  
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4.1.2 Muscle mass 
Loss of muscle mass is assessed as part of the screening test for sarcopenia using the gold 
standards Computer Tomography (CT) and Magnetic Resonance Imaging (MRI) [168], but 
also using Dual energy X-ray Absorptiometry (DXA) [169-173] or Bioimpedance Analysis 
(BIA) [174-179] according to the European Working Group on Sarcopenia [180]. Janssen 
et al. introduced an equation enabling the calculation of skeletal muscle mass from BIA 
observations [181]. As decreases in muscle mass vary among different parts of the body, 
whole-body analysis was preferred for the data pooling. The decline of the maximum 
skeletal muscle mass from 37 % of body weight in female adults to 22 % in the 
centenarians follows a degressive trend and differs to the progressive reduction for males 
from 44% in adults to 34 % of body weight in the extremely old.  
4.1.3 Fat mass 
Similar to muscle mass, fat mass can generally be assessed using CT [182], MRI, BIA 
[165, 174, 183-187] or DXA [163, 188-200]. Estimations based on skinfold thickness and 
whole-body counter for total potassium content were not included due to the varying 
methods of calculation [201].  
During aging, fat mass in females increases to an absolute maximum at the age of 70 years, 
whereas in males the peak is reached by the age of 65 years. Due to the diminished body 
weight and the severe loss of lean body mass from 70 to 100 years of life, the relative fat 
mass continues to increase, to as much as 45.8 % in female, and 31.5 % in male 
centenarians. Here, the increases are constant in males, with 0.98 kg fat mass /decade. 
Females, however, experience an accelerated gain of 3.5 kg fat mass /decade in the first 
two decades after menopause, and then a slower gain exhibiting the same rate as in males 
of the same age group. 
4.1.4 Kidney weight 
Four studies were included for model building [202-205]. These revealed that maximum 
kidney weight is achieved in the 4th decade and remains constant for almost 20 years 
before continuously declining. This decrease is associated with a loss of renal tissue and a 
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reduction in the number of nephrons, particularly in the renal cortex [206]. This results in a 
reduction of tubular and glomerular cells, and thus affects the GFR [207, 208]. 
4.1.5 Liver weight 
The number of hepatocytes is reduced in the elderly, whereas the single-cell volume 
initially increases but subsequently decreases [209]. Thus, the number of hepatic lobules is 
constant over the course of aging, but the size of the liver declines, whereas collagen 
accumulation induces a widening of the perisinusoidal space [210]. In females liver mass 
decreases almost linearly, at the rate of 8.3 % per decade after the age of 40 years, whereas 
in males it proceeds in two steps: an initial decline of 6.1 % per decade to the age of 
60 years, followed by a more rapid loss of 11.4 % per decade [203-205, 211, 212]. This 
tendency was determined from autopsy analysis, but was also detected in imaging studies 
[213-215]. 
4.1.6 Brain  
Results of five studies in European subjects indicated that in both genders a minor decrease 
in brain weight begins in early adulthood and continues at a steady rate until the 5th decade, 
at which point the rate accelerates [204, 216-219]. These findings are in line with results 
from a large autopsy study on brains of white North Americans conducted by Dekaban et 
al. [220], as well as with recent longitudinal observations [221]. Also this tendency is 
consistent with findings from earlier studies in Europeans [222, 223]. These data were 
utilized to simulate the age distribution of brain weight, and subsequently verified using a 
nomogram developed by Hartmann et al. [224], as shown in Figure 4-4. Given that patients 
with Alzheimer’s Disease show a severe cortical atrophy [225], they were excluded from 
the current analysis. 
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Figure 4-4  Simulated age distribution of brain weight compared to the nomogram of 
Hartmann et al. [224]. Simulated individuals are represented in grey dots 
[n=5000] whereas the nomogram is visualized with the black line. 
4.1.7 Heart 
Aging is associated with a loss of myocytes (which is particularly evident in males) and a 
concomitant increase in volume of the remaining myocytes [226, 227]. At the same time, 
amyloid disposition advances uniformly throughout the myocardium [228]. Ventricular 
mass thus increases continuously over the course of aging. Studies analyzing the volume 
and composition of heart tissue were carried out mainly by autopsy [203, 204, 229-235]. 
Analysis of the data in the literature was followed by verification of the results with the 
recent centile charts of Gaitskell et al. as shown in Figure 4-5 [236]. 
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Figure 4-5  Simulated age distribution for heart weight compared to the nomogram of 
Gaitskell et al. [236]. Simulated individuals are represented in grey dots 
[n=5000] whereas the nomogram is visualized with the black line. 
4.1.8 Bone 
Bone mass is often described by the term bone mineral density (BMD), which is calculated 
by dividing the bone mineral content (BMC) by the bone area. Analysis of BMD indicates 
that body size has a marked influence on the bone mass, and thus is adequate for 
longitudinal assessment of the risk of osteoporosis and as an indicator of bone strength, but 
not for inter-individual comparisons [237]. Instead, analysis of whole-body BMC 
normalized to the surface area of the bone is usually used for a direct comparison over the 
course of maturation [238, 239] and in older adults [240], as well as for cross-sectional 
data. It is therefore applied in this analysis for inter-study comparison in elderly 
individuals.  
European Caucasians gain bone mass through the age of 25 years and maintain this mass 
for at least a decade. In men, the loss of bone mass begins at the age of 40 years with a 
decrease of 0.54 % per year. In women, this rate increases to 1.41 % per year after 
menopause and is continuing at this rate over the following 5 to 10 years [163, 188, 196-
200, 241-243]. In men, the rate of bone loss is constant and increases only slightly in old 
age. The rate in women reverts to one similar to that in men after the faster loss related to 
menopause, but during the 10th decade gradually increases in women to a rate of 6.75 %. 
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4.1.9 Gonads 
Studies carried out in females on hormone replacement therapy were excluded, as this 
treatment has a dominant impact on uterine size following the menopause. The size of the 
uterus is markedly decreased during menopause due to atrophy. Volumetric decrease rates 
are highest during the initial decade after menopause, with a loss in weight of almost 50 %. 
After the age of 60 years, this rate is attenuated to a nearly constant decrease of 1.89 % per 
decade [223, 244].  
Men undergo a gradual involution of the testis, at a rate of 3.40 % per decade. The size 
ratio of the tunica albuginea to rete testis is unaffected over the course of aging, and this is 
also true for the sizes of the two testes. [245-248].  
4.1.10 Lung 
Whereas the functional capability of the pulmonary system declines slowly but gradually 
after the age of 25 years, lung mass is not reduced in the same manner. In men lung tissue 
mass reaches its maximum at the age of 60 years, and in women it does so a decade earlier. 
In women, the subsequent decrease progresses gradually, at a rate of 50.3 g/decade. In 
men, however, the loss initiates at 77.1 g/decade and advances to 130.5 g/decade [205, 
223]. 
4.1.11 Pancreas 
The pancreas undergoes atrophy and fatty infiltration as well as intra-lobular fibrosis in 
older individuals. With a cellular weight of 140 g in adults, decline of weight initiates at 
13.8 g/decade and continues at a rate of 5.85 g/decade between the ages of 80 and 
100 years, mainly due to a loss of parenchymal tissue [111, 249-251].  
4.1.12 Skin 
The skin includes both the epidermis and the dermis, a deeper connective-tissue layer. 
Most common areas of skin thickness studied are the forearm and trunk or limbs, and this 
is analyzed by ultrasound. Only a few studies have examined the changes in skin thickness 
of more than two parts of the body and thus have visualized the overall changes in skin 
thickness during the aging process [252]. Changes in skin thickness and aging are driven 
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mainly by sun exposure and smoking but not pigmentation. Age has only a minor influence 
and can be described by a decrease in skin thickness in the cellular part of the epidermis 
and dermis after the age of 40 years in women, and after the age of 45 in men [253-256]. 
The stratum corneum remains unaffected [257, 258] with respect to thickness but 
undergoes a decrease in its moisture content. However, the skin barrier function is 
maintained even in extreme old age. In the basal layer, the number of cells per unit area 
decreases due to constrained proliferation. The abundance of microvilli, Langerhans cells 
and keratocytes declines, and thus the transdermal permeability to drugs altered [259]. In 
the dermis, the collagen fibers become reduced in number, thicker and less soluble. The 
decrease in collagen is linear [255, 260, 261]. 
4.1.13 Spleen 
Studies of changes in splenic weight over the course of aging have produced inconsistent 
results. Autopsy studies reporting data for various age bins have concluded that spleen 
volume declines after early adulthood [203-205, 262]. Other autopsy and in vivo 
measurement studies have reported that spleen size is neither affected by age nor by 
gender; however, these do not describe the data that are the basis for this conclusion [263, 
264]. An analysis of the available data suggested that in men a moderate absolute loss of 
cells (6.08 g/decade) occurs from adulthood to the age of 70 years, and that it progresses at 
a rate of 13.5 g/decade until the age of 100 years. In women, the initial decrease of cellular 
mass is 3.96 g/decade until the age of 60 years, and it rises to 8.45 g/decade thereafter until 
the age of 100 years. Thus, loss of spleen weight in relation to body weight can be up to 
two fold.  
4.1.14 Cardiac output 
Williams conducted a comprehensive literature analysis on changes over the course of 
aging in cardiac output and cardiac index, a parameter which relates the cardiac output to 
the BSA [265]. His study revealed that an initial decrease in cardiac index after the age of 
20 years developed into a marked reduction after the 6th decade of life. Given that Williams 
summarized predominantly North-American reports and a large Japanese trial, European 
studies were screened to control for potential racial variations. The studies taken into 
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account for evaluating both changes in cardiac output [266-269] over the course of aging 
and the underlying distributions are listed in Table 4-2. 
Females showed an almost linear decrease in cardiac index of 3.22 % per decade after the 
age of 30 years. The slowing of the cardiac blood circulation is more precipitous in males; 
whereas it starts out at 1.46 % per decade during early adulthood, followed by a stronger 
decrease of 8.30 % per decade in the elderly age range. These results have been confirmed 
by studies on stroke volume [270-272], assuming that heart rate remains constant over the 
lifespan. However, due to contradictory reports on changes in heart rate over the course of 
aging (some reports support a decrease in heart rate, due to the dropout of pacemaker cells 
[273, 274], whereas others indicate that heart rate increases in female subjects [275]), 
reports on isolated stroke volumes were not taken into account. 
4.1.15 Cardiac output distribution 
Kidney blood flow 
In the kidney, the age-dependent decrease in absolute perfusion rate is more severe than 
weight loss. In comparison to the perfusion rate, the overall reduction in cardiac output 
proceeds at a slower rate. Correlation of kidney perfusion and filtration performance was 
shown in a larger population ranging from 20 to nearly 90 years of age [276]. Para-
aminohippuric acid (PAH) is the marker substance of choice for the assessment of renal 
blood flow; in the past it was diodrast [277-279]. 
Hepatic and splanchnic blood flow 
In healthy adults, the pre-portal organs, including the stomach, intestines, pancreas and 
spleen, provide about 75 % of the portal blood flow [113]. This relationship seems to be 
maintained over the course of aging, although the total flow rate decreases [280]. 
Additional shunting is negligible when blood flow rate is reduced and portal pressure 
remains constant. The hepatic blood flow itself is measured using the dye dilution method, 
where a subject is catheterized in the portal and the hepatic veins [214]. In order to 
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eliminate potential anastomosis, additional studies based on Doppler measurements were 
integrated into this analysis. 
Although no absolute information is obtainable for splanchnic blood flow, relative 
alterations can be analyzed by Laser-Doppler flowmetry. Analysis of the blood flow in the 
superior mesenteric artery is the most common assessment of alteration in splanchnic 
perfusion [281-283]. Although the superior mesenteric artery is one of three vessels that 
contribute to the splanchnic blood supply, it is the major sustenance vessel of the small 
intestine, the duodenum and the colon. Alterations in perfusion of the stomach, pancreas 
and spleen can also be captured by this method. The ratio of splanchnic blood flow to 
cardiac output gradually decreases from 22.5 % in adults to 17.5 % during the tenth decade 
of life [284-287]. 
Adipose tissue blood flow 
Only two studies have quantified absolute values for changes in blood flow to adipose 
tissue over the course of aging in humans [288, 289]. For this tissue, it is only possible to 
assess general decreases in specific blood flow rates; shifts in the disposition of body fat 
and in fatty tissue hydration during aging impede studies in single fat depots. 
Cerebral blood flow 
Cerebral perfusion decreases linearly over the course of aging. Age-associated regional 
differences of reduction in perfusion have been discovered recently by Chen et al. [290]. 
Although the results indicate that the reduction in older age is severe due to increasingly 
pronounced decreases in perfusion in the cortical area, this study failed to support a non-
linear trend. However, studies that included data from additional sources revealed a linear 
reduction of 3.27 ml/year in female subjects, and a 3.01 ml/year decline in males [291-
294].  
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Muscle blood flow 
Although muscle mass is reduced with age, the blood flow to this tissue is unaffected over 
time [295-298]. However, the redistribution cascade initiated by physical load is altered in 
older adults, and is not adequate to support higher workloads [285]. 
Myocardial blood flow 
Single-photon emission computed tomography (SPECT), cardiac magnetic resonance 
(CMR), and positron emission tomography (PET) are reliable methods for assessing the 
development of myocardial perfusion, and are used primarily to evaluate obstructive 
coronary artery disease [299]. Although diastolic relaxation is impaired during the 
progression of healthy aging, the myocardial blood flow increases only minimally [300-
305]. Deviations by ethnicity have been observed [306], and multiethnic studies have 
confirmed this phenomenon [307]. Notably, although the myocardial blood flow is 
generally higher in women, the increase in flow rate over age is higher in men.  
Skin blood flow 
The decrease in blood supply to the dermal tissue layers is caused not only by the overall 
restriction in cardiac output; it has also been attributed to a diminished microvasculature. 
The loss of small vessels can be accelerated by photo damage, an effect that varies by body 
region [308]. For assessment of changes in skin blood flow, microdialysis in combination 
with Laser-Doppler flowmetry studies have predominated. Given that the results of these 
studies are reported in relative values with arbitrary units, it is not possible to interpret the 
data as a whole. Although the variability of the individual studies is high, no significant 
changes in cutaneous blood flow per unit were observed [309-312]. The response was 
impaired only in the context of exposure to heat or stress, due to reduced coverage of 
cutaneous tissue with capillary vessels. 
In summary, information on blood flow alterations implemented into the elderly PBPK 
approach is listed in Table 4-2. The general lack of perfusion data impeded the 
computation of a robust variability for each blood flow rate, so that a 5 % coefficient of 
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variation was assumed as accepted for other approaches [313]. In total, 118 studies 
comprising 47029 male and 67419 female subjects were included to build the elderly 
PBPK database. All studies considered for the elderly PBPK population model and the 
total numbers of subjects comprised in these studies used to inform the changes in the 
respective organ are listed in Table 4-3.  
Table 4-2  Cardiac index and organ blood flow rates used in the elderly PBPK model 
Parameter 
 Age [years] 
 30 c 40 50 60 70 80 90 100 
Cardiac 
index (L/m2) 
f 3.34 3.33 3.08 2.89 2.75 2.68 2.52 2.41 
m 3.23 3.22 3.09 2.86 2.58 2.36 2.18 2.04 
 
Organ blood flow (ml/min) 
Adipose 
f 501.1 528.2 578.0 655.3 684.7 630.2 607.0 491.5 
m 324.7 352.1 357.3 381.4 408.0 419.8 429.2 357.3 
          
Cerebral 
f 707.8 686.9 666.1 632.1 601.2 562.8 514.2 467.6 
m 779.7 747.6 727.9 692.9 650.6 623.8 594.4 536.1 
          
Gonads 
f 1.2 1.2 0.6 0.5 0.5 0.5 0.5 0.4 
m 3.2 3.3 2.8 2.7 2.6 2.5 2.4 2.4 
          
Myocardial 
f 295.0 311.2 313.2 363.1 376.3 445.8 464.8 445.2 
m 260.1 271.1 278.0 299.1 308.7 334.7 332.1 322.3 
          
Renal 
f 1121.0 1061.8 943.8 825.8 707.8 589.8 471.8 353.8 
m 1325.0 1339.3 1116.3 913.3 730.3 567.3 424.3 301.3 
          
Splanchnic 
a 
f 1239.0 1254.3 1187.2 1015.3 862.6 771.5 679.1 570.5 
m 1235.0 1241.9 1237.7 1056.7 813.1 610.6 512.9 413.5 
          
Hepatic 
f 383.4 388.1 367.3 314.2 266.9 238.7 210.1 176.5 
m 423.0 425.4 423.9 361.9 278.5 209.1 175.7 141.6 
          
Muscle 
f 665.1 774.8 636.6 568.4 479.8 405.6 369.0 298.8 
m 1105.7 1086.8 1036.8 975.0 922.3 861.7 751.9 625.9 
          
Skeleton 
f 294.9 287.3 280.5 271.6 252.6 225.7 214.0 202.5 
m 324.9 325.8 315.7 305.0 284.7 265.0 246.6 228.2 
          
Skin 
f 295.7 301.1 307.9 307.2 295.9 277.8 270.7 241.4 
m 325.1 327.7 323.8 319.2 314.3 305.8 297.4 270.0 
f:female, m:male 
a Splanchnic blood flow rate combines gastro-intestinal, pancreatic and splenic blood flow and describes the portal blood 
flow 
b Cardiac output distribution information of the 30 years old individual is derived from the International Commission on 
Radiological Protection (ICRP) reference man [102] 
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Table 4-3  Studies (including the numbers of subjects) utilized for model building to 
determine changes in organ volume and specific organ blood flow 
development over the course of aging in healthy European Caucasians 
Physiological 
measure 
Number of Subjects 
References Females Males Females Males 
30-65 years >65 years 
Anthropometry 2580 2514 12643 5283 [157-167] 
      
Volumes 
Bone 1360 264 7896 105 [163, 188, 197, 199, 200, 241, 242] 
Brain 672 1388 421 421 [204, 216-219, 221] 
Fat 6548 5638 12824 2011 [163, 165, 174, 182-186, 188-194, 197] 
Gonads 426 71 268 205 [223, 244-248] 
Heart 1208 1739 2647 2852 [203, 204, 229-235] 
Kidney 2300 3798 2635 3871 [202-205] 
Liver 1226 2380 1419 2568 [203-205, 211, 212] 
Lung 604 609 369 331 [205, 223] 
Muscle 1829 2129 577 579 [174, 175] 
Pancreas 521 336 1006 734 [111, 249, 251] 
Skin 164 117 222 214 [253-256] 
Spleen 1882 2775 2639 3223 [203-205, 262] 
 
Blood flow rates 
Cardiac Output 97 174 79 97 [266-269] 
Adipose 26 15 4 5 [288, 289] 
Cerebral 130 197 59 48 [291-294] 
Splanchnic 0 19 21 16 [284-287] 
Kidney 0 39 3 14 [277-279] 
Muscle 0 16 13 16 [295-297] 
Myocardial 100 191 1 13 [300, 302, 304, 305] 
Skin 0 7 0 7 [311] 
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4.1.16 Total body water distribution 
Total body water remains stable throughout most of adulthood but decreases starting in the 
6th decade of life. Race and sex have been associated with differences observed over the 
complete lifespan [314]. Normalization of total body water to body weight reveals that the 
ratio declines gradually during the aging process. This reduction is mainly due to the loss 
of intracellular water; the ratio of extracellular water to body weight is maintained during 
aging. These changes are visualized in Figure 4-6, together with observed data in healthy 
Caucasians [165, 185, 315-318].  
 
Figure 4-6  Distribution of body water in females and males over the course of aging. 
Extracellular (dark grey lines) and total (light grey lines) body water as 
percentage of body weight. Values reported in the literature for extracellular 
water (triangles) and total body water (circles) are shown for comparison. 
4.1.17 Albumin 
The mean serum albumin concentration decreases marginally with advancing age. Health 
conditions and nutritional status have a more pronounced impact [319, 320]. The decline of 
mean serum albumin is linear from 65 to 90 years, but becomes more severe thereafter 
[321-324]. No gender effect has been observed. 
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4.1.18 Alpha-1-acid glycoprotein 
The acute-phase protein alpha-1-acid glycoprotein (AAG) is a predominant binding partner 
for basic lipophilic and neutral drugs. As its levels have large intra-individual variability, 
particularly in the context of disease and disease progression [325], estimates of changes in 
mean plasma levels over the course of aging have been inconsistent. However, a general 
stepwise regression analysis of available data for Europeans suggested that the mean AAG 
concentration was unchanged across the elderly age range, not differing between males and 
females [321, 323, 324]. This was consistent with data from healthy North Americans; 
there was no evidence for a difference between these groups. 
4.1.19 Hematocrit 
Similar to serum albumin levels, mean hematocrit (HCT) values in the elderly are only 
slightly lower than those in younger adults, although the range is amplified on the lower 
end [324, 326-328]. In the elderly age range, health conditions and nutritional status may 
account for the observed differences. Furthermore, the HCT range in Europeans does not 
differ from that in white Americans [320]. 
4.1.20 Glomerular filtration rate (GFR) 
Although serum creatinine is widely used to predict GFR in the elderly population, it does 
not lead to reliable results. Due to the dependence on food intake [329], concentration of 
lipids [330], age, muscle mass and race [331], the variability in serum levels of this marker 
may lead to an under- or overestimation of GFR. Even small changes in serum creatinine 
levels can reflect major changes in GFR as the relationship is not linear. Furthermore, 
creatinine clearance is inversely correlated with blood pressure [332]. Moreover, a second 
endogenous marker of GFR, cystatin C, has its own pitfalls and is not sufficiently reliable 
in older people, especially in males, smokers, overweight individuals, tall individuals, or 
individuals with elevated levels of C-reactive protein [333]. 
A better but more time consuming method for assessing GFR is the use of exogenous 
markers, the gold standard being inulin [334]. However, this requires continuous inulin 
infusion, during which its clearance via the urine is measured. This procedure is not 
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feasible within large trials. However, results from analyses using non-radiolabeled markers 
should be interpreted carefully as they might slightly underestimate the GFR [335].  
Another potential source of bias for GFR estimations is the standardization to BSA. 
Currently, different equations are in use for calculating the BSA, and only a few studies 
mention which equations were applied.  
Almost as precise and more routinely used are the markers 125Iothalamate [335], 99mTc-
diethylen-etriamine-pentaacetate (Tc-DTPA) [336, 337], 51Cr-ethylene-diamine-
tetraacetate (Cr-EDTA) [336, 338] and iohexol [339]. In the case of the non-radioactive 
iohexol, measurements suggest that GFR decreases by about 1.0 mL/min/1.73 m2/year 
(157). Comparing the results obtained from all of these methods can lead to reliable results 
[340]. 
In order to generate population samples large enough to investigate GFR, most studies 
have been carried out in prospective renal transplant donors using exogenous markers 
[335, 336, 338, 341]. An analysis of the gathered and BSA-adjusted data for 1213 females 
and 1081 males was performed. This resulted in a slight reduction starting at the age of 
30 years, and a more rapid reduction starting at the age of 40 years. 
The GFR in PK-Sim® is linked to maturation of the kidney volume and described by a Hill 
function [342]. To describe the effect of aging on GFR, a new, reverse sigmoid hyperbolic 
maturation function was developed and optimized with the MATLAB function lsqnonlin 
starting (for both sexes) at the age of 30 years. 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝐺𝐹𝑅30−100𝑦 = 𝐹𝑃𝑀𝐴 ∙ (1 −
𝑉𝑚𝑎𝑥 ∙ (𝑎𝑔𝑒 − 30𝑦𝑒𝑎𝑟𝑠)
𝐻𝑖𝑙𝑙
𝑇𝐴50
𝐻𝑖𝑙𝑙 + (𝑎𝑔𝑒 − 30𝑦𝑒𝑎𝑟𝑠)𝐻𝑖𝑙𝑙
) 
(Eq. 8) 
Here, FPMA is the specific GFR derived from the sigmoid hyperbolic maturation function 
[342] after full maturation is achieved in the 40th week of gestation (26.6 ml/min/100 g 
kidney weight) [343]. In order to describe the effects of aging on kidney function, the 
maximal decreasing rate factor (Vmax) was set to 0.9 ml/min/100 g kidney weight, the aging 
half-time (TA50) to 59 years for females and 54 years for males. The Hill coefficient is 
parameterized at 1.5. The resulting function over the aging period is visualized in Figure 
4-7. Whereas the specific GFR function is parameterized using the observed GFR values 
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and assuming the mean kidney weight at the respective age, the variability is entirely 
dependent on the deviation in kidney weight. 
 
Figure 4-7  Changes in kidney function in females and males over the course of ageing 
compared to literature values. The solid black line represents the new GFR 
function in relation to kidney weight, whereas the dashed black line 
represents the maturation of GFR function according to Rhodin et al. [342]. 
The grey shaded areas represent the predicted 95% percentile range based 
on kidney size variability. The black circles depict the observed GFR rates 
[335, 336, 338, 341]. 
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4.2 Predictability of PK data in the elderly 
In the next step, the paradigm compounds furosemide and morphine were applied to 
qualify the capability of the PBPK population model and to predict drug distribution and 
elimination of drugs.  
Morphine 
The literature screen for observed PK data led to inclusion of several studies for morphine 
[344-353] as listed in Table 4-4.  
Table 4-4  Summary of clinical studies after intravenous dosing for the test compound 
morphine used to compare the simulated data 
Dose Age [years] n Height [cm] Weight [kg] Reference 
Morphine      
0.125 mg/kg 30.6 (24-40) 11  62.6 (47-85) [344] 
      
10 mg 
27.4 (26-30) 8  67.6 ± 4.5 
[345] 
74.0 (68-90) 9  66.4 ± 3.2 
      
5 mg 31 (26-40) 6   [346] 
      
5 mg 30.2 (25-44) 10  72 (63-83) [347] 
      
5 mg 25.8 (20-40) 6  71.4 (49.2-102.1) [348] 
      
0.05 mg/kg 76.1 ± 4.5 16 167.4 ± 8.3 77.8 ± 16.9 [349] 
      
10 mg (22-29) 12  76.4 ± 7.4 [350] 
      
10 mg (20-39) 14  74.9 ± 11.0 [351] 
      
7.5 mg 26 (23-30) 6 176 (165-187) 71 (54-98) [352] 
      
0.15 mg/kg (22-54) 6   [353] 
Values in curved brackets indicate the range; ± indicates standard deviation 
The simulated plasma concentration-time profiles of morphine in healthy adults were 
consistent with the observed data, as visualized in Figure 4-8. Whereas 42 % of the 
simulations for young adults were outside the 1.25-fold range, only 18 % of the predicted 
plasma concentration-time points were outside this range for older adults. For both age 
groups, the number of under- and overpredicted plasma concentration-time points were 
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equally distributed to both sides of the 1.25-fold range. All plasma concentration-time 
points were predicted within the 2-fold range. 
 
Figure 4-8  Predicted and observed plasma concentration-time profiles of morphine in 
younger adults vs. the elderly. Predicted mean plasma concentration-time 
profiles (left) for younger adults are visualized with a grey dashed line and 
with a black line for the elderly. The concentrations are normalized to a 
10 g dose for morphine. Observed data are superimposed (black open 
symbols represent values for the elderly [345, 349]; grey open symbols 
represent values for younger adults [344, 345, 348, 351-353]). Goodness-of-
fit plots (right) for model predictions in the adult (black dots) and elderly 
(grey dots) populations. Solid line indicates line of identity, 1.25-fold and 2-
fold error ranges are indicated by dashed lines and dotted lines, 
respectively. 
The scaling to higher ages reported in the above-mentioned drug studies led to an accurate 
description of the estimated PK parameters, as shown in Figure 4-9 for individual values 
and Figure 4-10 for average values from the included trials. Reliable predictions were 
obtained for the Vss and t1/2 of morphine. Only 3 individual values for Vss and 2 of 8 
individual values for t1/2 were outside of the 1.25-fold level without any age-related 
pattern. For the trial group predictions, both PK parameters were predicted within the 2-
fold range. 
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Figure 4-9  Trial individual observed vs. predicted values for volume of distribution at 
steady-state and the elimination half-life for the test compound morphine. 
The solid black lines represent the line of identity; the dashed black lines 
represent the 1.25-fold level and the solid grey lines represent the 2-fold 
level of accuracy. 
 
Figure 4-10  Trial group observed vs. predicted values for volume of distribution at 
steady-state and the elimination half-life for the test compound morphine. 
The solid black lines represent the line of identity; the dashed black lines 
represent the 1.25-fold level and the solid grey lines represent the 2-fold 
level of accuracy.  
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The predictive performance of the PBPK model for morphine is summarized in Table 4-5. 
The precision for the predictions of plasma concentrations improved by 0.212 for 
morphine when using the age-informed physiology for the simulations of the elderly 
studies. This is a relative improvement in prediction by 49 % for morphine. The plasma 
concentrations were under-predicted in the absence of consideration of age-informed 
physiology. The bias was considerably reduced when age-informed physiology was 
applied. 
Table 4-5  Predictive performance analysis of the morphine PBPK model with and 
without the age-informed physiology 
 Adult physiology Age-informed physiology 
 Adult Elderly Elderly 
Morphine 
Bias    
ME 0.082 
(0.001, 0.163) 
-0.093 
(-0.231, 0.045) 
0.050 
(-0.072, 0.172) 
    
Precision    
RMSE 0.286 
(0.189, 0.358) 
0.437 
(0.001, 0.656) 
0.224 
(0.004, 0.384) 
ΔRMSE 
 
0.212 
(0.001, 0.635) 
Relative 
ΔRMSE 
 49 % 
ME: mean prediction error, RMSE: root mean squared prediction error, ΔRMSE: Difference in RMSE  
Values [mg/L] are stated with the 95 % confidence interval in parentheses 
Furosemide 
The literature screen for observed PK data led to inclusion of several studies for 
furosemide [120, 354-357] as listed in Table 4-6. Only for two doses, plasma 
concentration-time profiles were available.  
The simulated plasma concentration-time profiles of furosemide in healthy adults were 
consistent with the observed data, as visualized in Figure 4-11. Only 13 % of the 
simulations for young adults were outside the 1.25-fold range, with no predicted plasma 
concentration-time point outside this range for older adults. The majority of these outliers 
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were underpredictons especially for later time-points. All plasma concentration-time points 
were predicted within the 2-fold range.  
Table 4-6  Summary of clinical studies after intravenous dosing for the test compound 
furosemide used to compare the simulated data 
Dose Age [years] n Height [cm] Weight [kg] Reference 
Furosemide      
80 mg 27.1 (20-35) 10  71.4 ± 6.7 [120] 
      
80 mg 
27 ± 4.8 8  71 ± 6.7 
[354] 
64 ± 4.0 8  76 ± 7.3 
      
40 mg 30 (20-45) 7   [355] 
      
20 mg 76 1  70 [356] 
      
40 mg 74 (64-84) 20  73.1 ± 12.8 [357] 
Values in curved brackets indicate the range; ± indicates standard deviation 
 
Figure 4-11  Predicted and observed plasma concentration-time profiles of furosemide in 
younger adults vs. the elderly. Simulated mean plasma concentration-time 
profiles (left) for younger adults are visualized with a grey dashed line and 
with a black line for the elderly. The concentrations are normalized to a 
40 mg dose for furosemide. Observed data are superimposed (black open 
symbols represent values for the elderly[354]; grey open symbols represent 
values for younger adults[354, 355]). Goodness-of-fit plots (right) for model 
predictions in the adult (black dots) and elderly (grey dots) populations. 
Solid line indicates the line of identity, 1.25-fold and 2-fold error ranges are 
indicated by dashed lines and dotted lines, respectively.  
Results 68 
_________________________________________________________________________ 
The scaling to higher ages reported in the above-mentioned drug studies led to an accurate 
description of the estimated PK parameters, as shown in Figure 4-12 for individual values 
and Figure 4-13 for average values from the included trials. All but 4 of 36 predicted Vss 
value of furosemide were within the 1.25-fold level of the experimental values. The t1/2 
values for furosemide for individuals with a longer half-life were underpredicted. Here, 8 
of 36 values for t1/2 were not within the 1.25-fold range including two values outside the 2-
fold range. On trial population level, all predicted values were within the 2-fold and only a 
single t1/2 value predicted outside the bioequivalence criteria.  
 
Figure 4-12  Trial individual observed vs. predicted values for volume of distribution at 
steady-state and the elimination half-life as well as the corresponding fold 
over/under prediction, for the test compound furosemide. The solid black 
lines represent the line of identity; the dashed black lines represent the 1.25-
fold level and the solid grey lines represent the 2-fold level of accuracy. 
The predictive performance of the PBPK model for furosemide is summarized in Table 
4-7. The precision for the prediction of plasma concentrations improved by 0.132 when 
using the age-informed physiology for the simulations of the elderly studies. This is a 
relative improvement in prediction by 32 %. The plasma concentrations were under-
predicted in the absence of consideration of age-informed physiology. The bias was 
considerably reduced when age-informed physiology was applied.  
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Figure 4-13  Trial group observed vs. predicted values for volume of distribution at 
steady-state and the elimination half-life as well as the corresponding fold 
over/under prediction, for the test compound furosemide. The solid black 
lines represent the line of unity; the dashed black lines represent the 1.25-
fold level and the solid grey lines represent the 2-fold level of accuracy. 
Table 4-7  Predictive performance analysis of the furosemide PBPK model with and 
without the age-informed physiology 
 Adult physiology Age-informed physiology 
 Adult Elderly Elderly 
Furosemide 
Bias    
ME 0.032 
(-0.034, 0.010) 
-0.339 
(-0.621, -0.057) 
0.076 
(-0.015, 0.137) 
    
Precision    
RMSE 0.180 
(0.141, 0.212) 
0.408 
(0.004, 0.721) 
0.276 
(0.185, 0.343) 
ΔRMSE 
 
0.132 
(0.005, 0.695) 
Relative 
ΔRMSE 
 32 % 
ME: mean prediction error, RMSE: root mean squared prediction error, ΔRMSE: Difference in RMSE  
Values [mg/L] are stated with the 95 % confidence interval in parentheses 
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4.3 Application of a ciprofloxacin lifespan PBPK population model 
According to the previously defined PBPK model building, verification and scaling 
workflow in Figure 3-2, the model was parametrized based on experimental data in adults 
for intravenous and oral administration of ciprofloxacin. The model was then scaled to the 
pediatric and geriatric age range considering age-dependent physiological changes. For 
both ends of the age-scale, previously studied dosing scenarios were predicted based on 
prior knowledge and subsequently compared to the observed exposure. 
4.3.1 Intravenous ciprofloxacin PBPK model simulations for adults 
Parameters describing the drug distribution (octanol-water partition coefficient Log P), 
metabolism (mediated by CYP1A2) and excretion (tubular secretion and biliary clearance) 
processes were identified based on human plasma concentration-time data (octanol-water 
partition coefficient Log P), mass-balance information (CYP1A2 metabolism, tubular 
secretion and biliary clearance) and urinary excretion profiles (tubular secretion) following 
single or multiple intravenous administrations with doses ranging from 25 to 400 mg using 
the parameter identification process. Studies applied for this step are indicated in Table 
A-1. The results of the multi-parametric fit to inform the lipophilicity as well as the 
metabolism and elimination processes are listed in Table 4-8. The correlation matrix for 
this fit shown in Figure 4-14 revealed no or weak correlations among the three processes 
and lipophilicity, but a stronger correlation between the two hepatic pathways. Since mass 
balance information applied to run the parameter identification clearly defined the fraction 
of administered dose metabolized and the unchanged fecal excretion, the retrieved pathway 
kinetic parametrization for hepatic metabolism and biliary clearance was accepted for 
further application. 
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Table 4-8  Input data values and model parameters for ciprofloxacin PBPK model 
Parameter 
Ciprofloxacin PBPK model 
Model input value Source 
Physicochemical 
Molecular mass (g/mol) 331.3 Drugbank (http://www.drugbank.ca) 
Log P 0.95 Estimated using parameter identification 
pKa 6.09 (acidic) Experimentally determined [358] 
 8.62 (basic) Experimentally determined [358] 
Fraction unbound 0.67 Experimentally determined [359] 
Aqueous solubility at pH 7 (mg/ml) 38.4 Experimentally determined [360] 
Absorption 
Enhancement factor 
Duodenum 255.8 Estimated using parameter identification 
Upper and lower jejunum 10.4 Estimated using parameter identification 
Upper and lower ileum 11.0 Estimated using parameter identification 
Large intestine 2.3 Estimated using parameter identification 
Distribution 
Partition coefficient model PK-Sim® standard Willmann et al. [108, 109] 
Cellular permeability model PK-Sim® standard Willmann et al. [108, 109] 
Metabolism 
CYP1A2 mediated  
clearance (L/min) 
0.067 Estimated using parameter identification 
Excretion  
GFR fraction  
for passive renal clearance 
1  
Tubular secretion clearance (L/min) 0.706 Estimated using parameter identification 
Biliary clearance (mL/min/kg) 1.286 Estimated using parameter identification 
Log P: octanol-water partition coefficient, pKa:negative decadic logarithm acid dissociation constant in log scale, GFR 
fraction: defines, if drug is only filtrated (1), reabsorbed (<1) or additionally secreted (>1) 
In a subsequent application, the developed ciprofloxacin PBPK model for intravenous 
administration in adults was able to describe the plasma concentration-time profiles 
following different intravenous administration protocols. An exemplary profile is shown in 
Figure 4-15. 
  
Results 72 
_________________________________________________________________________ 
 
Figure 4-14  Correlation matrix for parameter identification of distribution, metabolism 
and elimination parameters after intravenous administration. 
 
Figure 4-15  Exemplary ciprofloxacin plasma concentration-time profile after a 200 mg 
intravenous administration and the respective goodness-of-fit plot. The 
symbols (black dots) represent the median of the observed plasma 
concentration with the corresponding standard deviation indicated with error 
bars [359] for the plasma concentration-time profile (left). The thick black 
line represents the simulated population median and the grey shaded area 
covers the 5th to 95th percentile prediction interval of simulated plasma 
concentration-time profiles. The simulated versus reported study population 
mean plasma concentration-time points (right) were used for model 
verification in the adult age range. Here, the thick black line represents the 
line of identity, the dashed lines indicate the 2-fold range.  
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4.3.2 Oral ciprofloxacin PBPK model simulations for adults 
After the ciprofloxacin PBPK model was parametrized for intravenous administration in 
adults, the model was expanded to simulate oral absorption from the GI tract. Following 
the multi-parametric fit, the respective parameters were adjusted as shown in Table 4-8 and 
Table 4-9, where estimated parameters were not or only weakly correlated (Figure 4-16).  
Table 4-9  Results of the parameter identification for oral administration 
Parameter name Best value 
Dissolution shape  
Sucrose suspension 0.53 
100 mg tablet 0.30 
250 mg tablet 0.70 
500 mg tablet 0.81 
750 mg tablet 0.65 
  
Dissolution time  
Sucrose suspension 73.49 min 
100 mg tablet 43.54 min 
250 mg tablet 60.68 min 
500 mg tablet 44.75 min 
750 mg tablet 60.85 min 
  
Solubility change per charge 1212.64 
The subsequent simulations of plasma concentration–time profiles following oral 
administration of ciprofloxacin doses ranging from 50 to 1000 mg were sufficiently 
reliable compared with experimental data. Although the in vivo dissolution profile of each 
formulation for a certain dose strength was identified, the fraction dissolved was almost 
complete and a fraction absorbed of nearly 80 % was achieved allowing a bioavailability 
around 70 % across all formulations. The formulations differed in the initial phase after 
absorption leading to differences within the bioequivalence range for the time at which 
maximum plasma concentration occurred. An exemplary profile is shown in Figure 4-17. 
Results 74 
_________________________________________________________________________ 
 
Figure 4-16  Correlation matrix for parameter identification of oral absorption 
parameters. 
4.3.3 PBPK model verification 
The ciprofloxacin PBPK model for adults was verified by comparing independent datasets 
that were not used for model building with corresponding simulations. Reliable simulations 
were obtained for the mean plasma concentration-time data after intravenous and oral 
administration as visualized in Figure 4-15 and Figure 4-17. Only 4.82 % of the reported 
mean data points for intravenous and 12.13 % for oral administration were outside the 
simulated 2-fold range with no concentration-related bias. 
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Figure 4-17  Exemplary ciprofloxacin plasma concentration-time profile after a 500 mg 
oral administration and the respective goodness-of-fit plot. The symbols 
(black dots) represent the median of the individually observed plasma 
concentration with the corresponding standard deviation indicated with 
error bars [361] for the plasma concentration-time profile (left). The thick 
black line represents the simulated population median and the grey shaded 
area covers the 5th to 95th percentile prediction interval of simulated 
plasma concentration-time profiles. The simulated versus reported study 
population mean plasma concentration-time points (right) were used for 
model verification in the adult age range. Here, the thick black line 
represents the line of identity; the dashed lines indicate the 2-fold range. 
The comparison of AUC and Cmax to literature observations showed no bias for the 
respective doses (Figure 4-18). Figure 4-18 illustrates that variability in AUC is higher in 
oral compared to intravenous dosing: 4 simulated to observed AUC ratios were outside the 
1.25-fold range after intravenous dosing compared to 21 out of 44 after oral dosing. Still, 
all Cmax ratios for oral administration were within the 2-fold range, whereas 10 out of the 
21 ratios were outside the 1.25-fold range. These results showed that, overall, the PBPK 
model is well suited to describe the pharmacokinetics of ciprofloxacin after intravenous 
and oral administration in adults.  
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Figure 4-18  Verification of the ciprofloxacin PBPK model for the investigated dose 
range by comparing simulation/observation ratios of pharmacokinetic 
measures.  The plots show the mean area under the curve (AUC) following 
intravenous (a) and oral (b) administration and maximum plasma 
concentration (Cmax) following oral administration (c) of ciprofloxacin from 
various clinical studies in healthy adults at indicated doses. The thick black 
line represents line of identity (sim./obs. ratio = 1); the grey shade 
represents the 1.25-fold window, the dashed lines indicate the 2-fold range. 
4.3.4 Prediction of age-related impact on ciprofloxacin pharmacokinetics 
Considering the physiological changes related to maturation and aging of the human body, 
the ciprofloxacin PBPK model was scaled to both ends of the age-span. The model 
successfully predicted the ciprofloxacin plasma concentration-time profiles from 3 month 
to 90 years of age. Mean data points for intravenous and oral administration were well 
predicted with only 7.61 % and 5.56 % of the predictions outside the 2-fold range with no 
concentration-related bias (Figure 4-19). No observed plasma concentration-time points 
following intravenous administration were available in the literature for pediatric patients, 
which allowed only an evaluation of the predictions for geriatric patients for this route of 
administration. 
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Figure 4-19  Predictive performance of the ciprofloxacin PBPK model indicated by 
predicted versus observed mean plasma concentration data of pediatric and 
geriatric patients. Data are stratified by age group and represented as 
diamonds for pediatric [134, 136] and squares for geriatric [130, 137-139, 
142, 143] patients following intravenous (left) and oral (right) 
administration. The thick black line represents the line of identity; the 
dashed lines indicate the 2-fold range. 
Predicting the exposure following several dosing schemes in different pediatric age groups 
and overlay plots with observed data revealed a wider variability for the clinical 
observations. Towards younger ages, Cmax was well predicted for the population mean but 
the observed data also showed some extremely high concentrations in these age groups. 
However, the model was able to cover these concentrations with the predicted maximum 
plasma concentration range. The deviation was less pronounced for the adult and geriatric 
population following oral administration (Figure 4-20). Overall, on a population level, the 
ciprofloxacin PBPK model was able to predict the exposure and the respective shifts over 
the entire lifespan well as shown in Figure 4-21 and Figure 4-22.   
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Figure 4-20  Comparison of predicted and individual observed plasma concentrations 
data for ciprofloxacin grouped by age. Predicted profiles are indicated by 
solid lines for the geometric mean, shaded area for the 5–95th percentiles 
deviation and dashed lines for minimum and maximum. Individual study 
data (dots) after intravenous (left panel) and oral (right panel) 
administration of 10mg/kg ciprofloxacin every 8 h in pediatric patients of 
different age are visualized for 0-1 year (a), 1-2 years (b), 2-6 years (c) and 
6-12 years (d). Intravenous doses in adults (e, left) and geriatric patients (f, 
left) were 400 mg, whereas oral dosing in adults was 750 mg (e, right) and 
250 mg in geriatric patients (f, right). The time indicates the time after the 
first dose (before axis break) and at steady-state (after axis break). 
Observed data are based on previous studies [121, 130-132, 134, 362]. 
 
Figure 4-21  Model predictions for AUC and Cmax following intravenous and oral 
administration.Predicted/observed ratios over age for both parameters 
following intravenous (left side) and oral (right side) administration. Here, a 
solid line represents the line of unity; the grey shaded area represents the 
1.25-fold level and dashed black lines represent the 2-fold level of predicted 
accuracy.  
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Figure 4-22  Model predictions for AUC and Cmax following intravenous and oral 
suspension administration. AUC after intravenous (left) and Cmax after oral 
(right) suspension dosing prediction over age for a dose of 1 mg/kg. Here, 
predicted population data are represented as geometric mean (thick black 
line) and 90 % prediction interval (grey shaded area). Observed, dose-
normalized pharmacokinetic measures indicate reported means (dots) and 
standard deviations (error bars). 
4.3.5 Sensitivity analysis 
The parameter sensitivity analysis shown in Figure A-1 to Figure A-3 revealed that, among 
all model parameters, dose had the highest and equal impact on the pharmacokinetic 
measures AUCinf and Cmax for all age groups followed by the unbound fraction and 
parameters related to elimination pathways. For the AUCinf, age-related patterns were 
observed for the impact of metabolism and excretion. Whereas the impact of the mainly 
hepatically located CYP metabolism and biliary secretion increased towards younger age 
groups, the renal tubular secretion had a greater impact towards older age groups. More 
model parameters contributed to achieve 90 % of the cumulated total sensitivity for Cmax. 
Besides parameters related to metabolism and elimination, distribution-related parameters 
were more important with increasing age. Generally, most parameters showed a similar 
impact of age, whereas only the dose has the same sensitivity for all age groups.  
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5 Discussion 
5.1 Database development 
The PBPK elderly database described here summarizes anatomical and (patho-) 
physiological changes from early adulthood to extreme old age. Data were extracted from 
the peer-reviewed literature for all relevant PBPK parameters, and analyzed in order to 
describe the systemic changes that occur with age.  
Only a few studies have attempted geriatric PBPK modeling by including ageing 
considerations in their databases. The recent approach by McNally et al. [313] included 
detailed considerations for age-related changes in brain weight and bone mass. Also, the 
implementation of muscle mass alterations according to Janssen et al. [168], as well as the 
analysis of change of the cardiac output by Luisada et al. [363], have proven to be useful 
for PBPK modeling for the elderly. By informing bone and muscle mass, this approach 
considers changes in fat mass indirectly. However, alterations in cardiac output distribution 
and changes in major organs (such as liver and kidney) were not captured by data from the 
literature [313, 363]. 
The gathering of data from the literature for PBPK application is a serious challenge. Some 
organs, such as the brain, are well described over the entire age range, due to advances in 
analytical methods and enhanced focus on research in these areas. This enables 
investigations on secular trends and tracking of longitudinal aging trends. For other organs, 
however, the available data are sparse or outdated. One of the main cited studies referring 
to changes in liver weight over the course of ageing is from Boyd from 1933 [364]; this 
study included severely diseased individuals. Generally, due to the higher survival rate of 
women, data yield for extreme old age was less representative for men. Another hurdle is 
the research on massive blood-containing organs like the lung and the spleen. Here, an 
infection prior to death can cause high variability in the reported weight at autopsy. 
Furthermore, contrary to gestation and maturation, which involve highly predictable 
biological changes over a defined time scale, the classification of individuals beyond the 
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age of 65 years has no physiological basis. This impedes the generation of a clear reference 
interval for a certain chronological sequence, and thus increases variability. 
In contrast to studies on changes in organ volume during the ageing process, studies on 
blood flow rates and cardiac output distribution were sparse or used questionable analytical 
methods. In these cases, our data collection included information from studies on North 
Americans and Australians, and linear regression was performed. Since no study covered 
the topic of gonadal perfusion, specific blood flow was kept constant and only volumetric 
change in this organ was taken into account. Moreover, the last data point for muscle blood 
flow was for a group of 73 year-old subjects, allowing only a linear regression from young 
adulthood up to 100 years of age. Similarly, no studies on body water distribution were 
available for females above the age of 80 years. Besides lack of data, the predicted 
variability for the GFR based on kidney size variability was too high along the course of 
ageing as it can be seen in Figure 4-7. Since the GFR is linked to the kidney size in this 
PBPK modelling framework, the propagation of kidney size variability causes a wider 
spread of simulated compared to estimated GFR values. Alternative approaches such as the 
correlation of GFR and renal plasma flow have been proposed by others [276] due to the 
uncertain extent of glomerulosclerosis. However, since the renal blood flow rate also scales 
with the kidney size and underlies an additional variability, a coupling of the GFR and 
renal blood flow rate would increase the simulated GFR variability. 
5.2  Database qualification 
In the current study, parameters relevant to a PBPK approach were gathered by a 
comprehensive review of the literature, and for the first time they were integrated into a 
knowledge-driven PBPK ageing approach that captures whole-body physiology. This 
methodology enables an age-dependent description of plasma concentration-time profiles 
for young adults and elderly (Figure 4-8 and Figure 4-11). Importantly, the clinically 
observed increasing plasma concentrations in elderly for furosemide and morphine are 
reflected by the ageing PBPK model. Along with this, this approach allows description of 
the shifts in Vss and t1/2 for the paradigm compounds furosemide and morphine for on a 
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population (Figure 4-10 and Figure 4-13), but also on an individual level (Figure 4-9 and 
Figure 4-12). Unfortunately, only a few studies providing plasma concentration-time 
profiles were available, and thus an age-grouped analysis was not feasible. Especially for 
the age range 40-60 years and 85-100 years there is hardly any stratified PK data. When 
the underlying physiological changes were used the predictions were reasonably precise 
over the investigated age range. There was an underprediction of higher t1/2 values for 
furosemide, which can be due to the temporary decrease of the kidneys hydrodynamic 
observed in several patients in the first 2-3 hours after intravenous administration [116]. 
Since the GFR initially increases after administration of furosemide, a subsequent fluid 
retention inside the nephron lumen and an increase in the intracapsular hydrostatic pressure 
lead to a temporary reduction in GFR. This effect is considered to be dose-dependent [365] 
and could be assessed with an additional pharmacodynamic model.  
Although predictive performance was generally increased towards the older adult age 
range by applying the developed age-informed physiological database, mispredictions in 
certain cases can be explained by peculiarities of morphine PK. Variability in morphine PK 
is associated with variation in protein concentrations. Perturbed levels of albumin and 
alpha-1-acid glycoprotein may occur in patients suffering from acute or chronic pain as a 
result from immobility. This, in turn, will strongly impact the extent of morphine binding 
to plasma proteins [119]. Due to the high extraction ratio, the age-related changes in the 
vasculature and hepatic tissue are more descriptive for the fate of morphine [119, 366]. 
The developed PBPK approach for elderly individuals is of high clinical relevance as this 
group receives the greatest number of drug prescriptions. With this approach, knowledge 
on anatomical and (patho-) physiological age-dependencies can be used to predict 
alterations in PK from early adulthood through extreme old age. This will improve the 
prediction of effective starting drug dosages for healthy elderly patients, as depicted in 
Figure 3-1 and emphasized by Jadhav et al. [2]. Further disease implementations are 
encouraged in order to distinguish between age- and/or disease-related physiological 
alterations in drug usage. In general, this knowledge-driven approach is expected to be 
effective for increasing the efficiency of clinical trial designs, as well as for optimizing 
drug therapy in the elderly population. 
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5.3 Application of the elderly PBPK population approach 
The PBPK approach for elderly individuals was used to perform the first lifespan 
pharmacokinetic predictions for ciprofloxacin. Furthermore, a model assessment for 
predictions based on a large-scale sensitivity analysis was introduced and performed. 
After development of a ciprofloxacin adult PBPK model for intravenous administration 
based on in vitro and adult pharmacokinetic data, the model was verified for extended 
simulations in a subsequent step. Visual prediction checks for mean plasma concentration-
time data revealed a successful description of the observed data. The assessment of the 
estimated pharmacokinetic parameters led to an equally well description over the 
investigated dose range verifying the distribution-, metabolism- and elimination-related 
parametrization. This also confirmed the underlying dose linearity of ciprofloxacin since 
the PBPK model was built solely with linear elimination processes.  
The model application for an exposure simulation following intravenous administration for 
adults was then extended by gastrointestinal absorption following oral administration. 
Similarly to a recent study by Martinez el al, effective surface area enhancement factors 
were estimated to describe the impact of segmental absorption [367]. Generally, the model-
based net absorption needed to be increased in all segments, showing a large uptake in the 
duodenum and jejunum. This is in line with previous observations following an 
administration of a Remote-Control Capsule [368]. A saturated absorption with increasing 
doses discussed previously was not observed in the estimation steps [369]. The previous 
observation might be due to an administration of multiple tablets to achieve higher dose 
levels and thereby causing limitations in tablet dissolution rather than in absorption. For 
the mean plasma concentration-time data, only 4.82 % after intravenous and 12.13 % after 
oral administration of the simulation to observation ratios were outside the 2-fold range 
(Figure 4-15 and Figure 4-17). The resulting simulation to observation ratio values for 
AUC and Cmax were evenly distributed across the line of identity. 
Subsequent scaling to both ends of the age scale revealed a robust estimation of age-related 
exposure changes. Trends in AUC changes reported in literature were adequately predicted 
for intravenous and oral dosing. Prediction to observation ratios revealed a similar 
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accuracy for the mean plasma concentration-time data compared to adults. The increasing 
variability in Cmax towards younger age groups was captured by the model predictions. 
Since small intestinal transit time has a notable impact on Cmax based on the sensitivity 
analysis, but was shown to be barely age-dependent [370], an even higher net absorption 
for some individuals in the duodenum or jejunum might explain the scattered instances of 
elevated maximum plasma exposure. Although pharmacokinetic observations of 
ciprofloxacin in neonates are published, these data were not considered in this analysis 
since neonates in the respective studies were pooled with other pediatric age-groups [371] 
or treated with varying dosing schemes [372, 373]. 
In this thesis, distribution and elimination parameters for intravenous administration as 
well as in vivo dissolution and segmental absorption parameters for oral administration had 
to be identified simultaneously. The influence of these initially uncertain parameters was 
later on assessed in a sensitivity analysis, which helped to identify model uncertainties and 
foster the communication between the model developer and the clinical pharmacologist, 
who gains a better understanding of the applicability of a model in a clinical setting. The 
sensitivity analysis was conducted to scrutinize how age-dependent changes affect 
systemic exposure and assess the impact of identified parameters on the model 
performance. Mainly, parameters related to the kinetics of metabolism and excretion were 
found to be crucial for the simulated pharmacokinetic profiles (Figure A-1 to Figure A-3). 
However, the metabolism and excretion kinetic rates for each pathway were informed by 
previously reported mass-balance studies which support the confidence in the identified 
rates [148]. 
Several PBPK models for ciprofloxacin have been published over the recent years with 
different grades of complexity depending on the purpose of the respective studies. First, a 
preliminary whole-body PBPK approach of the applied model in this thesis was published 
to exemplify the best practice in model building by following simple model learning steps 
which allowed already reasonable pharmacokinetic approximations but lacked generality 
[75]. Later, Sadiq et al. parametrized an ordinary differential equation system in 
NONMEM® based on plasma observations in intensive care patients in order to predict 
target tissue concentrations and the time-course of bacterial killing at different sites of 
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infection [374]. Ball et al. and Navid et al. evaluated the drug-drug interaction potential 
using ciprofloxacin as a perpetrator drug for renal transporters [375] and CYP1A2 [376]. 
In the latter case model verification was not described, whereas the only verification 
dataset used for the Ball et al. study was under-predicted after single dose administration. 
Only Ball et al. developed a full-PBPK model on a commercial PBPK platform which 
potentially allows for age-dependent ADME scaling using the underlying databases on 
physiology and ontogeny. Navid et al. conducted drug-drug interaction predictions in 
elderly by adjusting the unspecific clearance without taking general physiological changes 
in older adults into account. 
A mechanistic description of the oral absorption of ciprofloxacin has been covered by two 
publications. First, Martinez et al. investigated the peculiarities of the oral absorption of 
ciprofloxacin with dedicated clinical trials and sophisticated stepwise information of model 
processes [367]. Recently, Hansmann et al. focused on the dosage form dissolution 
mechanisms and tried to inform in vivo behavior with in vitro dissolution, transfer and two-
stage experiments [377]. Both approaches were conducted using a commercial platform, 
but described systemic exposure with a (non-)compartmental approach. Unevaluated 
model predictions by Hansmann et al. towards the older age range showed a lower Cmax 
than in adults, which is opposed to the published clinical observations [142] and the 
predictions presented here. All these PBPK models allocate between renal and non-renal 
clearance without a precise distinction of separate processes. This limits potential 
pharmacokinetic evaluation of age- or disease-related impact on these specific processes, 
which is explicitly considered and informed in the hereby presented PBPK model.  
In summary, this developed and verified ciprofloxacin lifespan PBPK model comprises a 
thoroughly informed basis for a mechanistic representation of the compound’s absorption, 
distribution, metabolism and excretion processes, which allows a reliable scaling to both 
ends of the age scale. Therefore, such a model can be used to support clinical trial designs 
or optimize dose regimens. Special pharmacokinetic-related questions triggered by certain 
clinical scenarios can be responded adequately for this multi-pathway drug over the entire 
age span. Further pharmacokinetic assessments in other special population groups or an 
evaluation of biopharmaceutical issues during formulation development are potential 
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application scenarios and support subsequent pharmacodynamic model extension. This 
work also demonstrates the importance of an adequately established and verified PBPK 
model incorporating profound prior knowledge to allow a scientifically sound prediction. 
5.4 Challenges and opportunities to streamline dosing regimens in 
the elderly 
5.4.1 Current challenges 
The inclusion of older patients in the testing of new medications as outlined in the ICH E7 
guidelines is not mandatory for pharmaceutical industry as long as reasonable justification 
for an evasion is provided. In addition, a comprehensive representation of the elderly in 
clinical trials remains hindered by the complex nature of this patient population including 
the heterogeneity in comorbidity, poly-medication, socio-economic backgrounds, and 
physiological state. It also disqualifies a direct comparison of the elderly population in its 
entirety to healthy adults. The situation is particularly challenging for narrow therapeutic 
index drugs, where small changes in PK and/or PD have the potential to change the 
benefit/risk profile of the drug, consequently warranting close assessment in older adults. 
In addition, adherence to medication and off-label use due to poly-medication, complex 
dosing regimens, cognitive and functional disabilities are major challenges in geriatric 
pharmacotherapy in general and individualization in particular. As discussed in greater 
detail in the previous sections of this thesis, the lack of geriatric information can be 
supplemented by the application of informative pharmacometric modeling and simulation 
methods. 
5.4.2 Opportunities 
Personalization of drug therapy holds tremendous potential to change the way drug 
therapies could be used in the elderly to better care for these patients. Over the past decade, 
FDA and other regulatory authorities have been on the forefront of establishing approaches 
that increase the benefit of drug therapies, while minimizing their risk in this vulnerable 
patient population. While pediatric guidelines have been frequently updated over the past 
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decade [378, 379], respective regulatory documents are not yet available for the elderly 
even when the concepts outlined for pediatrics may be used as reference point for geriatrics 
as well. 
Whenever possible, clinical trials should include elderly subjects in order to establish 
appropriate dosing regimens for this special patient population. The conduct of these trials 
can be supported through the use of modeling and simulation approaches that account for 
the dynamic interplay between genetic and non-genetic factors in older adults as well as 
their impact on the drug’s PK/PD as a function of age. These quantitative approaches can 
be used to optimize study designs based on sparse sampling strategies to overcome some of 
the practical limitations of performing clinical trials in older adults. The success and failure 
of these approaches is closely linked to the identification of reliable biomarkers of ageing. 
Whereas the identification of age-appropriate biomarkers is currently primarily subject to 
academic research [61], an increase in research efforts can be expected over the next 
decade given the importance of this growing patient population. In addition, to these 
“hard” endpoints, the impact of socio-economic factors and patient behavior on drug 
therapy needs to be better understood when attempting to optimize treatment on a patient-
by-patient basis. To that end, a promising approach was recently promoted by Novartis in 
order to personalize clinical development in the field of oncology. The program was for a 
couple of compounds associated with certain mutations independent from the affected 
tissue [380]. Based on a hierarchical Bayesian approach, information gained in one 
subgroup can verify the potency of a compound in another subgroup [381]. This approach 
can, for example, be used in elderly cancer patients who are highly variable in their tumor 
set of mutations. It is already feasible with small study groups and, thus, could facilitate 
and personalize geriatric clinical development. The development of large databases and big 
data management that integrate prescription payment and medical claims information 
provide an opportunity for post-marketing geriatric pharmacovigilance. Database analysis 
allows for pharmacovigilance of older generic medications that may no longer be under 
active investigation. The data mining of these large health care databases does not prove a 
medication-related adverse effect but shows association that could be used to generate the 
hypotheses for future studies. 
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Therapeutic drug monitoring (TDM) approaches are nowadays a useful tool to 
individualize the dose of compounds with a narrow therapeutic window in clinical settings. 
Whereas this approach is usually based on population pharmacokinetis knowledge, PBPK 
applications in patient care will help to individualize dosing for initiating a drug treatment 
once the approach is clinically robust. Knowledge of exposure and response under a certain 
medication can be translated and applied to introduce a new treatment in this patient or 
individually help to balance the potential hazard against the possible benefit by 
understanding specific system capabilities.  
The selection of the best quantitative approach to optimize and/or personalize drug 
therapies in the elderly should be evaluated on a case-by-case basis. The success depends 
on the available knowledge on the drug based on the drug development stage and the 
biological systems. Whereas PBPK models can be useful to establish dosing regimens in 
population subgroups based on specific patho-physiological conditions during drug 
development, Bayesian approaches usually aim at individualizing the dose at the patient 
level in the clinical environment. Both approaches can be used in combination to 
understand the underlying mechanism of age-related physiology and their impact on drug 
PK/PD and to establish the most appropriate dosing regimens for each population subgroup 
since the early drug development phases. In any case, the development and application of 
these approaches is complex and requires high-level training. Additionally, for those drugs 
that require a more precise selection of the dose due to a narrow therapeutic index and high 
variability, the development of practitioner-friendly decision support tool interfaces is 
needed to simplify their clinical application [74]. 
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6 Conclusion and perspectives 
This study was set up to develop, qualify and apply a physiologically based 
pharmacokinetic (PBPK) population model for elderly individuals that considers typical 
(patho-) physiological conditions associated with ageing and allows reliable exposure 
estimations for all ages.  Elderly people are more likely to experience adverse drug 
reactions due to polymedication and the impact of age-related physiological changes that 
do not occur in younger adults typically recruited in clinical trials. Due to this knowledge 
gap, pharmacokinetics (PK) and pharmacodynamics (PD) of drugs administered to elderly 
patients are difficult to estimate. 
The onset and course of ageing for different organs is highly heterogeneous due to the 
dynamic interplay between multiple, complex and poorly understood genetic, 
environmental, and disease-related risk factors as well as the difference between 
chronological and biological age. This results in a pharmacological heterogeneity in elderly 
patients. In this thesis, the anatomical and physiological changes with healthy ageing were 
analyzed from the literature and assembled to a PBPK database. Since this whole-body 
PBPK database is publicly accessible in the Open Systems Pharmacology Suite 
(https://github.com/open-systems-pharmacology), an open source platform, further 
research is encouraged and promoted by direct interaction of researchers on the platform.  
When analyzing the literature data, several knowledge gaps and inconsistencies were 
identified. Additionally, age-related process-specific information such as enzyme and 
transporter activities was not considered in this study. Therefore, the database allows 
distinguishing between functional capability and physiological changes. The open source 
platform enables the user to update and adapt the compiled database presented in this thesis 
once new information has become available. Furthermore, this study describes 
mechanistically the data processing from literature findings towards a PBPK population 
database. Since the approach provides the ability to differentiate between age- and disease-
related physiological alterations, the database facilitates an implementation of additional 
patho-physiological implications of certain disease states. 
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Both physiological qualification with unused datasets and pharmacokinetic verification 
with single elimination pathway compounds were successfully performed. With such 
stringent model qualification this work took into account the increasing awareness of 
model qualification during the development of new PBPK approaches in the scientific 
community. Statistical evaluation of PBPK population model performance for elderly 
showed a clear improvement compared to age-uninformed simulations. To allow a 
judgement on the confidence in a PBPK model, a global sensitivity analysis for every 
parameter of each simulated age-group was conducted. This analysis quantifies the 
uncertainty in a PBPK model due to the unknown underlying biology or mechanisms. 
Although this procedure is technically complex for generic whole-body PBPK models with 
usually more than 130 parameters per simulation, it will become common practice in 
PBPK model development, not least due to the recently issued European Medicines 
Agency (EMA) guideline [89]. 
In a final step, the predictive performance of the PBPK approach was assessed by scaling a 
comprehensively informed ciprofloxacin whole-body PBPK model to the elderly. The 
study showed reliable predictions outside of the tested adult age range towards the 
extremes of ages. The analysis indicated that the current dosing scheme for ciprofloxacin 
ensures a consistent exposure for the entire age-range. Furthermore, the established and 
verified ciprofloxacin model can be applied for further pharmacokinetic assessments in 
other special population groups or for the evaluation of biopharmaceutical issues during 
formulation development.  
Although exposure changes with increasing age were analyzed in this thesis by a thorough 
literature investigation on anatomical and physiological changes, guidance for 
pharmacotherapy in older adults will inevitable be driven by changes in drug response. 
However, alterations in pharmacodynamics with increasing age are poorly understood in 
many cases. In order to understand changes in drug response following a certain dose, 
exposure is a reliable link. The hereby presented approach supports drug exposure 
estimations at the target site and by that encourage additional research on target alterations 
in elderly patients. 
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In conclusion this model represents a valuable tool for the assessment of drug exposure in 
the elderly. Further, it facilitates the optimization of dosing regimens and clinical trials 
with regard to the safety and efficacy profile of a given compound. This would improve 
pharmacotherapy and increase drug safety, thereby reducing costs resulting from adverse 
events caused by inappropriate dosing. 
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7 Summary 
Clinical drug development is traditionally focused on young and middle-aged adults. The 
elderly are often underrepresented in clinical trials, even though persons aged 65 years and 
older receive the majority of drug prescriptions. Consequently, there is a knowledge gap on  
dose-exposure relationships in elderly subjects. This thesis aimed at contributing to a better 
understanding of the age-related mechanisms governing the pharmacokinetics (PK) in this 
clinically understudied population. 
First, a physiologically based pharmacokinetic (PBPK) database for the course of healthy 
ageing was successfully established. For parameterization of the PBPK model for healthy 
ageing individuals, anthropometric and physiological data were identified in the literature, 
which were incorporated into the PBPK software PK-Sim®. Although age-related changes 
occurring from 65 to 100 years of age were the main focus of this work, data on anatomical 
and physiological changes beginning from early adulthood to the elderly age range were 
also included for a sound and continuous description of ageing humans. In total, 118 
studies comprising 47029 male and 67419 female subjects were included to build the 
elderly PBPK database. 
As next step, the capability of the elderly PBPK approach to predict the distribution and 
elimination of drugs was verified using the test compounds morphine and furosemide 
administered intravenously. Both drugs are cleared by a single elimination pathway. PK 
parameters for the two compounds in younger adults and elderly individuals were obtained 
from the literature. Matching virtual populations – with regard to age, gender, 
anthropometric measures and dosage – were generated. Profiles of plasma drug 
concentration over time, volume of distribution at steady-state (Vss) and elimination half-
lives (t1/2) from the literature were compared to those predicted by PBPK simulations, for 
both younger adults and the elderly. Based on age-informed physiology, the predicted PK 
profiles described age-associated trends well. The root mean squared prediction error 
(RMSE) for the prediction of plasma concentrations for furosemide and morphine in the 
elderly was improved by 32% and 49%, respectively, compared to predictions without age-
informed physiology. The majority of the individual Vss and t1/2 values of the two model 
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compounds furosemide and morphine were well predicted in the elderly population, except 
for long furosemide half-lives. 
Finally, the reliability of predictions outside the tested adult age range towards the 
extremes of ages was assessed using the multi-elimination pathway compound 
ciprofloxacin as probe drug. Mean data of 69 published clinical trials were identified and 
used for model building, simulation as well as the verification process. The predictive 
performance on both ends of the age scale was assessed using individual data of 
236 pediatric and 22 geriatric patients observed in clinical trials. Ciprofloxacin model 
verification demonstrated no concentration-related bias and accurate predictions for the 
adult age range with only 4.8 % of the mean observed concentrations following 
intravenous and 12.1 % following oral administration outside the simulated 2-fold range. 
Predictions towards both extremes of ages for the area under the plasma concentration–
time curve (AUC) and the maximum plasma concentration (Cmax) were reliable. 
The results of this thesis support the feasibility of using a knowledge-driven PBPK ageing 
model to predict PK alterations throughout the entire course of ageing, and thus to 
optimize drug therapy also in older adult individuals. Overall, the predictive power of a 
thoroughly informed middle-out approach towards older adults to potentially support the 
decision making process for pharmacotherapy in the elderly was demonstrated. These 
results indicate that medication safety in geriatric patients may be greatly facilitated by the 
information gained from PBPK predictions.  
 
95  References 
_________________________________________________________________________ 
References 
1. Lesko LJ, Schmidt S. Individualization of drug therapy: history, present state, and 
opportunities for the future. Clin Pharmacol Ther 2012;92:458-66. 
2. Jadhav PR, Cook J, Sinha V, Zhao P, Rostami-Hodjegan A, Sahasrabudhe V, et al. A 
proposal for scientific framework enabling specific population drug dosing 
recommendations. J Clin Pharmacol 2015;55:1073-8. 
3. Patki KC, von Moltke LL, Harmatz JS, Hesse LM, Court MH, Greenblatt DJ. Effect of age 
on in vitro triazolam biotransformation in male human liver microsomes. J Pharmacol Exp 
Ther 2004;308:874-9. 
4. ICH. E7 studies in support of special populations: Geriatrics.  International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human 
Use (ICH); 1993 
5. Swanlund SL. Successful cardiovascular medication management processes as perceived by 
community-dwelling adults over age 74. Appl Nurs Res 2010;23:22-9. 
6. de Onis M, Habicht JP. Anthropometric reference data for international use: 
recommendations from a World Health Organization Expert Committee. Am J Clin Nutr 
1996;64:650-8. 
7. FDA. E7 Studies in Support of Special Populations: Geriatrics U.S. Department of Health 
and Human Services Food and Drug Administration (FDA); 2012 
8. EMA. Studies in Support of Special Populations: Geriatrics, Questions and Answers.  
European Medicines Agency (EMA); 2010 
9. Beers E, Egberts TC, Leufkens HG, Jansen PA. Information for adequate prescribing to 
older patients : an evaluation of the product information of 53 recently approved medicines. 
Drugs Aging 2013;30:255-62. 
10. Masoudi FA, Havranek EP, Wolfe P, Gross CP, Rathore SS, Steiner JF, et al. Most 
hospitalized older persons do not meet the enrollment criteria for clinical trials in heart 
failure. Am Heart J 2003;146:250-7. 
11. Martin K, Begaud B, Latry P, Miremont-Salame G, Fourrier A, Moore N. Differences 
between clinical trials and postmarketing use. Br J Clin Pharmacol 2004;57:86-92. 
12. Schaufler J, Telschow C. Arzneimittelverordnungen nach Alter und Geschlecht. In: Schwabe 
U, Paffrath D, editors. Arzneiverordnungs-Report 2016: Aktuelle Daten, Kosten, Trends und 
Kommentare. Berlin, Heidelberg: Springer Berlin Heidelberg; 2016. p. 763-73. 
13. Golden AG, Tewary S, Dang S, Roos BA. Care management's challenges and opportunities 
to reduce the rapid rehospitalization of frail community-dwelling older adults. Gerontologist 
2010;50:451-8. 
References 96 
_________________________________________________________________________ 
14. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. 
Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 
2003;21:1383-9. 
15. Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, Weinberg AD. Disparate 
inclusion of older adults in clinical trials: priorities and opportunities for policy and practice 
change. Am J Public Health 2010;100 Suppl 1:S105-12. 
16. Cherubini A, Del Signore S, Ouslander J, Semla T, Michel JP. Fighting against age 
discrimination in clinical trials. J Am Geriatr Soc 2010;58:1791-6. 
17. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for 
determining inappropriate medication use in nursing home residents. UCLA Division of 
Geriatric Medicine. Arch Intern Med 1991;151:1825-32. 
18. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the 
elderly. An update. Arch Intern Med 1997;157:1531-6. 
19. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers 
criteria for potentially inappropriate medication use in older adults: results of a US consensus 
panel of experts. Arch Intern Med 2003;163:2716-24. 
20. Fick DM, Semla TP. 2012 American Geriatrics Society Beers Criteria: new year, new 
criteria, new perspective. J Am Geriatr Soc 2012;60:614-5. 
21. Radcliff S, Yue J, Rocco G, Aiello SE, Ickowicz E, Hurd Z, et al. American Geriatrics 
Society 2015 updated beers criteria for potentially inappropriate medication use in older 
adults. J Am Geriatr Soc 2015;63:2227-46. 
22. Golden A, Silverman M, Daiello L, Llorente M. Inappropriate Medication Prescribing: 
Going Beyond The Beer’s Criteria. Long-Term Care Interface magazine 2005;6:31-4. 
23. Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially 
inappropriate Prescriptions): application to acutely ill elderly patients and comparison with 
Beers' criteria. Age Ageing 2008;37:673-9. 
24. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START 
criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 
2015;44:213-8. 
25. Hamilton H, Gallagher P, Ryan C, Byrne S, O'Mahony D. Potentially inappropriate 
medications defined by STOPP criteria and the risk of adverse drug events in older 
hospitalized patients. Arch Intern Med 2011;171:1013-9. 
26. Holt S, Schmiedl S, Thurmann PA. Potentially inappropriate medications in the elderly: the 
PRISCUS list. Dtsch Arztebl Int 2010;107:543-51. 
27. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in 
prescribing for elderly people: a national consensus panel. CMAJ 1997;156:385-91. 
97  References 
_________________________________________________________________________ 
28. Laroche ML, Charmes JP, Merle L. Potentially inappropriate medications in the elderly: a 
French consensus panel list. Eur J Clin Pharmacol 2007;63:725-31. 
29. Kuhn-Thiel AM, Weiss C, Wehling M, members Faep. Consensus validation of the FORTA 
(Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of 
pharmacotherapy in the elderly. Drugs Aging 2014;31:131-40. 
30. Wehling M, Burkhardt H, Kuhn-Thiel A, Pazan F, Throm C, Weiss C, et al. VALFORTA: a 
randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing 
2016;45:262-7. 
31. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for 
adverse drug events in older Americans. N Engl J Med 2011;365:2002-12. 
32. Golden A, Beers MH, Fick DM. Is it safe to conclude that Beers criteria medications led to 
few adverse events? Ann Intern Med 2008;148:628-9; author reply 9. 
33. Golden A, Troen B. Biology of aging. In: Hirth V, Wieland D, Dever-Bumba M, editors. 
Case-Based Geriatrics. New York: McGraw Hill; 2010. 
34. Butler RN, Sprott R, Warner H, Bland J, Feuers R, Forster M, et al. Biomarkers of aging: 
from primitive organisms to humans. J Gerontol A Biol Sci Med Sci 2004;59:B560-7. 
35. Brooks-Wilson AR. Genetics of healthy aging and longevity. Hum Genet 2013;132:1323-38. 
36. Miles C, Wayne M. Quantitative trait locus (QTL) analysis. Nature Education 2008;1:208. 
37. Oztaner SM, Taskaya Temizel T, Erdem SR, Ozer M. A Bayesian Estimation Framework for 
Pharmacogenomics Driven Warfarin Dosing: A Comparative Study. IEEE J Biomed Health 
Inform 2015;19:1724-33. 
38. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 
screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79. 
39. FDA. Table of Pharmacogenomic Biomarkers in Drug Labeling.  U.S. Department of Health 
and Human Services Food and Drug Administration (FDA); 2015 
40. Winner J. Pharmacogenomic Treatment Support. Today’s Geriatric Medicine 2014;4:20. 
41. Waade RB, Hermann M, Moe HL, Molden E. Impact of age on serum concentrations of 
venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. Eur J 
Clin Pharmacol 2014;70:933-40. 
42. Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and 
VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing 
regimen in Chinese patients. Eur J Clin Pharmacol 2007;63:1135-41. 
43. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, et al. Use of 
pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin 
Pharmacol Ther 2008;84:326-31. 
References 98 
_________________________________________________________________________ 
44. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of 
CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose 
requirements: proposal for a new dosing regimen. Blood 2005;106:2329-33. 
45. Bor JS. The search for effective Alzheimer's therapies: a work in progress. Health Aff 
(Millwood) 2014;33:527-33. 
46. Du YF, Ou HY, Beverly EA, Chiu CJ. Achieving glycemic control in elderly patients with 
type 2 diabetes: a critical comparison of current options. Clin Interv Aging 2014;9:1963-80. 
47. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older 
adults: a consensus report. J Am Geriatr Soc 2012;60:2342-56. 
48. Bonaventura A, Montecucco F, Dallegri F. Update on strategies limiting iatrogenic 
hypoglycemia. Endocr Connect 2015;4:R37-45. 
49. Meneilly GS, Ryan AS, Veldhuis JD, Elahi D. Increased disorderliness of basal insulin 
release, attenuated insulin secretory burst mass, and reduced ultradian rhythmicity of insulin 
secretion in older individuals. J Clin Endocrinol Metab 1997;82:4088-93. 
50. Geloneze B, de Oliveira Mda S, Vasques AC, Novaes FS, Pareja JC, Tambascia MA. 
Impaired incretin secretion and pancreatic dysfunction with older age and diabetes. 
Metabolism 2014;63:922-9. 
51. Leong R, Vieira ML, Zhao P, Mulugeta Y, Lee CS, Huang SM, et al. Regulatory experience 
with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin 
Pharmacol Ther 2012;91:926-31. 
52. FDA. General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and 
Biological Products.  U.S. Department of Health and Human Services Food and Drug 
Administration (FDA); 2014 
53. Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic 
changes in the elderly. Clinical implications. Clin Pharmacokinet 1998;35:49-64. 
54. Borst SE, Scarpace PJ. Reduced high-affinity alpha 1-adrenoceptors in liver of senescent 
rats: implications of assessment at various temperatures. Br J Pharmacol 1990;101:650-4. 
55. Morley JE, Flood JF, Silver AJ. Opioid peptides and aging. Ann N Y Acad Sci 
1990;579:123-32. 
56. Kane R, Ouslander J, Abrass I, Resnick B. Essentials of Clinical Geriatrics, 7th ed. New 
York: McGraw-Hill; 2013. 
57. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev 
Drug Discov 2006;5:956-70. 
58. Vozmediano V, Ortega I, Lukas JC, Gonzalo A, Rodriguez M, Lucero ML. Integration of 
preclinical and clinical knowledge to predict intravenous PK in human: bilastine case study. 
Eur J Drug Metab Pharmacokinet 2014;39:33-41. 
99  References 
_________________________________________________________________________ 
59. Encinas E, Calvo R, Lukas JC, Vozmediano V, Rodriguez M, Suarez E. A predictive 
pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates 
based on a semi-physiologic approach. Paediatr Drugs 2013;15:247-57. 
60. Samant TS, Mangal N, Lukacova V, Schmidt S. Quantitative clinical pharmacology for size 
and age scaling in pediatric drug development: A systematic review. J Clin Pharmacol 2015. 
61. Lagishetty C. Covariates in Pharmacometrics [PhD thesis] Chapter 1; p.26-27: University of 
Otago; 2013. 
62. BMS-Pfizer. Eliquis (apixaban) - Summary of Product Characteristics.  Bristol-Myers 
Squibb (BMS) Pfizer European economic interest grouping (EEIG); 2013 
63. Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and 
pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014;53:1-16. 
64. Saeed MA, Vlasakakis G, Della Pasqua O. Rational use of medicines in older adults: Can we 
do better during clinical development? Clin Pharmacol Ther 2015;97:440-3. 
65. Rogers JA, Polhamus D, Gillespie WR, Ito K, Romero K, Qiu R, et al. Combining patient-
level and summary-level data for Alzheimer's disease modeling and simulation: a beta 
regression meta-analysis. J Pharmacokinet Pharmacodyn 2012;39:479-98. 
66. Oteo I, Lukas JC, Leal N, Suarez E, Valdivieso A, Gastaca M, et al. Tacrolimus 
pharmacokinetics in the early post-liver transplantation period and clinical applicability via 
Bayesian prediction. Eur J Clin Pharmacol 2013;69:65-74. 
67. Hennig S, Norris R, Kirkpatrick CM. Target concentration intervention is needed for 
tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic 
study. Br J Clin Pharmacol 2008;65:502-10. 
68. Valdivieso N, Oteo I, Valdivieso A, Lukas JC, Leal N, Gastaca M, et al. Tacrolimus dose 
individualization in "de novo" patients after 10 years of experience in liver transplantation: 
pharmacokinetic considerations and patient pathophysiology. Int J Clin Pharmacol Ther 
2013;51:606-14. 
69. Oteo I, Lukas JC, Leal N, Suarez E, Valdivieso A, Gastaca M, et al. Pathophysiological 
idiosyncrasies and pharmacokinetic realities may interfere with tacrolimus dose titration in 
liver transplantation. Eur J Clin Pharmacol 2011;67:671-9. 
70. Sanchez A, Cabrera S, Santos D, Valverde MP, Fuertes A, Dominguez-Gil A, et al. 
Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in 
Caucasian HIV-infected patients. Antimicrob Agents Chemother 2011;55:5314-24. 
71. Karafoulidou A, Suarez E, Anastasopoulou I, Katsarou O, Kouramba A, Kotsi P, et al. 
Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative 
and HIV-positive haemophilia patients. Eur J Clin Pharmacol 2009;65:1121-30. 
  
References 100 
_________________________________________________________________________ 
72. Krauss M, Tappe K, Schuppert A, Kuepfer L, Goerlitz L. Bayesian Population 
Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic 
Characterization of Interindividual Variability in Clinically Relevant Populations. PLoS One 
2015;10:e0139423. 
73. Krauss M, Burghaus R, Lippert J, Niemi M, Neuvonen P, Schuppert A, et al. Using 
Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup 
stratification. In Silico Pharmacol 2013;1:6. 
74. Zineh I, Huang SM. Biomarkers in drug development and regulation: a paradigm for clinical 
implementation of personalized medicine. Biomark Med 2011;5:705-13. 
75. Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, et al. Applied 
Concepts in PBPK Modeling: How to Build a PBPK/PD Model. CPT Pharmacometrics Syst 
Pharmacol 2016;5:516-31. 
76. Huang SM, Abernethy DR, Wang Y, Zhao P, Zineh I. The utility of modeling and simulation 
in drug development and regulatory review. J Pharm Sci 2013;102:2912-23. 
77. Jones HM, Dickins M, Youdim K, Gosset JR, Attkins NJ, Hay TL, et al. Application of 
PBPK modelling in drug discovery and development at Pfizer. Xenobiotica 2012;42:94-106. 
78. Polasek TM, Patel F, Jensen BP, Sorich MJ, Wiese MD, Doogue MP. Predicted metabolic 
drug clearance with increasing adult age. Br J Clin Pharmacol 2013;75:1019-28. 
79. Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, et al. Development of 
a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the 
Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet 2016;55:1573-89. 
80. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA. Prediction of human 
pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 
clinically tested drugs. Drug Metab Dispos 2007;35:1766-80. 
81. Sinha VK, Snoeys J, Osselaer NV, Peer AV, Mackie C, Heald D. From preclinical to human-
-prediction of oral absorption and drug-drug interaction potential using physiologically based 
pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using 
case example. Biopharm Drug Dispos 2012;33:111-21. 
82. Schaller S, Willmann S, Lippert J, Schaupp L, Pieber TR, Schuppert A, et al. A Generic 
Integrated Physiologically based Whole-body Model of the Glucose-Insulin-Glucagon 
Regulatory System. CPT Pharmacometrics Syst Pharmacol 2013;2:e65. 
83. Vidal EI, Mayoral VF, Villas Boas PJ, Jacinto AF, Fukushima FB. Physical Frailty As a 
Clinical Marker of Biological Age and Aging. J Am Geriatr Soc 2015;63:837-8. 
84. Turnheim K. Drug dosage in the elderly. Is it rational? Drugs Aging 1998;13:357-79. 
85. Thompson CM, Johns DO, Sonawane B, Barton HA, Hattis D, Tardif R, et al. Database for 
physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and 
health-impaired elderly. J Toxicol Environ Health B Crit Rev 2009;12:1-24. 
101  References 
_________________________________________________________________________ 
86. Kawamura H. Development of the Japanese reference man model for age-specific phantoms. 
Radiat Prot Dosimetry 2012;149:28-34. 
87. Shepard T, Scott G, Cole S, Nordmark A, Bouzom F. Physiologically Based Models in 
Regulatory Submissions: Output From the ABPI/MHRA Forum on Physiologically Based 
Modeling and Simulation. CPT Pharmacometrics Syst Pharmacol 2015;4:221. 
88. EPA. Physiologically-Based Pharmacokinetic (PBPK) Modeling White Paper: Addressing 
the Use of PBPK Models to Support Derivation of Acute Exposure Guideline Levels.  US 
Environmental Protection Agency (EPA); 2010 
89. EMA. Draft guideline on the qualification and reporting of physiologically based 
pharmacokinetic (PBPK) modelling and simulation.  European Medicines Agency (EMA); 
2016 
90. FDA. Physiologically Based Pharmacokinetic Analyses — Format and Content U.S. 
Department of Health and Human Services Food and Drug Administration (FDA); 2016 
91. Rowland M, Tozer TN. Clinical pharmacokinetics/pharmacodynamics. 4th ed. ed: Lippincott 
Williams and Wilkins Philadelphia; 2005. 
92. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol 
Rev 2004;56:163-84. 
93. Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J 2011;13:519-
47. 
94. Le Couteur DG, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion 
barrier hypothesis. Clin Pharmacokinet 1998;34:359-73. 
95. Benedetti MS, Whomsley R, Canning M. Drug metabolism in the paediatric population and 
in the elderly. Drug Discov Today 2007;12:599-610. 
96. Dean L. Clopidogrel Therapy and CYP2C19 Genotype. 2012 Mar 8 [Updated 2013 Mar 18].  
Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology 
Information (US). http://www.ncbi.nlm.nih.gov/books/NBK84114. Accessed June 1, 2017.; 
2012. 
97. Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2004;2:274-302. 
98. Kinirons MT, O'Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol 
2004;57:540-4. 
99. Liukas A, Kuusniemi K, Aantaa R, Virolainen P, Niemi M, Neuvonen PJ, et al. 
Pharmacokinetics of intravenous paracetamol in elderly patients. Clin Pharmacokinet 
2011;50:121-9. 
100. WHO. International Programme on Chemical Safety Harmonization Project. 
Characterization and application of physiologically based pharmacokinetic models in risk 
assessment. Harmonization Project Document No. 9. 2010 
References 102 
_________________________________________________________________________ 
101. Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically Based 
Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of 
Published Models, Applications, and Model Verification. Drug Metab Dispos 2015;43:1823-
37. 
102. Valentin J. Basic anatomical and physiological data for use in radiological protection: 
reference values: ICRP Publication 89. Annals of the ICRP 2002;32:1-277. 
103. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for 
oral drug absorption: immediate release dosage forms. Pharm Res 1998;15:11-22. 
104. Poulin P, Theil FP. A priori prediction of tissue:plasma partition coefficients of drugs to 
facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J 
Pharm Sci 2000;89:16-35. 
105. Poulin P, Schoenlein K, Theil FP. Prediction of adipose tissue: plasma partition coefficients 
for structurally unrelated drugs. J Pharm Sci 2001;90:436-47. 
106. Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: 
predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005;94:1259-76. 
107. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the 
tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 
2006;95:1238-57. 
108. Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, W. S. PK-Sim: a physiologically 
based pharmacokinetic 'whole-body' model. . Biosilico 2003;1:121-4. 
109. Willmann S, Lippert J, Schmitt W. From physicochemistry to absorption and distribution: 
predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol 
2005;1:159-68. 
110. Loidl-Stahlhofen A, Hartmann T, Schottner M, Rohring C, Brodowsky H, Schmitt J, et al. 
Multilamellar liposomes and solid-supported lipid membranes (TRANSIL): screening of 
lipid-water partitioning toward a high-throughput scale. Pharm Res 2001;18:1782-8. 
111. Saisho Y, Butler AE, Meier JJ, Monchamp T, Allen-Auerbach M, Rizza RA, et al. Pancreas 
volumes in humans from birth to age one hundred taking into account sex, obesity, and 
presence of type-2 diabetes. Clin Anat 2007;20:933-42. 
112. Willmann S, Hohn K, Edginton A, Sevestre M, Solodenko J, Weiss W, et al. Development of 
a physiology-based whole-body population model for assessing the influence of individual 
variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 2007;34:401-
31. 
113. Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic 
physiologically based pharmacokinetic model for children. Clin Pharmacokinet 
2006;45:1013-34. 
103  References 
_________________________________________________________________________ 
114. Tiseo PJ, Thaler HT, Lapin J, Inturrisi CE, Portenoy RK, Foley KM. Morphine-6-
glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 
1995;61:47-54. 
115. Waller ES, Massarella JW, Tomkiw MS, Smith RV, Doluisio JT. Pharmacokinetics of 
furosemide after three different single oral doses. Biopharm Drug Dispos 1985;6:109-17. 
116. Ponto LL, Schoenwald RD. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic 
review (Part I). Clin Pharmacokinet 1990;18:381-408. 
117. Avdeef A, Barrett DA, Shaw PN, Knaggs RD, Davis SS. Octanol-, chloroform-, and 
propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other 
related opiates. J Med Chem 1996;39:4377-81. 
118. Cutler RE, Blair AD. Clinical pharmacokinetics of frusemide. Clin Pharmacokinet 
1979;4:279-96. 
119. Glare PA, Walsh TD. Clinical pharmacokinetics of morphine. Ther Drug Monit 1991;13:1-
23. 
120. Andreasen F, Christensen CK, Jacobsen FK, Jansen J, Mogensen CE, Pedersen OL. The 
individual variation in pharmacokinetics and pharmacodynamics of furosemide in young 
normal male subjects. Eur J Clin Invest 1982;12:247-55. 
121. Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric 
patients. J Clin Pharmacol 2003;43:698-710. 
122. van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes 
AR. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J 
Crit Care 2008;23:422-30. 
123. Lipman J, Scribante J, Gous AG, Hon H, Tshukutsoane S. Pharmacokinetic profiles of high-
dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study 
Group. Antimicrob Agents Chemother 1998;42:2235-9. 
124. Ruhnke M, Trautmann M, Borner K, Hopfenmuller W. Pharmacokinetics of ciprofloxacin in 
liver cirrhosis. Chemotherapy 1990;36:385-91. 
125. Frost RW, Lettieri JT, Krol G, Shamblen EC, Lasseter KC. The effect of cirrhosis on the 
steady-state pharmacokinetics of oral ciprofloxacin. Clin Pharmacol Ther 1989;45:608-16. 
126. Hackam DJ, Christou N, Khaliq Y, Duffy DR, Vaughan D, Marshall JC, et al. 
Bioavailability of oral ciprofloxacin in early postsurgical patients. Arch Surg 
1998;133:1221-5. 
127. Cohn SM, Cohn KA, Rafferty MJ, Smith AH, Degutis LC, Kowalsky SF, et al. Enteric 
absorption of ciprofloxacin during the immediate postoperative period. J Antimicrob 
Chemother 1995;36:717-21. 
References 104 
_________________________________________________________________________ 
128. Gattis WA, Petros WP, Pickard WW, Drew RH, May DB, Hathorn JW. A prospective, open-
label study of single-dose ciprofloxacin absorption after chemotherapy in patients with 
malignancy. Pharmacotherapy 1997;17:836-40. 
129. Johnson EJ, MacGowan AP, Potter MN, Stockley RJ, White LO, Slade RR, et al. Reduced 
absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. J 
Antimicrob Chemother 1990;25:837-42. 
130. Shah A, Lettieri J, Nix D, Wilton J, Heller AH. Pharmacokinetics of high-dose intravenous 
ciprofloxacin in young and elderly and in male and female subjects. Antimicrob Agents 
Chemother 1995;39:1003-6. 
131. Bayer A, Gajewska A, Stephens M, Stark JM, Pathy J. Pharmacokinetics of ciprofloxacin in 
the elderly. Respiration 1987;51:292-5. 
132. Israel D, Gillum JG, Turik M, Harvey K, Ford J, Dalton H, et al. Pharmacokinetics and 
serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in 
healthy volunteers. Antimicrob Agents Chemother 1993;37:2193-9. 
133. Aggarwal P, Dutta S, Garg SK, Narang A. Multiple dose pharmacokinetics of ciprofloxacin 
in preterm babies. Indian Pediatr 2004;41:1001-7. 
134. Peltola H, Ukkonen P, Saxen H, Stass H. Single-dose and steady-state pharmacokinetics of a 
new oral suspension of ciprofloxacin in children. Pediatrics 1998;101:658-62. 
135. Salam MA, Dhar U, Khan WA, Bennish ML. Randomised comparison of ciprofloxacin 
suspension and pivmecillinam for childhood shigellosis. Lancet 1998;352:522-7. 
136. Peltola H, Vaarala M, Renkonen OV, Neuvonen PJ. Pharmacokinetics of single-dose oral 
ciprofloxacin in infants and small children. Antimicrob Agents Chemother 1992;36:1086-90. 
137. Hirata CA, Guay DR, Awni WM, Stein DJ, Peterson PK. Steady-state pharmacokinetics of 
intravenous and oral ciprofloxacin in elderly patients. Antimicrob Agents Chemother 
1989;33:1927-31. 
138. Kees F, Naber KG, Meyer GP, Grobecker H. Pharmacokinetics of ciprofloxacin in elderly 
patients. Arzneimittelforschung 1989;39:523-7. 
139. Naber KG, Sorgel F, Kees F, Jaehde U, Schumacher H. Pharmacokinetics of ciprofloxacin in 
young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal 
fluid, and prostatic adenoma tissue following intravenous administration. Am J Med 
1989;87:57S-9S. 
140. Pea F, Milaneschi R, Baraldo M, Lugatti E, Talmassons G, Furlanut M. Ciprofloxacin 
disposition in elderly patients with LRTI being treated with sequential therapy (200 mg 
intravenously twice daily followed by 500 mg per os twice daily): comparative 
pharmacokinetics and the role of therapeutic drug monitoring. Ther Drug Monit 
2000;22:386-91. 
105  References 
_________________________________________________________________________ 
141. Cios A, Wyska E, Szymura-Oleksiak J, Grodzicki T. Population pharmacokinetic analysis of 
ciprofloxacin in the elderly patients with lower respiratory tract infections. Exp Gerontol 
2014;57:107-13. 
142. Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of ciprofloxacin in the elderly: increased oral 
bioavailability and reduced renal clearance. Eur J Clin Microbiol Infect Dis 1989;8:515-20. 
143. LeBel M, Barbeau G, Bergeron MG, Roy D, Vallee F. Pharmacokinetics of ciprofloxacin in 
elderly subjects. Pharmacotherapy 1986;6:87-91. 
144. Chandler MH, Toler SM, Rapp RP, Muder RR, Korvick JA. Multiple-dose pharmacokinetics 
of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. Antimicrob Agents 
Chemother 1990;34:442-7. 
145. Dan M, Golomb J, Gorea A, Braf Z, Berger SA. Concentration of ciprofloxacin in human 
prostatic tissue after oral administration. Antimicrob Agents Chemother 1986;30:88-9. 
146. Guay DR, Awni WM, Peterson PK, Obaid S, Stein D, Breitenbucher R, et al. Single and 
multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients. Int J Clin Pharmacol 
Ther Toxicol 1988;26:279-84. 
147. Dan M, Verbin N, Gorea A, Nagar H, Berger SA. Concentrations of ciprofloxacin in human 
liver, gallbladder, and bile after oral administration. Eur J Clin Pharmacol 1987;32:217-8. 
148. Rohwedder RW, Bergan T, Thorsteinsson SB, Scholl H. Transintestinal elimination of 
ciprofloxacin. Diagn Microbiol Infect Dis 1990;13:127-33. 
149. Alvarez AI, Perez M, Prieto JG, Molina AJ, Real R, Merino G. Fluoroquinolone efflux 
mediated by ABC transporters. J Pharm Sci 2008;97:3483-93. 
150. Vanwert AL, Srimaroeng C, Sweet DH. Organic anion transporter 3 (oat3/slc22a8) interacts 
with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. 
Mol Pharmacol 2008;74:122-31. 
151. Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases 
concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-
mediated presystemic metabolism. Clin Pharmacol Ther 2004;76:598-606. 
152. Sorgel F, Naber KG, Jaehde U, Reiter A, Seelmann R, Sigl G. Gastrointestinal secretion of 
ciprofloxacin. Evaluation of the charcoal model for investigations in healthy volunteers. Am 
J Med 1989;87:62S-5S. 
153. Parry MF, Smego DA, Digiovanni MA. Hepatobiliary kinetics and excretion of 
ciprofloxacin. Antimicrob Agents Chemother 1988;32:982-5. 
154. Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J. Evolution of a 
detailed physiological model to simulate the gastrointestinal transit and absorption process in 
humans, part 1: oral solutions. J Pharm Sci 2011;100:5324-45. 
155. Edginton AN, Schmitt W, Voith B, Willmann S. A mechanistic approach for the scaling of 
clearance in children. Clin Pharmacokinet 2006;45:683-704. 
References 106 
_________________________________________________________________________ 
156. Willmann S, Becker C, Burghaus R, Coboeken K, Edginton A, Lippert J, et al. Development 
of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin 
Pharmacokinet 2014;53:89-102. 
157. Perissinotto E, Pisent C, Sergi G, Grigoletto F. Anthropometric measurements in the elderly: 
age and gender differences. Br J Nutr 2002;87:177-86. 
158. Wahren J. [Average body weight and correlation weight in relation to age and sex]. Z 
Morphol Anthropol 1981;72:65-76. 
159. Rea IM, Gillen S, Clarke E. Anthropometric measurements from a cross-sectional survey of 
community dwelling subjects aged over 90 years of age. Eur J Clin Nutr 1997;51:102-6. 
160. Ravaglia G, Morini P, Forti P, Maioli F, Boschi F, Bernardi M, et al. Anthropometric 
characteristics of healthy Italian nonagenarians and centenarians. Br J Nutr 1997;77:9-17. 
161. Eiben G, Dey DK, Rothenberg E, Steen B, Bjorkelund C, Bengtsson C, et al. Obesity in 70-
year-old Swedes: secular changes over 30 years. Int J Obes (Lond) 2005;29:810-7. 
162. Bartali B, Benvenuti E, Corsi AM, Bandinelli S, Russo CR, Di Iorio A, et al. Changes in 
anthropometric measures in men and women across the life-span: findings from the 
InCHIANTI study. Soz Praventivmed 2002;47:336-48. 
163. Gillette-Guyonnet S, Nourhashemi F, Andrieu S, Cantet C, Albarede JL, Vellas B, et al. 
Body composition in French women 75+ years of age: the EPIDOS study. Mech Ageing Dev 
2003;124:311-6. 
164. Delarue J, Constans T, Malvy D, Pradignac A, Couet C, Lamisse F. Anthropometric values 
in an elderly French population. Br J Nutr 1994;71:295-302. 
165. Dey DK, Bosaeus I, Lissner L, Steen B. Changes in body composition and its relation to 
muscle strength in 75-year-old men and women: a 5-year prospective follow-up study of the 
NORA cohort in Goteborg, Sweden. Nutrition 2009;25:613-9. 
166. de Groot LC, Sette S, Zajkas G, Carbajal A, Amorim JA. Nutritional status: anthropometry. 
Euronut SENECA investigators. Eur J Clin Nutr 1991;45 Suppl 3:31-42. 
167. Moody A. Adult anthropometric measures, overweight and obesity.In: Series Craig R MJ, 
editor. Health Survey for England. London: Health and Social Care Information Centre; 
2013.1-39. 
168. Janssen I, Heymsfield SB, Wang Z, Ross R. Skeletal muscle mass and distribution in 468 
men and women aged 18–88 yr. J Appl Physiol 2000;89:81-8. 
169. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. 
Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 
1998;147:755-63. 
170. Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of 
skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci 
2002;57:M772-7. 
107  References 
_________________________________________________________________________ 
171. Gallagher D, Visser M, De Meersman RE, Sepúlveda D, Baumgartner RN, Pierson RN, et al. 
Appendicular skeletal muscle mass: effects of age, gender, and ethnicity. J Appl Physiol 
1997;83:229-39. 
172. Rolland Y, Lauwers-Cances V, Cournot M, Nourhashemi F, Reynish W, Riviere D, et al. 
Sarcopenia, calf circumference, and physical function of elderly women: a cross-sectional 
study. J Am Geriatr Soc 2003;51:1120-4. 
173. Gouveia E, Blimkie CJ, Maia JA, Lopes C, Gouveia BR, Freitas DL. Multivariate analysis of 
lifestyle, constitutive and body composition factors influencing bone health in community-
dwelling older adults from Madeira, Portugal. Arch Gerontol Geriatr 2014;59:83-90. 
174. Kyle UG, Genton L, Slosman DO, Pichard C. Fat-free and fat mass percentiles in 5225 
healthy subjects aged 15 to 98 years. Nutrition 2001;17:534-41. 
175. Dittmar M. Reliability and variability of bioimpedance measures in normal adults: effects of 
age, gender, and body mass. Am J Phys Anthropol 2003;122:361-70. 
176. Tichet J, Vol S, Goxe D, Salle A, Berrut G, Ritz P. Prevalence of sarcopenia in the French 
senior population. J Nutr Health Aging 2008;12:202-6. 
177. Zoico E, Di Francesco V, Guralnik JM, Mazzali G, Bortolani A, Guariento S, et al. Physical 
disability and muscular strength in relation to obesity and different body composition 
indexes in a sample of healthy elderly women. Int J Obes Relat Metab Disord 2004;28:234-
41. 
178. Legrand D, Adriaensen W, Vaes B, Mathei C, Wallemacq P, Degryse J. The relationship 
between grip strength and muscle mass (MM), inflammatory biomarkers and physical 
performance in community-dwelling very old persons. Arch Gerontol Geriatr 2013;57:345-
51. 
179. Masanes F, Culla A, Navarro-Gonzalez M, Navarro-Lopez M, Sacanella E, Torres B, et al. 
Prevalence of sarcopenia in healthy community-dwelling elderly in an urban area of 
Barcelona (Spain). J Nutr Health Aging 2012;16:184-7. 
180. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: 
European consensus on definition and diagnosis: Report of the European Working Group on 
Sarcopenia in Older People. Age Ageing 2010;39:412-23. 
181. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older 
persons is associated with functional impairment and physical disability. J Am Geriatr Soc 
2002;50:889-96. 
182. Seidell JC, Oosterlee A, Deurenberg P, Hautvast JG, Ruijs JH. Abdominal fat depots 
measured with computed tomography: effects of degree of obesity, sex, and age. Eur J Clin 
Nutr 1988;42:805-15. 
183. Schutz Y, Kyle UU, Pichard C. Fat-free mass index and fat mass index percentiles in 
Caucasians aged 18-98 y. Int J Obes Relat Metab Disord 2002;26:953-60. 
References 108 
_________________________________________________________________________ 
184. Yliharsila H, Kajantie E, Osmond C, Forsen T, Barker DJ, Eriksson JG. Body mass index 
during childhood and adult body composition in men and women aged 56-70 y. Am J Clin 
Nutr 2008;87:1769-75. 
185. Vache C, Rousset P, Gachon P, Gachon AM, Morio B, Boulier A, et al. Bioelectrical 
impedance analysis measurements of total body water and extracellular water in healthy 
elderly subjects. Int J Obes Relat Metab Disord 1998;22:537-43. 
186. Deurenberg P, van der Kooij K, Evers P, Hulshof T. Assessment of body composition by 
bioelectrical impedance in a population aged greater than 60 y. Am J Clin Nutr 1990;51:3-6. 
187. Gomez-Cabello A, Pedrero-Chamizo R, Olivares PR, Luzardo L, Juez-Bengoechea A, Mata 
E, et al. Prevalence of overweight and obesity in non-institutionalized people aged 65 or over 
from Spain: the elderly EXERNET multi-centre study. Obes Rev 2011;12:583-92. 
188. Gillette-Guyonnet S, Nourhashemi F, Lauque S, Grandjean H, Vellas B. Body composition 
and osteoporosis in elderly women. Gerontology 2000;46:189-93. 
189. Dey DK, Bosaeus I, Lissner L, Steen B. Body composition estimated by bioelectrical 
impedance in the Swedish elderly. Development of population-based prediction equation and 
reference values of fat-free mass and body fat for 70- and 75-y olds. Eur J Clin Nutr 
2003;57:909-16. 
190. Santana H, Zoico E, Turcato E, Tosoni P, Bissoli L, Olivieri M, et al. Relation between body 
composition, fat distribution, and lung function in elderly men. Am J Clin Nutr 2001;73:827-
31. 
191. Tanko LB, Movsesyan L, Mouritzen U, Christiansen C, Svendsen OL. Appendicular lean 
tissue mass and the prevalence of sarcopenia among healthy women. Metabolism 
2002;51:69-74. 
192. Bedogni G, Pietrobelli A, Heymsfield SB, Borghi A, Manzieri AM, Morini P, et al. Is body 
mass index a measure of adiposity in elderly women? Obes Res 2001;9:17-20. 
193. Movsesyan L, Tanko LB, Larsen PJ, Christiansen C, Svendsen OL. Variations in percentage 
of body fat within different BMI groups in young, middle-aged and old women. Clin Physiol 
Funct Imaging 2003;23:130-3. 
194. Sardinha LB, Teixeira PJ, Guedes DP, Going SB, Lohman TG. Subcutaneous central fat is 
associated with cardiovascular risk factors in men independently of total fatness and fitness. 
Metabolism 2000;49:1379-85. 
195. Maden-Wilkinson TM, Degens H, Jones DA, McPhee JS. Comparison of MRI and DXA to 
measure muscle size and age-related atrophy in thigh muscles. J Musculoskelet Neuronal 
Interact 2013;13:320-8. 
196. Bazzocchi A, Diano D, Ponti F, Andreone A, Sassi C, Albisinni U, et al. Health and ageing: 
a cross-sectional study of body composition. Clin Nutr 2013;32:569-78. 
197. Horber FF, Gruber B, Thomi F, Jensen EX, Jaeger P. Effect of sex and age on bone mass, 
body composition and fuel metabolism in humans. Nutrition 1997;13:524-34. 
109  References 
_________________________________________________________________________ 
198. Puggaard L, Larsen JB, Ebbesen E, Jeune B. Body composition in 85 year-old women: 
effects of increased physical activity. Aging (Milano) 1999;11:307-15. 
199. Ravaglia G, Forti P, Maioli F, Boschi F, Cicognani A, Gasbarrini G. Measurement of body 
fat in healthy elderly men: a comparison of methods. J Gerontol A Biol Sci Med Sci 
1999;54:M70-6. 
200. Svendsen OL, Hassager C, Christiansen C. Age- and menopause-associated variations in 
body composition and fat distribution in healthy women as measured by dual-energy X-ray 
absorptiometry. Metabolism 1995;44:369-73. 
201. Wang ZM, Deurenberg P, Guo SS, Pietrobelli A, Wang J, Pierson RN, Jr., et al. Six-
compartment body composition model: inter-method comparisons of total body fat 
measurement. Int J Obes Relat Metab Disord 1998;22:329-37. 
202. Tauchi H, Tsuboi K, Okutomi J. Age changes in the human kidney of the different races. 
Gerontologia 1971;17:87-97. 
203. Meyer WW, Peter B, Solth K. [the Weight of Organs in the Older Age Groups (70-92 Years) 
and Their Relation to Age and Body Weight]. Virchows Arch Pathol Anat Physiol Klin Med 
1963;337:17-32. 
204. Puggaard L, Bjornsbo KS, Kock K, Luders K, Thobo-Carlsen B, Lammert O. Age-related 
decrease in energy expenditure at rest parallels reductions in mass of internal organs. Am J 
Hum Biol 2002;14:486-93. 
205. Raab F. Post-mortale Organgewichte von Milz, Leber, Niere und Lunge in Relation zu 
Lebensalter, Körpergewicht und Körperlänge [PhD thesis]. Heidelberg: University of 
Heidelberg; 1984. 
206. Griffiths GJ, Robinson KB, Cartwright GO, McLachlan MS. Loss of renal tissue in the 
elderly. Br J Radiol 1976;49:111-17. 
207. Nyengaard JR, Bendtsen TF. Glomerular number and size in relation to age, kidney weight, 
and body surface in normal man. Anat Rec 1992;232:194-201. 
208. Goyal VK. Changes with age in the human kidney. Exp Gerontol 1982;17:321-31. 
209. Schmucker DL. Age-related changes in liver structure and function: Implications for disease 
? Exp Gerontol 2005;40:650-9. 
210. Grasedyck K, Jahnke M, Friedrich O, Schulz D, Lindner J. Aging of liver: morphological 
and biochemical changes. Mech Ageing Dev 1980;14:435-42. 
211. Chouker A, Martignoni A, Dugas M, Eisenmenger W, Schauer R, Kaufmann I, et al. 
Estimation of liver size for liver transplantation: the impact of age and gender. Liver Transpl 
2004;10:678-85. 
212. Thompson EN, Williams R. Effect of age on liver function with particular reference to 
bromsulphalein excretion. Gut 1965;6:266-9. 
References 110 
_________________________________________________________________________ 
213. Swift CG, Homeida M, Halliwell M, Roberts CJ. Antipyrine disposition and liver size in the 
elderly. Eur J Clin Pharmacol 1978;14:149-52. 
214. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age 
upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989;9:297-
301. 
215. Marchesini G, Bua V, Brunori A, Bianchi G, Pisi P, Fabbri A, et al. Galactose elimination 
capacity and liver volume in aging man. Hepatology 1988;8:1079-83. 
216. Spann W, Dustmann HO. Das menschliche Hirngewicht und seine Abhängigkeit von 
Lebensalter, Körperlänge, Todesursache und Beruf. Dtsch Z Gesamte Gerichtl Med 
1965;56:299-317. 
217. Howell TH. Brain weights in octogenarians. J Am Geriatr Soc 1981;29:450-2. 
218. Howell TH. Brain weights in septuagenarians. J Am Geriatr Soc 1982;30:754-5. 
219. Pakkenberg H, Voigt J. Brain weight of the Danes. Cells Tissues Organs 1964;56:297-307. 
220. Dekaban AS. Changes in brain weights during the span of human life: relation of brain 
weights to body heights and body weights. Ann Neurol 1978;4:345-56. 
221. Driscoll I, Davatzikos C, An Y, Wu X, Shen D, Kraut M, et al. Longitudinal pattern of 
regional brain volume change differentiates normal aging from MCI. Neurology 
2009;72:1906-13. 
222. Handmann E. Über das Hirngewicht des Menschen auf Grund von 1414 im Pathologischen 
Institut zu Leipzig vorgenommenen Hirnwägungen: Veit & Co.; 1906. 
223. Roessle R, Roulet F. Mass und Zahl in der Pathologie: Springer; 1932. 
224. Hartmann P, Ramseier A, Gudat F, Mihatsch MJ, Polasek W. Das Normgewicht des Gehirns 
beim Erwachsenen in Abhängigkeit von Alter, Geschlecht, Körpergrösse und Gewicht. 
Pathologe 1994;15:165-70. 
225. Waldemar G, Hogh P, Paulson OB. Functional brain imaging with single-photon emission 
computed tomography in the diagnosis of Alzheimer's disease. Int Psychogeriatr 1997;9 
Suppl 1:223-7; discussion 47-52. 
226. Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart. 
Myocyte loss and reactive cellular hypertrophy. Circ Res 1991;68:1560-8. 
227. Olivetti G, Cigola E, Maestri R, Lagrasta C, Corradi D, Quaini F. Recent advances in cardiac 
hypertrophy. Cardiovasc Res 2000;45:68-75. 
228. Lie JT, Hammond PI. Pathology of the senescent heart: anatomic observations on 237 
autopsy studies of patients 90 to 105 years old. Mayo Clin Proc 1988;63:552-64. 
229. Olivetti G, Giordano G, Corradi D, Melissari M, Lagrasta C, Gambert SR, et al. Gender 
differences and aging: effects on the human heart. J Am Coll Cardiol 1995;26:1068-79. 
111  References 
_________________________________________________________________________ 
230. Pomerance A, Davies MJ. Pathological features of hypertrophic obstructive cardiomyopathy 
(HOCM) in the elderly. Br Heart J 1975;37:305-12. 
231. Linzbach AJ, Akuamoa-Boateng E. Die Alternsveränderungen des menschlichen Herzens. 
Klin Wochenschr 1973;51:156-63. 
232. Heath D, Edwards C, Harris P. Post-mortem size and structure of the human carotid body. 
Thorax 1970;25:129-40. 
233. Howell TH. Heart weights among octogenarians. J Am Geriatr Soc 1981;29:572-5. 
234. Kumar NT, Liestol K, Loberg EM, Reims HM, Maehlen J. Postmortem heart weight: 
relation to body size and effects of cardiovascular disease and cancer. Cardiovasc Pathol 
2014;23:5-11. 
235. Paulsen S, Vetner M, Hagerup LM. Relationship between length of the left main coronary 
artery and heart weight. Acta Pathol Microbiol Scand A 1975;83:369-72. 
236. Gaitskell K, Perera R, Soilleux EJ. Derivation of new reference tables for human heart 
weights in light of increasing body mass index. J Clin Pathol 2011;64:358-62. 
237. Prentice A, Parsons TJ, Cole TJ. Uncritical use of bone mineral density in absorptiometry 
may lead to size-related artifacts in the identification of bone mineral determinants. Am J 
Clin Nutr 1994;60:837-42. 
238. Fewtrell MS. Bone densitometry in children assessed by dual x ray absorptiometry: uses and 
pitfalls. Arch Dis Child 2003;88:795-8. 
239. Nelson DA, Barondess DA. Whole body bone, fat and lean mass in children: comparison of 
three ethnic groups. Am J Phys Anthropol 1997;103:157-62. 
240. Barondess DA, Nelson DA, Schlaen SE. Whole body bone, fat, and lean mass in black and 
white men. J Bone Miner Res 1997;12:967-71. 
241. Gnudi S, Sitta E, Fiumi N. Relationship between body composition and bone mineral density 
in women with and without osteoporosis: relative contribution of lean and fat mass. J Bone 
Miner Metab 2007;25:326-32. 
242. Bosy-Westphal A, Mast M, Eichhorn C, Becker C, Kutzner D, Heller M, et al. Validation of 
air-displacement plethysmography for estimation of body fat mass in healthy elderly 
subjects. Eur J Nutr 2003;42:207-16. 
243. Henche SA, Torres RR, Pellico LG. An evaluation of patterns of change in total and regional 
body fat mass in healthy Spanish subjects using dual-energy X-ray absorptiometry (DXA). 
Eur J Clin Nutr 2008;62:1440-8. 
244. Gull B, Karlsson B, Milsom I, Granberg S. Factors associated with endometrial thickness 
and uterine size in a random sample of postmenopausal women. Am J Obstet Gynecol 
2001;185:386-91. 
References 112 
_________________________________________________________________________ 
245. Sosnik H. Studies on the participation of tunica albuginea and rete testis (TA and RT) in the 
quantitative structure of human testis. Gegenbaurs Morphol Jahrb 1985;131:347-56. 
246. Lanz Tv, Neuhäuser G. Metrische Untersuchungen an den Tubuli contorti des menschlichen 
Hodens. Z Anat Entwicklungsgesch 1963;123:462-89. 
247. Stearns EL, MacDonnell JA, Kaufman BJ, Padua R, Lucman TS, Winter JS, et al. Declining 
testicular function with age. Hormonal and clinical correlates. Am J Med 1974;57:761-6. 
248. Mahmoud AM, Goemaere S, El-Garem Y, Van Pottelbergh I, Comhaire FH, Kaufman JM. 
Testicular volume in relation to hormonal indices of gonadal function in community-
dwelling elderly men. J Clin Endocrinol Metab 2003;88:179-84. 
249. Westermark P, Wilander E. The influence of amyloid deposits on the islet volume in 
maturity onset diabetes mellitus. Diabetologia 1978;15:417-21. 
250. Roessle R. [Beitrag zur Kenntnis der gesunden und der kranken Bauchspeicheldrüse] 
german. Beitr path Anat 1921;69:163-84. 
251. Wittingen J, Frey CF. Islet concentration in the head, body, tail and uncinate process of the 
pancreas. Ann Surg 1974;179:412-4. 
252. Sandby-Moller J, Poulsen T, Wulf HC. Epidermal thickness at different body sites: 
relationship to age, gender, pigmentation, blood content, skin type and smoking habits. Acta 
Derm Venereol 2003;83:410-3. 
253. Leveque JL, Corcuff P, de Rigal J, Agache P. In vivo studies of the evolution of physical 
properties of the human skin with age. Int J Dermatol 1984;23:322-9. 
254. Escoffier C, de Rigal J, Rochefort A, Vasselet R, Leveque JL, Agache PG. Age-related 
mechanical properties of human skin: an in vivo study. J Invest Dermatol 1989;93:353-7. 
255. Shuster S, Black MM, McVitie E. The influence of age and sex on skin thickness, skin 
collagen and density. Br J Dermatol 1975;93:639-43. 
256. Tan CY, Statham B, Marks R, Payne PA. Skin thickness measurement by pulsed ultrasound: 
its reproducibility, validation and variability. Br J Dermatol 1982;106:657-67. 
257. Lock-Andersen J, Therkildsen P, de Fine Olivarius F, Gniadecka M, Dahlstrom K, Poulsen 
T, et al. Epidermal thickness, skin pigmentation and constitutive photosensitivity. 
Photodermatol Photoimmunol Photomed 1997;13:153-8. 
258. Whitton JT, Everall JD. The thickness of the epidermis. Br J Dermatol 1973;89:467-76. 
259. Tosti A, Fazzini M, Villardita S. Quantitative changes in epidermis of aged humans. G Ital 
Chir Dermatol Oncol 1987;2:180-4. 
260. Gniadecka M, Nielsen OF, Wessel S, Heidenheim M, Christensen DH, Wulf HC. Water and 
protein structure in photoaged and chronically aged skin. J Invest Dermatol 1998;111:1129-
33. 
113  References 
_________________________________________________________________________ 
261. Braverman IM, Fonferko E. Studies in cutaneous aging: I. The elastic fiber network. J Invest 
Dermatol 1982;78:434-43. 
262. Krumbhaar E, Lippincott S. The postmortem weight of the "normal" human spleen at 
different ages. Am J Med Sci 1939;197:344-57. 
263. Prassopoulos P, Daskalogiannaki M, Raissaki M, Hatjidakis A, Gourtsoyiannis N. 
Determination of normal splenic volume on computed tomography in relation to age, gender 
and body habitus. Eur Radiol 1997;7:246-8. 
264. Sprogoe-Jakobsen S, Sprogoe-Jakobsen U. The weight of the normal spleen. Forensic Sci Int 
1997;88:215-23. 
265. Williams LR. Reference Values for total blood volume and cardiac output in humans.In: 
Series. Tennessee: Dosimetry Research Group; 1994.49. 
266. Kuikka JT, Lansimies E. Effect of age on cardiac index, stroke index and left ventricular 
ejection fraction at rest and during exercise as studied by radiocardiography. Acta Physiol 
Scand 1982;114:339-43. 
267. Granath A, Strandell T. Relationships between Cardiac Output, Stroke Volume and 
Intracardiac Pressures at Rest and during Exercise in Supine Position and Some 
Anthropometric Data in Healthy Old Men. Acta Med Scand 1964;176:447-66. 
268. Mezzani A, Grassi B, Giordano A, Corra U, Colombo S, Giannuzzi P. Age-related 
prolongation of phase I of VO2 on-kinetics in healthy humans. Am J Physiol Regul Integr 
Comp Physiol 2010;299:R968-76. 
269. Podlesch I, Ulmer WT. Über die Abhängigkeit von Herzminutenvolumen, Herzindex, 
Schlagvolumen, Schlagvolumenindex und Sauerstoffverbrauch vom Lebensalter. Arch 
Kreislaufforsch 1965;48:232-48. 
270. Germing A, Gotzmann M, Rausse R, Brodherr T, Holt S, Lindstaedt M, et al. Normal values 
for longitudinal function of the right ventricle in healthy women >70 years of age. Eur J 
Echocardiogr 2010;11:725-8. 
271. Chahal NS, Lim TK, Jain P, Chambers JC, Kooner JS, Senior R. Population-based reference 
values for 3D echocardiographic LV volumes and ejection fraction. JACC Cardiovasc 
Imaging 2012;5:1191-7. 
272. Cain PA, Ahl R, Hedstrom E, Ugander M, Allansdotter-Johnsson A, Friberg P, et al. Age 
and gender specific normal values of left ventricular mass, volume and function for gradient 
echo magnetic resonance imaging: a cross sectional study. BMC Med Imaging 2009;9:2. 
273. Cheitlin MD. Cardiovascular physiology-changes with aging. Am J Geriatr Cardiol 
2003;12:9-13. 
274. Umetani K, Singer DH, McCraty R, Atkinson M. Twenty-four hour time domain heart rate 
variability and heart rate: relations to age and gender over nine decades. J Am Coll Cardiol 
1998;31:593-601. 
References 114 
_________________________________________________________________________ 
275. Ryan SM, Goldberger AL, Pincus SM, Mietus J, Lipsitz LA. Gender- and age-related 
differences in heart rate dynamics: are women more complex than men? J Am Coll Cardiol 
1994;24:1700-7. 
276. Hoang K, Tan JC, Derby G, Blouch KL, Masek M, Ma I, et al. Determinants of glomerular 
hypofiltration in aging humans. Kidney Int 2003;64:1417-24. 
277. Bauer JH, Brooks CS, Burch RN. Renal function and hemodynamic studies in low- and 
normal-renin essential hypertension. Arch Intern Med 1982;142:1317-23. 
278. Fuiano G, Sund S, Mazza G, Rosa M, Caglioti A, Gallo G, et al. Renal hemodynamic 
response to maximal vasodilating stimulus in healthy older subjects. Kidney Int 
2001;59:1052-8. 
279. Ghose K, Burch A. Measurement of renal functions by double isotope techniques in elderly 
patients during tenoxicam therapy. Arch Gerontol Geriatr 1989;9:115-22. 
280. Zoli M, Magalotti D, Bianchi G, Gueli C, Orlandini C, Grimaldi M, et al. Total and 
functional hepatic blood flow decrease in parallel with ageing. Age Ageing 1999;28:29-33. 
281. Gentilcore D, Hausken T, Meyer JH, Chapman IM, Horowitz M, Jones KL. Effects of 
intraduodenal glucose, fat, and protein on blood pressure, heart rate, and splanchnic blood 
flow in healthy older subjects. Am J Clin Nutr 2008;87:156-61. 
282. Gentilcore D, Nair NS, Vanis L, Rayner CK, Meyer JH, Hausken T, et al. Comparative 
effects of oral and intraduodenal glucose on blood pressure, heart rate, and splanchnic blood 
flow in healthy older subjects. Am J Physiol Regul Integr Comp Physiol 2009;297:R716-22. 
283. Gentilcore D, Vanis L, Wishart JM, Rayner CK, Horowitz M, Jones KL. The alpha (alpha)-
glucosidase inhibitor, acarbose, attenuates the blood pressure and splanchnic blood flow 
responses to intraduodenal sucrose in older adults. J Gerontol A Biol Sci Med Sci 
2011;66:917-24. 
284. Dunbar SL, Kenney WL. Effects of hormone replacement therapy on hemodynamic 
responses of postmenopausal women to passive heating. J Appl Physiol 2000;89:97-103. 
285. Ho CW, Beard JL, Farrell PA, Minson CT, Kenney WL. Age, fitness, and regional blood 
flow during exercise in the heat. J Appl Physiol 1997;82:1126-35. 
286. Minson CT, Wladkowski SL, Cardell AF, Pawelczyk JA, Kenney WL. Age alters the 
cardiovascular response to direct passive heating. J Appl Physiol 1998;84:1323-32. 
287. Vanis L, Gentilcore D, Lange K, Gilja OH, Rigda RS, Trahair LG, et al. Effects of variations 
in intragastric volume on blood pressure and splanchnic blood flow during intraduodenal 
glucose infusion in healthy older subjects. Am J Physiol Regul Integr Comp Physiol 
2012;302:R391-9. 
288. Lesser GT, Deutsch S. Measurement of adipose tissue blood flow and perfusion in man by 
uptake of 85Kr. J Appl Physiol 1967;23:621-30. 
115  References 
_________________________________________________________________________ 
289. Andersson J, Karpe F, Sjostrom LG, Riklund K, Soderberg S, Olsson T. Association of 
adipose tissue blood flow with fat depot sizes and adipokines in women. Int J Obes (Lond) 
2012;36:783-9. 
290. Chen JJ, Rosas HD, Salat DH. Age-associated reductions in cerebral blood flow are 
independent from regional atrophy. Neuroimage 2011;55:468-78. 
291. Lu H, Xu F, Rodrigue KM, Kennedy KM, Cheng Y, Flicker B, et al. Alterations in cerebral 
metabolic rate and blood supply across the adult lifespan. Cereb Cortex 2011;21:1426-34. 
292. Hagstadius S, Risberg J. Regional cerebral blood flow characteristics and variations with age 
in resting normal subjects. Brain Cogn 1989;10:28-43. 
293. Shin W, Horowitz S, Ragin A, Chen Y, Walker M, Carroll TJ. Quantitative cerebral 
perfusion using dynamic susceptibility contrast MRI: evaluation of reproducibility and age- 
and gender-dependence with fully automatic image postprocessing algorithm. Magn Reson 
Med 2007;58:1232-41. 
294. Devous MD, Sr., Stokely EM, Chehabi HH, Bonte FJ. Normal distribution of regional 
cerebral blood flow measured by dynamic single-photon emission tomography. J Cereb 
Blood Flow Metab 1986;6:95-104. 
295. Proctor DN, Newcomer SC, Koch DW, Le KU, MacLean DA, Leuenberger UA. Leg blood 
flow during submaximal cycle ergometry is not reduced in healthy older normally active 
men. J Appl Physiol 2003;94:1859-69. 
296. Proctor DN, Koch DW, Newcomer SC, Le KU, Leuenberger UA. Impaired leg vasodilation 
during dynamic exercise in healthy older women. J Appl Physiol 2003;95:1963-70. 
297. Amery A, Bossaert H, Verstraete M. Muscle blood flow in normal and hypertensive subjects. 
Influence of age, exercise, and body position. Am Heart J 1969;78:211-6. 
298. Lassen NA, Lindbjerg J, Munck O. Measurement of Blood-Flow through Skeletal Muscle by 
Intramuscular Injection of Xenon-133. Lancet 1964;1:686-9. 
299. Jaarsma C, Leiner T, Bekkers SC, Crijns HJ, Wildberger JE, Nagel E, et al. Diagnostic 
performance of noninvasive myocardial perfusion imaging using single-photon emission 
computed tomography, cardiac magnetic resonance, and positron emission tomography 
imaging for the detection of obstructive coronary artery disease: a meta-analysis. J Am Coll 
Cardiol 2012;59:1719-28. 
300. Baliga RR, Rosen SD, Camici PG, Kooner JS. Regional myocardial blood flow 
redistribution as a cause of postprandial angina pectoris. Circulation 1998;97:1144-9. 
301. Uren NG, Camici PG, Melin JA, Bol A, de Bruyne B, Radvan J, et al. Effect of aging on 
myocardial perfusion reserve. J Nucl Med 1995;36:2032-6. 
302. Chareonthaitawee P, Kaufmann PA, Rimoldi O, Camici PG. Heterogeneity of resting and 
hyperemic myocardial blood flow in healthy humans. Cardiovasc Res 2001;50:151-61. 
References 116 
_________________________________________________________________________ 
303. Byrne C, Kuhl JT, Zacho M, Nordestgaard BG, Fuchs A, Frestad D, et al. Sex- and age-
related differences of myocardial perfusion at rest assessed with multidetector computed 
tomography. J Cardiovasc Comput Tomogr 2013;7:94-101. 
304. Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjo L, et al. In vivo 
visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 
2013;54:213-20. 
305. Weinberg SL, Cagirgan CM, Grove GR, Smith G. Measurement of Relative Coronary Blood 
Flow by Precordial Monitoring. Am J Cardiol 1964;13:801-7. 
306. Rosen BD, Fernandes VR, Nasir K, Helle-Valle T, Jerosch-Herold M, Bluemke DA, et al. 
Age, increased left ventricular mass, and lower regional myocardial perfusion are related to 
greater extent of myocardial dyssynchrony in asymptomatic individuals: the multi-ethnic 
study of atherosclerosis. Circulation 2009;120:859-66. 
307. Czernin J, Muller P, Chan S, Brunken RC, Porenta G, Krivokapich J, et al. Influence of age 
and hemodynamics on myocardial blood flow and flow reserve. Circulation 1993;88:62-9. 
308. Braverman IM, Fonferko E. Studies in cutaneous aging: II. The microvasculature. J Invest 
Dermatol 1982;78:444-8. 
309. Smith CJ, Alexander LM, Kenney WL. Nonuniform, age-related decrements in regional 
sweating and skin blood flow. Am J Physiol Regul Integr Comp Physiol 2013;305:R877-85. 
310. Kelly RI, Pearse R, Bull RH, Leveque JL, de Rigal J, Mortimer PS. The effects of aging on 
the cutaneous microvasculature. J Am Acad Dermatol 1995;33:749-56. 
311. Rooke GA, Savage MV, Brengelmann GL. Maximal skin blood flow is decreased in elderly 
men. J Appl Physiol (1985) 1994;77:11-4. 
312. Tikhonova IV, Tankanag AV, Chemeris NK. Age-related changes of skin blood flow during 
postocclusive reactive hyperemia in human. Skin Res Technol 2013;19:e174-81. 
313. McNally K, Cotton R, Hogg A, Loizou G. PopGen: A virtual human population generator. 
Toxicology 2014;315:70-85. 
314. Chumlea WC, Guo SS, Zeller CM, Reo NV, Baumgartner RN, Garry PJ, et al. Total body 
water reference values and prediction equations for adults. Kidney Int 2001;59:2250-8. 
315. Bruce A, Andersson M, Arvidsson B, Isaksson B. Body composition. Prediction of normal 
body potassium, body water and body fat in adults on the basis of body height, body weight 
and age. Scand J Clin Lab Invest 1980;40:461-73. 
316. Lesser GT, Markofsky J. Body water compartments with human aging using fat-free mass as 
the reference standard. Am J Physiol 1979;236:R215-20. 
317. Sergi G, Lupoli L, Volpato S, Bertani R, Coin A, Perissinotto E, et al. Body fluid distribution 
in elderly subjects with congestive heart failure. Ann Clin Lab Sci 2004;34:416-22. 
117  References 
_________________________________________________________________________ 
318. Steen B, Bruce A, Isaksson B, Lewin T, Svanborg A. Body composition in 70-year-old 
males and females in Gothenburg, Sweden. A population study. Acta Med Scand Suppl 
1977;611:87-112. 
319. Cals MJ, Bories PN, Devanlay M, Desveaux N, Luciani L, Succari M, et al. Extensive 
laboratory assessment of nutritional status in fit, health-conscious, elderly people living in 
the Paris area. Research Group on Aging. J Am Coll Nutr 1994;13:646-57. 
320. Dirren H, Decarli B, Lesourd B, Schlienger JL, Deslypere JP, Kiepurski A. Nutritional 
status: haematology and albumin. Euronut SENECA investigators. Eur J Clin Nutr 1991;45 
Suppl 3:43-52. 
321. Veering BT, Burm AG, Souverijn JH, Serree JM, Spierdijk J. The effect of age on serum 
concentrations of albumin and alpha 1-acid glycoprotein. Br J Clin Pharmacol 1990;29:201-
6. 
322. Gardner MD, Scott R. Age- and sex-related reference ranges for eight plasma constituents 
derived from randomly selected adults in a Scottish new town. J Clin Pathol 1980;33:380-5. 
323. Maes M, DeVos N, Wauters A, Demedts P, Maurits VW, Neels H, et al. Inflammatory 
markers in younger vs elderly normal volunteers and in patients with Alzheimer's disease. J 
Psychiatr Res 1999;33:397-405. 
324. Faulkner WR, Meites S, editors. Geriatric clinical chemistry: Reference values. Washington 
(DC): American Association for Clinical Chemistry; 1994. 
325. Holt DW, Hayler AM, Healey GF. Effect of age and plasma concentrations of albumin and 
alpha 1-acid glycoprotein on protein binding of disopyramide. Br J Clin Pharmacol 
1983;16:344-5. 
326. Mattila KS, Kuusela V, Pelliniemi TT, Rajamaki A, Kaihola HL, Juva K. Haematological 
laboratory findings in the elderly: influence of age and sex. Scand J Clin Lab Invest 
1986;46:411-5. 
327. Tietz NW, Shuey DF, Wekstein DR. Laboratory values in fit aging individuals--
sexagenarians through centenarians. Clin Chem 1992;38:1167-85. 
328. Fulop T, Jr., Worum I, Csongor J, Foris G, Leovey A. Body composition in elderly people. I. 
Determination of body composition by multiisotope method and the elimination kinetics of 
these isotopes in healthy elderly subjects. Gerontology 1985;31:6-14. 
329. Praga M, Morales E. Obesity-related renal damage: changing diet to avoid progression. 
Kidney Int 2010;78:633-5. 
330. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal 
disease: a meta-analysis. Kidney Int 2001;59:260-9. 
331. Luft FC, Fineberg NS, Miller JZ, Rankin LI, Grim CE, Weinberger MH. The effects of age, 
race and heredity on glomerular filtration rate following volume expansion and contraction 
in normal man. Am J Med Sci 1980;279:15-24. 
References 118 
_________________________________________________________________________ 
332. Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of 
decline in renal function with age. Kidney Int 1984;26:861-8. 
333. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, et al. Factors 
influencing serum cystatin C levels other than renal function and the impact on renal 
function measurement. Kidney Int 2004;65:1416-21. 
334. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for 
estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-92. 
335. Rule AD, Gussak HM, Pond GR, Bergstralh EJ, Stegall MD, Cosio FG, et al. Measured and 
estimated GFR in healthy potential kidney donors. Am J Kidney Dis 2004;43:112-9. 
336. Peters AM, Perry L, Hooker CA, Howard B, Neilly MD, Seshadri N, et al. Extracellular fluid 
volume and glomerular filtration rate in 1878 healthy potential renal transplant donors: 
effects of age, gender, obesity and scaling. Nephrol Dial Transplant 2012;27:1429-37. 
337. Walser M, Drew HH, Guldan JL. Prediction of glomerular filtration rate from serum 
creatinine concentration in advanced chronic renal failure. Kidney Int 1993;44:1145-8. 
338. Grewal GS, Blake GM. Reference data for 51Cr-EDTA measurements of the glomerular 
filtration rate derived from live kidney donors. Nucl Med Commun 2005;26:61-5. 
339. Back SE, Ljungberg B, Nilsson-Ehle I, Borga O, Nilsson-Ehle P. Age dependence of renal 
function: clearance of iohexol and p-amino hippurate in healthy males. Scand J Clin Lab 
Invest 1989;49:641-6. 
340. Effersoe H, Rosenkilde P, Groth S, Jensen LI, Golman K. Measurement of renal function 
with iohexol. A comparison of iohexol, 99mTc-DTPA, and 51Cr-EDTA clearance. Invest 
Radiol 1990;25:778-82. 
341. Barnfield M, Burniston M. Reference data for Tc99m-DTPA measurements of the GFR 
derived from live kidney donors. Paper presented at: 38th annual meeting of the Britisch 
Nuclear Medicine Society; 2010 April 26-28; Harrogate, United Kingdom 
342. Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, et al. Human 
renal function maturation: a quantitative description using weight and postmenstrual age. 
Pediatr Nephrol 2009;24:67-76. 
343. Claassen K, Thelen K, Coboeken K, Gaub T, Lippert J, Allegaert K, et al. Development of a 
Physiologically-Based Pharmacokinetic Model for Preterm Neonates: Evaluation with In 
Vivo Data. Curr Pharm Des 2015;21:5688-98. 
344. Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G. Pharmacokinetics of single-dose 
i.v. morphine in normal volunteers and patients with end-stage renal failure. Br J Anaesth 
1984;56:813-9. 
345. Baillie SP, Bateman DN, Coates PE, Woodhouse KW. Age and the pharmacokinetics of 
morphine. Age Ageing 1989;18:258-62. 
119  References 
_________________________________________________________________________ 
346. Hoskin PJ, Hanks GW, Aherne GW, Chapman D, Littleton P, Filshie J. The bioavailability 
and pharmacokinetics of morphine after intravenous, oral and buccal administration in 
healthy volunteers. Br J Clin Pharmacol 1989;27:499-505. 
347. Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different 
routes of morphine administration: demonstration of the importance of the active metabolite 
morphine-6-glucuronide. Clin Pharmacol Ther 1990;47:12-9. 
348. Stuart-Harris R, Joel SP, McDonald P, Currow D, Slevin ML. The pharmacokinetics of 
morphine and morphine glucuronide metabolites after subcutaneous bolus injection and 
subcutaneous infusion of morphine. Br J Clin Pharmacol 2000;49:207-14. 
349. Villesen HH, Banning AM, Petersen RH, Weinelt S, Poulsen JB, Hansen SH, et al. 
Pharmacokinetics of morphine and oxycodone following intravenous administration in 
elderly patients. Ther Clin Risk Manag 2007;3:961-7. 
350. Westerling D, Hoglund P, Lundin S, Svedman P. Transdermal administration of morphine to 
healthy subjects. Br J Clin Pharmacol 1994;37:571-6. 
351. Westerling D, Persson C, Hoglund P. Plasma concentrations of morphine, morphine-3-
glucuronide, and morphine-6-glucuronide after intravenous and oral administration to 
healthy volunteers: relationship to nonanalgesic actions. Ther Drug Monit 1995;17:287-301. 
352. Skarke C, Schmidt H, Geisslinger G, Darimont J, Lotsch J. Pharmacokinetics of morphine 
are not altered in subjects with Gilbert's syndrome. Br J Clin Pharmacol 2003;56:228-31. 
353. Patwardhan RV, Johnson RF, Hoyumpa A, Jr., Sheehan JJ, Desmond PV, Wilkinson GR, et 
al. Normal metabolism of morphine in cirrhosis. Gastroenterology 1981;81:1006-11. 
354. Andreasen F, Hansen U, Husted SE, Jansen JA. The pharmacokinetics of frusemide are 
influenced by age. Br J Clin Pharmacol 1983;16:391-7. 
355. Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P. Influence of hepatic cirrhosis and end-
stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur J Clin 
Pharmacol 1981;20:27-33. 
356. Kerremans AL, Tan Y, van Baars H, van Ginneken CA, Gribnau FW. Furosemide kinetics 
and dynamics in aged patients. Clin Pharmacol Ther 1983;34:181-9. 
357. Muhlberg W, Platt D, Neubig E. Pharmacokinetics and pharmacodynamics of furosemide in 
geriatric patients. Arch Gerontol Geriatr 1986;5:249-63. 
358. Barbosa J, Barrón D, Jiménez-Lozano E, Sanz-Nebot V. Comparison between capillary 
electrophoresis, liquid chromatography, potentiometric and spectrophotometric techniques 
for evaluation of pK a values of zwitterionic drugs in acetonitrile–water mixtures. Analytica 
Chimica Acta 2001;437:309-21. 
359. Borner K, Hoffken G, Lode H, Koeppe P, Prinzing C, Glatzel P, et al. Pharmacokinetics of 
ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin 
Microbiol 1986;5:179-86. 
References 120 
_________________________________________________________________________ 
360. Varanda F, Pratas de Melo MJ, Caco AI, Dohrn R, Makrydaki FA, Voutsas E, et al. 
Solubility of antibiotics in different solvents. 1. Hydrochloride forms of tetracycline, 
moxifloxacin, and ciprofloxacin. Ind Eng Chem Res 2006;45:6368-74. 
361. Gallicano K, Sahai J. Lack of gender effect on ciprofloxacin pharmacokinetics in humans. Br 
J Clin Pharmacol 1996;42:632-4. 
362. Leibovitz E, Janco J, Piglansky L, Press J, Yagupsky P, Reinhart H, et al. Oral ciprofloxacin 
vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. 
Pediatr Infect Dis J 2000;19:1060-7. 
363. Luisada AA, Bhat PK, Knighten V. Changes of cardiac output caused by aging: an 
impedance cardiographic study. Angiology 1980;31:75-81. 
364. Boyd E. Normal variability in weight of the adult human liver and spleen. Arch Pathol Lab 
Med 1933;16:350-72. 
365. Benet LZ. Pharmacokinetics/pharmacodynamics of furosemide in man: a review. J 
Pharmacokinet Biopharm 1979;7:1-27. 
366. Macintyre PE, Jarvis DA. Age is the best predictor of postoperative morphine requirements. 
Pain 1996;64:357-64. 
367. Martinez M, Mistry B, Lukacova V, Polli J, Hoag S, Dowling T, et al. Use of Modeling and 
Simulation Tools for Understanding the Impact of Formulation on the Absorption of a Low 
Solubility Compound: Ciprofloxacin. AAPS J 2016;18:886-97. 
368. Staib AH, Beermann D, Harder S, Fuhr U, Liermann D. Absorption differences of 
ciprofloxacin along the human gastrointestinal tract determined using a remote-control drug 
delivery device (HF-capsule). Am J Med 1989;87:66S-9S. 
369. Tartaglione TA, Raffalovich AC, Poynor WJ, Espinel-Ingroff A, Kerkering TM. 
Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. 
Antimicrob Agents Chemother 1986;29:62-6. 
370. Maharaj AR, Edginton AN. Examining Small Intestinal Transit Time as a Function of Age: 
Is There Evidence to Support Age-Dependent Differences among Children? Drug Metab 
Dispos 2016;44:1080-9. 
371. Payen S, Serreau R, Munck A, Aujard Y, Aigrain Y, Bressolle F, et al. Population 
pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. 
Antimicrob Agents Chemother 2003;47:3170-8. 
372. Leroux S, Turner MA, Guellec CB, Hill H, van den Anker JN, Kearns GL, et al. 
Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design. Clin 
Pharmacokinet 2015;54:1273-85. 
373. Zhao W, Hill H, Le Guellec C, Neal T, Mahoney S, Paulus S, et al. Population 
pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of 
age. Antimicrob Agents Chemother 2014;58:6572-80. 
121  References 
_________________________________________________________________________ 
374. Sadiq MW, Nielsen EI, Khachman D, Conil JM, Georges B, Houin G, et al. A whole-body 
physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards 
predicting bacterial killing at sites of infection. J Pharmacokinet Pharmacodyn 2017;44:69-
79. 
375. Ball K, Jamier T, Parmentier Y, Denizot C, Mallier A, Chenel M. Prediction of renal 
transporter-mediated drug-drug interactions for a drug which is an OAT substrate and 
inhibitor using PBPK modelling. Eur J Pharm Sci 2017;106:122-32. 
376. Navid A, Ng DM, Wong SE, Lightstone FC. Application of a Physiologically Based 
Pharmacokinetic Model to Study Theophylline Metabolism and Its Interactions With 
Ciprofloxacin and Caffeine. CPT Pharmacometrics Syst Pharmacol 2016;5:74-81. 
377. Hansmann S, Miyaji Y, Dressman J. An in silico approach to determine challenges in the 
bioavailability of ciprofloxacin, a poorly soluble weak base with borderline solubility and 
permeability characteristics. Eur J Pharm Biopharm 2017;122:186-96. 
378. EP. Regulation (EC) No 1901/2006 of the European Parliament and of the Council on 
medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 
2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004.  European Parliament 
(EP) and of the Council EEC; 2006 
379. FDA. Pediatric Study Plans.  U.S. Department of Health and Human Services Food and Drug 
Administration (FDA); 2013 
380. Kang BP, Slosberg E, Snodgrass S, Lebedinsky C, Berry DA, Corless CL, et al. The 
Signature Program: Bringing the Protocol to the Patient. Clin Pharmacol Ther 2015;98:124-
6. 
381. Berry SM, Broglio KR, Groshen S, Berry DA. Bayesian hierarchical modeling of patient 
subpopulations: efficient designs of Phase II oncology clinical trials. Clin Trials 
2013;10:720-34. 
382. Wacha H, Wagner D, Schafer V, Knothe H. Concentration of ciprofloxacin in bone tissue 
after single parenteral administration to patients older than 70 years. Infection 1990;18:173-
6. 
383. Gonzalez MA, Moranchel AH, Duran S, Pichardo A, Magana JL, Painter B, et al. Multiple-
dose ciprofloxacin dose ranging and kinetics. Clin Pharmacol Ther 1985;37:633-7. 
384. Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of intravenous ciprofloxacin at three 
different doses. J Antimicrob Chemother 1988;22:715-20. 
385. Hoffken G, Lode H, Prinzing C, Borner K, Koeppe P. Pharmacokinetics of ciprofloxacin 
after oral and parenteral administration. Antimicrob Agents Chemother 1985;27:375-9. 
386. Dudley MN, Ericson J, Zinner SH. Effect of dose on serum pharmacokinetics of intravenous 
ciprofloxacin with identification and characterization of extravascular compartments using 
noncompartmental and compartmental pharmacokinetic models. Antimicrob Agents 
Chemother 1987;31:1782-6. 
References 122 
_________________________________________________________________________ 
387. Bergan T, Thorsteinsson SB, Kolstad IM, Johnsen S. Pharmacokinetics of ciprofloxacin after 
intravenous and increasing oral doses. Eur J Clin Microbiol 1986;5:187-92. 
388. Bergan T, Thorsteinsson SB, Solberg R, Bjornskau L, Kolstad IM, Johnsen S. 
Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. Am J Med 
1987;82:97-102. 
389. Wingender W, Graefe KH, Gau W, Forster D, Beermann D, Schacht P. Pharmacokinetics of 
ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin 
Microbiol 1984;3:355-9. 
390. Wise R, Lockley RM, Webberly M, Dent J. Pharmacokinetics of intravenously administered 
ciprofloxacin. Antimicrob Agents Chemother 1984;26:208-10. 
391. Drusano GL, Plaisance KI, Forrest A, Standiford HC. Dose ranging study and constant 
infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother 1986;30:440-3. 
392. Gonzalez MA, Moranchel AH, Duran S, Pichardo A, Magana JL, Painter B, et al. Multiple-
dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. 
Antimicrob Agents Chemother 1985;28:235-9. 
393. Nix DE, Spivey JM, Norman A, Schentag JJ. Dose-ranging pharmacokinetic study of 
ciprofloxacin after 200-, 300-, and 400-mg intravenous doses. Ann Pharmacother 1992;26:8-
10. 
394. Garraffo R, Drugeon HB. Comparative assessment of the pharmacokinetics and 
pharmacodynamics of ciprofloxacin after single i.v. doses of 200 and 400mg. Drugs 1995;49 
Suppl 2:317-20. 
395. Plaisance KI, Drusano GL, Forrest A, Bustamante CI, Standiford HC. Effect of dose size on 
bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1987;31:956-8. 
396. Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC. Pharmacokinetics of 
intravenously administered ciprofloxacin in patients with various degrees of renal function. 
Antimicrob Agents Chemother 1987;31:860-4. 
397. Jaehde U, Sorgel F, Reiter A, Sigl G, Naber KG, Schunack W. Effect of probenecid on the 
distribution and elimination of ciprofloxacin in humans. Clin Pharmacol Ther 1995;58:532-
41. 
398. Davis RL, Koup JR, Williams-Warren J, Weber A, Heggen L, Stempel D, et al. 
Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother 
1987;31:915-9. 
399. Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J. Absolute oral 
bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1986;30:444-6. 
400. Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH. Pharmacokinetic profiles of 
ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 
1992;36:993-6. 
123  References 
_________________________________________________________________________ 
401. Catchpole C, Andrews JM, Woodcock J, Wise R. The comparative pharmacokinetics and 
tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J Antimicrob 
Chemother 1994;33:103-10. 
402. Shah A, Lettieri J, Kaiser L, Echols R, Heller AH. Comparative pharmacokinetics and safety 
of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily. J Antimicrob 
Chemother 1994;33:795-801. 
403. Shah A, Liu MC, Vaughan D, Heller AH. Oral bioequivalence of three ciprofloxacin 
formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 
mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral 
suspension. J Antimicrob Chemother 1999;43 Suppl A:49-54. 
404. Davis RL, Koup JR, Williams-Warren J, Weber A, Smith AL. Pharmacokinetics of three oral 
formulations of ciprofloxacin. Antimicrob Agents Chemother 1985;28:74-7. 
405. Hoffler D, Dalhoff A, Gau W, Beermann D, Michl A. Dose- and sex-independent disposition 
of ciprofloxacin. Eur J Clin Microbiol 1984;3:363-6. 
406. Gonzalez MA, Uribe F, Moisen SD, Fuster AP, Selen A, Welling PG, et al. Multiple-dose 
pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents 
Chemother 1984;26:741-4. 
407. Ledergerber B, Bettex JD, Joos B, Flepp M, Luthy R. Effect of standard breakfast on drug 
absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents 
Chemother 1985;27:350-2. 
408. Aronoff GE, Kenner CH, Sloan RS, Pottratz ST. Multiple-dose ciprofloxacin kinetics in 
normal subjects. Clin Pharmacol Ther 1984;36:384-8. 
409. LeBel M, Bergeron MG, Vallee F, Fiset C, Chasse G, Bigonesse P, et al. Pharmacokinetics 
and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents 
Chemother 1986;30:260-6. 
410. Brumfitt W, Franklin I, Grady D, Hamilton-Miller JM, Iliffe A. Changes in the 
pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to 
human volunteers. Antimicrob Agents Chemother 1984;26:757-61. 
411. Loi CM, Parker BM, Cusack BJ, Vestal RE. Aging and drug interactions. III. Individual and 
combined effects of cimetidine and cimetidine and ciprofloxacin on theophylline metabolism 
in healthy male and female nonsmokers. J Pharmacol Exp Ther 1997;280:627-37. 
412. Bergan T, Delin C, Johansen S, Kolstad IM, Nord CE, Thorsteinsson SB. Pharmacokinetics 
of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. Antimicrob 
Agents Chemother 1986;29:298-302. 
413. Wagenlehner FM, Wydra S, Onda H, Kinzig-Schippers M, Sorgel F, Naber KG. 
Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 
milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a 
single oral dose. Antimicrob Agents Chemother 2003;47:3789-94. 
References 124 
_________________________________________________________________________ 
414. Kara M, Hasinoff BB, McKay DW, Campbell NR. Clinical and chemical interactions 
between iron preparations and ciprofloxacin. Br J Clin Pharmacol 1991;31:257-61. 
415. Crump B, Wise R, Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. 
Antimicrob Agents Chemother 1983;24:784-6. 
416. Boy D, Well M, Kinzig-Schippers M, Sorgel F, Ankel-Fuchs D, Naber KG. Urinary 
bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) 
versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. Int J Antimicrob 
Agents 2004;23 Suppl 1:S6-16. 
417. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary 
concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 
2001;119:1114-22. 
418. Esposito S, Miniero M, Barba D, Sagnelli E. Pharmacokinetics of ciprofloxacin in impaired 
liver function. Int J Clin Pharmacol Res 1989;9:37-41. 
419. Gasser TC, Ebert SC, Graversen PH, Madsen PO. Ciprofloxacin pharmacokinetics in 
patients with normal and impaired renal function. Antimicrob Agents Chemother 
1987;31:709-12. 
420. Boerema JB, Dalhoff A, Debruyne FM. Ciprofloxacin distribution in prostatic tissue and 
fluid following oral administration. Chemotherapy 1985;31:13-8. 
421. Frost RW, Carlson JD, Dietz AJ, Jr., Heyd A, Lettieri JT. Ciprofloxacin pharmacokinetics 
after a standard or high-fat/high-calcium breakfast. J Clin Pharmacol 1989;29:953-5. 
422. Overholser BR, Kays MB, Forrest A, Sowinski KM. Sex-related differences in the 
pharmacokinetics of oral ciprofloxacin. J Clin Pharmacol 2004;44:1012-22. 
423. Dan M, Zuabi T, Quassem C, Rotmensch HH. Distribution of ciprofloxacin in ascitic fluid 
following administration of a single oral dose of 750 milligrams. Antimicrob Agents 
Chemother 1992;36:677-8. 
424. Weinstein MP, Deeter RG, Swanson KA, Gross JS. Crossover assessment of serum 
bactericidal activity and pharmacokinetics of ciprofloxacin alone and in combination in 
healthy elderly volunteers. Antimicrob Agents Chemother 1991;35:2352-8. 
425. Yuk JH, Nightingale CN, Quintiliani R. Ciprofloxacin levels when receiving sucralfate. 
JAMA 1989;262:901. 
426. Lubart E, Berkovitch M, Leibovitz A, Britzi M, Soback S, Bukasov Y, et al. 
Pharmacokinetics of ciprofloxacin in hospitalized geriatric patients: comparison between 
nasogastric tube and oral administration. Ther Drug Monit 2013;35:653-6. 
 
A
p
p
en
d
ix
 
1
2
5
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
Appendix 
Table A-1  Patient characteristics and mean pharmacokinetic parameters in ciprofloxacin studies using intravenous dosing 
reported in the literature 
Dosage 
Infusion 
Time [min] 
Population 
AUC [mg·h/L] CL [L/h] Reference 
[mg] Regime Age [years] (Range) Weight [kg] (Range) n 
Females 
[%] 
20 
 
30 80.85 (60-96) 
 
20 60 
  
[382] 
25 BID 10 (19-45) (49.9-71.8) 9 0 0.73±0.12 1.878±0.324e [383] 
50 
 
3 28 (21-34) 69.3 (61-79) 8 0 1.45±0.33 33.72±7.29 [384] 
50 
 
15 30 (22-34) 67 (52-80) 12 50 1.23±0.2 41.58±7.2 [359] 
50 
 
15 30 (22-34) 67.5 (51-80.5) 12 50 1.2±0.2 41.22±7.8d [385] 
50 BID 10 (19-45) (49.9-71.8) 9 0 1.59±0.15 1.908±0.18e [383] 
75 BID 10 (19-45) (49.9-71.8) 9 0 2.47±0.4 2.124±0.408e [383] 
100 
 
30 23 81.5 9 0 2.24±0.54 0.576±0.1254e [386] 
100 
 
3 26 (21-40) 68 (54-85) 12 50 2.54±0.51 40.71±7.01 [387, 388] 
100 
 
3 28 (21-34) 69.3 (61-79) 8 0 2.9±0.36 32.82±4.344 [384] 
100 
 
5 29 75 6 0 
 
9.62±2.29e [389] 
100 
 
60 29.2 (23-42) 78.5 (65-85) 6 0 2.81±0.57 34.02±5.32 [390] 
100 
 
15 30 (22-34) 67 (52-80) 12 50 2.88±0.52 36±8.4 [359] 
100 
 
15 30 (22-34) 67.5 (51-80.5) 12 50 3±0.5 31.8±6.24d [385] 
100 
 
30 (21-29) 
 
6 0 
 
23±9.1d [391] 
100 
 
30 (21-29) 
 
6 0 
 
22.5±8.9d [391] 
100 
 
30 (21-29) 
 
6 0 3.94±1.25 24.6±10.4d [391] 
100 BID 30 (18-46) (54.8-73) 9 0 3.4±0.49 30.1±3.4d [392] 
150 
 
30 23 81.5 9 0 3.36±0.74 0.5742±0.1212e [386] 
150 BID 30 (18-46) (54.8-73) 9 0 5.14±0.77 29.8±4d [392] 
200 
 
30 23 81.5 9 0 5.17±0.87 0.489±0.0726e [386] 
200 
 
30 24.3 (20-30) 78 (64-91) 12 0 5.2021±1.3916 41±11.3 [393] 
200 
  
25.4 (19-39) 66.6 (50-82) 10 50 5.52±1.95 
 
[394] 
200 
 
30 27 (19-33) 79 (67-83) 12 0 5.37±0.72 37.92±4.5 [139] 
200 
 
10 27.1 (22-30) 77.3 (60.5-89.4) 8 0 5.97±0.91 26.8±5.71d [395] 
200 
 
10 27.125 (22-30) 77.3375 (60.5-89.4) 8 0 
 
26.8±5.7d [396] 
200 
 
30 29.3 (21-38) 67.1 12 50 5.73±1.38 36.66±8.04 [397] 
200 
 
20 28 (23-34) 66 (58-73) 10 50 5.31±1.12 39.12±7.98 [359] 
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Dosage 
Infusion 
Time [min] 
Population 
AUC [mg·h/L] CL [L/h] Reference 
[mg] Regime Age [years] (Range) Weight [kg] (Range) n 
Females 
[%] 
200 BID 60 72.6 (65.4-87.6) 65.6 (42-101) 17 35 5.5±1.8b 0.588±0.258e [140] 
200 BID 30 72.96 (44-96) 67.09 (40-111) 44 95.5 13.71±5.5b 
 
[141] 
200 
 
30 74 (57-84) 72 (52-80) 17 0 8.17±2.62 26.46±7.02 [138] 
200 
 
30 74 (57-84) 72 (50-80) 14 0 8.79±2.73 24.42±6.24 [139] 
200 BID 60 77 (66-90) 66 (49.1-102.7) 9 78 13.3±4.8 0.2598±0.1194e [137] 
200 
 
30 (23-32) 75.9 12 0 6.38±1.05 32±4.77 [398] 
200 
 
30 (21-29) 
 
6 0 
 
23.7±5.1d [391] 
200 
 
30 (21-29) 
 
6 0 
 
23.3±5d [391] 
200 
 
30 (21-29) 
 
6 0 7.22±1.77 25.2±5.8d [391] 
200 
 
10 (21-29) 
 
12 0 
 
28.5±4.7d [399] 
200 BID 30 (18-46) (54.8-73) 9 0 7.7±1.38 26.9±4.1d [392] 
250 
 
5 28 (21-34) 69.3 (61-79) 8 0 8.11±0.94 29.28±3.504 [384] 
250 
 
5 69 (63-76) 76.9 8 0 8.9±0.83 26.04±3.222d [142] 
300 
 
30 24.3 (20-30) 78 (64-91) 12 0 8.7143±1.8886 35.7±5.8 [393] 
300 
 
60 27.3 (21-35) 73 12 0 8.6±1.5 36.18±7.62 [400] 
400 BID 30 24.3 (20-30) 78 (64-91) 12 0 11.0999±1.0934 36.5±3.8 [393] 
400 
 
60 24.7 77.3 12 0 11.2±0.672 35.6±2.136 [130] 
400 
  
25.4 (19-39) 66.6 (50-82) 10 50 11.22±3.5 
 
[394] 
400 TID 60 25.75 74.95 12 50 8.75±1.165 31.5±5.355 [130] 
400 
 
60 26.8 60.2 12 100 14.4±2.304 27.7±4.432 [130] 
400 
 
60 27.3 74.9 (63.3-84.5) 6 0 14.2±1.1 
 
[401] 
400 
 
60 27.3 (21-35) 73 12 0 11.4±1.6 35.82±4.92 [400] 
400 
 
60 28.2 73.3 18 0 24.2±5.1c 51.72±11.28d [402] 
400 TID 60 28.2 73.3 18 0 32.9±8.83c 38.94±9.96d [402] 
400 
 
60 67.7 90 12 0 13.7±0.822 29.2±1.752 [130] 
400 BID 60 68.25 73.3 12 50 0±0 24.8±5.208 [130] 
400 
 
60 68.8 67.9 12 100 19±3.23 21.1±3.587 [130] 
Grey shading indicated studies used for model building 
Frequency of dose administration: BID: twice daily; TID: thrice daily 
a Dose on mg/kg basis;  
b AUC0-12h  
c AUC0-24h 
d Clearance normalized to body surface area [L/h/1.73m2] 
e Clearance normalized to body weight [L/h/kg] 
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Table A-2  Patient characteristics and mean pharmacokinetic parameters in ciprofloxacin studies using oral dosing reported in the 
literature 
Dosage Population 
AUC [mg·h/L] CL [L/h] Cmax [mg/L] Study 
[mg] Regime Age [years] (Range) Weight [kg] (Range) n Females [%] 
Suspension 
10a BID (2-4)  11 35   1.43 [135] 
10a BID (5-10)  12 35   1.44 [135] 
10a BID (11-15)  10 35   1.48 [135] 
10a TID 0.675 (0.3-0.8) 7.675 (6.4-8.8) 4 50 10.8±1.28 16.4±1.44 e 2.83±1.49 [134] 
10a 
 
0.675 (0.3-0.8) 7.675 (6.4-8.8) 4 50 
  
1.99±1.3 [134] 
10a TID 1.33 (1.1-1.6) 11 (10.7-11.4) 3 33 7.7±1.09 18.3±1.22 e 3.57±0.35 [134] 
10a 
 
1.33 (1.1-1.6) 11 (10.7-11.4) 3 33 
  
2.43±1.07 [134] 
10a TID 3.733 (2.5-5.3) 15.86 (11.9-20) 5 33 9±1.33 17.3±1.73 e 2.73±1.61 [134] 
10a 
 
3.733 (2.5-5.3) 15.86 (11.9-20) 5 33 
  
2.67±1.12 [134] 
10a TID 6.66 (6.3-7.1) 22.46 (20.7-23.8) 4 100 8.1±1.4 24.4±1.28 e 1.95±1.14 [134] 
10a  6.66 (6.3-7.1) 22.46 (20.7-23.8) 4 100   2.08±1.53 [134] 
15.00a 
 
0.2 (0.096154-
0.26923) 
5.5 (4.1-7.1) 7 43 16.1±7.4 
 
3.3±1.3 [136] 
15.00a 
 
2 (1-4.667) 11.8 (8.3-17.3) 7 43 3.93±1.83 
 
1.59±0.73 [136] 
500 
 
25.7 (19-39) 71.3 (57.6-90.7) 36 0 12.0 
 
2.4 [403] 
500 
 
29.6 (20-40) 76.7 (61.9-89.8) 32 0 7.3 
 
1.5 [403] 
500 
 
29.6 (20-40) 76.7 (61.9-89.8) 32 0 8.0 
 
1.6 [403] 
500 
 
(24-40) 78 18 0 13.5±3.01 38.8±9.05 3.23±1.13 [404] 
Tablet 
50 
 
30 (22-34) 67.5 (51-80.5) 12 50 1±0.3 
 
0.28±0.08 [385] 
100 
 
19 67.5 (58.5-74) 6 50 
  
0.52±0.14 [375] 
100 
 
26 (21-40) 68 (54-85) 12 50 2.1±0.97 
 
0.73±0.28 [387, 388] 
100 
 
28 
 
8 0 1.289±0.529 
 
0.381±0.153 [405] 
100 
 
28 
 
7 100 1.485±0.549 
 
0.437±0.154 [405] 
100 
 
29.4 (21-35) 67 (52-80) 12 50 1.77±0.64 
 
0.37±0.11 [359] 
100 
 
30 (22-34) 67.5 (51-80.5) 12 50 1.9±0.6 
 
0.49±0.13 [385] 
100 
 
74 60.25 (30.5-84.2) 9 50 
   
[375] 
100 
 
(30-40) 76.9 (70-85.7) 4 50 
   
[375] 
200 
 
27.1 (22-30) 77.3 (60.5-89.4) 8 0 4.18±1.1 39.1±7.28 d 1.18±0.2 [395] 
200 
 
(21-29) 
 
12 0 
 
41.67±6.44 1.2055±0.229 [399] 
250 
 
24 (20-30) 72 (61-81) 10 0 5.55±0.34 
 
1.2±0.1 [131] 
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Dosage Population 
AUC [mg·h/L] CL [L/h] Cmax [mg/L] Study 
[mg] Regime Age [years] (Range) Weight [kg] (Range) n Females [%] 
250 BID 24.7 (19-45) 68.4 (55.2-91) 9 0 5.33±0.61 
 
1.35±0.19 [406] 
250 
 
25.7 (22-37) 63 (47.5-79) 10 50 
  
1.35±0.17 [407] 
250 BID 25.7 (22-37) 63 (47.5-79) 10 50 
  
1.41±0.32 [407] 
250 
 
26 (21-40) 68 (54-85) 12 50 5.28±2.41 
 
1.59±0.57 [387, 388] 
250 
 
27.3 75 12 0 
 
0.823±0.297 e 
 
[408] 
250 BID 27.3 75 12 0 
 
0.629±0.164 e 
 
[408] 
250 BID 28 
 
8 0 3.02±0.965 
 
0.935±0.331 [405] 
250 BID 28 
 
8 100 4.195±1.07 
 
1.182±0.236 [405] 
250 
 
28 (22-34) 69.4 8 0 4.7±0.7 
 
1.24±0.32 [142] 
250 
 
29 75 6 0 
  
0.94±0.28 [389] 
250 
 
29.4 (21-35) 67 (52-80) 10 50 4.23±1.11 
  
[359] 
250 
 
67 (60-73) 65 (57-74) 10 40 7.43±0.77 c 
 
1.7±0.1 [131] 
250 
 
69 (63-76) 76.9 8 0 6.4±1.08 
 
1.47±0.4 [142] 
250 
 
(22-26) 
 
8 0 3.7±1 c 
 
0.76±0.22 [369] 
500 
 
22.3 (19-25) 62 (59.8-75) 12 50 10±2.78 38.238±10.14 2.26±0.75 [409] 
500 TID 22.3 (19-25) 62 (59.8-75) 12 50 13.93±5.32 41.436±17.82 3.51±1.33 [409] 
500 BID 24.7 (19-45) 68.4 (55.2-91) 9 0 13.94±2.86 b 
 
2.89±0.54 [406] 
500 
 
24.8 (19-40) 73.3 (57.3-95.5) 12 0 11.8±3.6 
  
[410] 
500 BID 24.8 (19-40) 73.3 (57.3-95.5) 12 0 18.5±5.8 
  
[410] 
500 
 
25 76.2 14 0 10.6±2.3 b 
 
2.5±0.6 [132] 
500 BID 25 76.2 14 0 14.7±2.7 b 
 
3±0.6 [132] 
500 BID 25 (22-40) 77.4 8 0 10.35±0.86 b 
  
[411] 
500 BID 25.7 (19-39) 71.3 (57.6-90.7) 36 0 11.8 
 
2.2 [403] 
500 
 
26 (21-30) 68 (54-85) 12 50 9.6±4.2 
 
2.8±1.3 [412] 
500 BID 26 (21-30) 68 (54-85) 12 50 9.6±4.5 
 
2.3±1.1 [412] 
500 
 
26 (21-40) 68 (54-85) 12 50 9.61±4.18 
 
2.77±1.26 [387, 388] 
500 
 
27 (19-42) 68.3 (57.8-86.6) 12 50 10.2±1.9 c 60.06±13.212 2.46±0.481 [413] 
500 
 
27.3 (21-35) 73 12 0 10.7±2.6 
 
2.7±0.8 [400] 
500 
 
28 
 
8 0 7.383±1.6 
 
2.158±0.646 [405] 
500 
 
28 
 
7 100 7.084±2.86 
 
1.959±0.503 [405] 
500 
 
28 (22-34) 69.4 8 0 10.3±2.6 
 
2.35±0.52 [142] 
500 BID 28 (22-34) 69.4 8 0 14.3±2.8 
 
3.1±0.79 [142] 
500 BID 28 (22-33) 70.4 8 100 12.97±0.75 b 
  
[411] 
500 
 
28.3 (20-42) 
 
8 12.5 16.2±4.6 
 
3±1 [414] 
500 
 
29 (23-41) 78 (69-83) 6 0 9.9±2.43 
 
2.3±0.7 [415] 
500 
 
28 (23-34) 67 (52-80) 10 50 6.78±1.32 
 
1.51±0.36 [359] 
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Dosage Population 
AUC [mg·h/L] CL [L/h] Cmax [mg/L] Study 
[mg] Regime Age [years] (Range) Weight [kg] (Range) n Females [%] 
500 
 
30 (19-43) 74.8 (63-91) 12 50 10.6±2.3 48.84±13.86 2.12±0.5 [416] 
500 BID 31 (21-48) 77.3 12 50 
   
[417] 
500 
 
36 
 
7 57 10.1 
 
2.35±0.95 [418] 
500 
 
60 
 
17 0 9.8±4 60.12±27.78 2.2±1.1 [419] 
500 
 
65.3 75.8 8 0 
   
[420] 
500 BID 67.3 77.1 8 0 
   
[420] 
500 
 
69 (63-76) 76.9 8 0 13.8±1.75 
 
2.83±0.61 [142] 
500 BID 69 (63-76) 76.9 8 0 20.5±3.4 
 
3.3±0.38 [142] 
500 BID 71 (65-76) 84.5 8 0 13.68±0.74 b 
  
[411] 
500 BID 72 (65-78) 67.5 8 100 19.28±1.03 b 
  
[411] 
500 BID 72.6 (65.4-87.6) 65.6 (42-101) 17 35 11.4±4.3 b 0.636±0.222 e 2.6±1 [140] 
500 
 
75.4 (71-86) 65.1 (51-79) 12 0 20.88±8.68 23.64±4.35 
 
[143] 
500 
 
(24-40) 78 18 0 10±2.18 50.2±11.8 2.83±0.68 [404] 
500 
 
(24-40) 78 18 0 12.7±2.89 42±10.2 2.91±0.74 [404] 
500 
 
(22-26) 
 
11 0 7.6±2.6 c 
 
1.6±0.79 [369] 
750 
 
23 (19-26) 78.7 12 0 12.71±2.58 28.94±16.43 2.23±0.5 [421] 
750 BID 24.7 (19-45) 68.4 (55.2-91) 9 0 22.07±6.37 b 
 
4.15±0.72 [406] 
750 
 
25 76.2 14 0 15.6±3.1 b 
 
3.3±0.7 [132] 
750 BID 25 76.2 14 0 21.1±6.1 b 
 
4.4±1.1 [132] 
750 
 
26 (24-37) 54.6 (52.3-71.8) 7 100 
 
28.3 5.2 [422] 
750 
 
27.1 (22-30) 77.3 (60.5-89.4) 8 0 15.3±3.77 42.2±8.05 d 2.97±0.64 [395] 
750 
 
27.3 74.9 (63.3-84.5) 6 0 19.2±1.1 
 
3.9±1.7 [401] 
750 
 
27.3 (21-35) 
 
12 0 16.8±4.8 
 
3.8±15 [400] 
750 
 
28.2 73.3 18 0 23.8±7.22 c 70.5±31.14 d 3.01±0.88 [402] 
750 BID 28.2 73.3 18 0 31.6±12.3 c 53.76±18.36 d 3.59±1.34 [402] 
750 
 
28 (23-34) 67 (52-80) 12 50 8.77±1.09 
 
1.97±0.5 [359] 
750 
 
30 (22-34) 67.5 (51-80.5) 12 50 12.2±2.9 
 
2.65±0.48 [385] 
750 
 
30 (24-43) 86.6 (67.9-106.8) 8 0 
 
44.4 3.6 [422] 
750 
 
33 65 24 100 16.1±3.95 47.33±15.46 3.19±0.5 [361] 
750 
 
36 74 24 0 13.42±2.59 54.27±10.6 3.14±0.77 [361] 
750 
 
60 
 
17 0 15.6±9.1 70.38±48.9 2.8±1.5 [419] 
750 
 
60.8 (58-77) 64.3 (50-93) 10 90 
   
[147] 
750 
 
65.3 (42-85) 71.8 (62-88) 10 50 
   
[423] 
750 
 
67.8 75.8 6 50 20.9±7.7 42.1±20 5.1±1.4 [424] 
750 
 
68.6 
 
5 0 
   
[425] 
750 
 
70 (61-82) 70 (58-80) 5 50 
   
[145] 
  
1
3
0
 
A
p
p
en
d
ix
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
Dosage Population 
AUC [mg·h/L] CL [L/h] Cmax [mg/L] Study 
[mg] Regime Age [years] (Range) Weight [kg] (Range) n Females [%] 
750 
 
73 (68-76) 62.1 (47.7-69.5) 6 0 35.1±6.3 0.35±0.06 e 5.9±0.7 [144] 
750 BID 73 (68-76) 62.1 (47.7-69.5) 6 0 33.1±12.2 0.41±0.15 e 6.2±1.8 [144] 
750 BID 73 (68-76) 62.1 (47.7-69.5) 6 0 34.7±9.8 0.38±0.11 e 6.2±1.6 [144] 
750 BID 78 (66-90) 63.4 (49.1-66.6) 6 78 39.9±11.2 
 
7.6±2.2 [137] 
750 
 
79.1 (64-92) 56.5 (43.6-95.7) 20 40 41.92±17.22 b 0.4014±0.2238 e 6.58±2.88 [146] 
750 BID 79.1 (64-92) 56.5 (43.6-95.7) 20 40 47.7±19.61 0.3366±0.1518 e 8.83±2.79 [146] 
750 BID 81.3 
 
10 60 
  
3.3±2.16 [426] 
750 
 
(23-32) 75.9 12 0 16.7±5.1 51.9±28.4 3.34±1.34 [398] 
750 
 
(22-26) 
 
11 0 12.9±3 c 
 
2.54±0.54 [369] 
1000 
 
26 (21-40) 68 (54-85) 12 50 22.84±9.41 
 
5.57±1.21 [387, 388] 
1000 
 
28 
 
7 0 11.611±2.998 
 
3.619±0.844 [405] 
1000 
 
28 
 
8 100 14.683±5.413 
 
3.763±0.924 [405] 
1000 
 
(22-26) 
 
11 0 16.6±2.4 c 
 
3.38±0.56 [369] 
Grey shading indicated studies used for model building 
Frequency of dose administration: BID: twice daily; TID: thrice daily 
a Dose on mg/kg basis;  
b AUC0-12h  
c AUC0-24h 
d Clearance normalized to body surface area [L/h/1.73m2] 
e Clearance normalized to body weight [L/h/kg]
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Figure A-1 Listing of the most sensitive parameters comprising 90 % of the entire 
variability in a descending order towards AUCinf after intravenous 
administration.  The X-axis describes sensitivity values and their positive or 
negative impact on AUCinf. Model parameters are classified of either 
compound or system origin. The color code represents the different ages. 
Parameters assigned with the term Reference represent compound-specific 
reference values applied to convert plasma clearance to an intrinsic 
clearance normalized to the organ or tissue size where the process occurs.  
* Dose is not depicted and contributes with a sensitivity of 1 
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Figure A-2  Listing of the most sensitive parameters comprising 90 % of the entire 
variability in a descending order towards AUCinf after oral administration. 
The X-axis describes sensitivity values and their positive or negative impact 
on AUCinf. Model parameters are classified of either compound or system 
origin. The color code represents the different ages. Parameters assigned 
with the term Reference represent compound-specific reference values 
applied to convert plasma clearance to an intrinsic clearance normalized to 
the organ or tissue size where the process occurs. 
* Dose is not depicted and contributes with a sensitivity of 1 
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Figure A-3 Listing of the most sensitive parameters comprising 90 % of the entire 
variability in a descending order towards Cmax after oral administration. The 
X-axis describes sensitivity values and their positive or negative impact on 
Cmax. Model parameters are classified of either compound or system origin. 
The color code represents the different ages. Parameters assigned with the 
term Reference represent compound-specific reference values applied to 
convert plasma clearance to an intrinsic clearance normalized to the organ 
or tissue size where the process occurs. 
* Dose is not depicted and contributes with a sensitivity of 1 
